


Annual Report on the Notified Tuberculosis in the Republic of Korea, 2025

TB incidence rate

33.5 cases
/100,000 population



Korea Disease Control and
Prevention Agency

CONTENTS

I

Overview

1. Purpose	2
2. Legal Basis	2
3. History and Publication of Results	2
4. Overview of Tuberculosis Notification and Reporting	5
5. Definitions	7
6. Study Subjects	10
7. Notes on Data Interpretation	13

II

Trends in Tuberculosis Cases, 2001–2025

[Table 1] Number and Incidence Rates of (New) TB Cases, 2001–2025	16
[Table 2] Number of (New) TB Cases by Treatment History, 2001–2025	17
[Figure 1] (New) TB Incidence Rates, 2001–2025	18
[Figure 2] Age-standardized (New) TB Incidence Rates, 2001–2025	18

III

Statistics on Tuberculosis Cases, 2025

[Table 3] Number and Incidence Rates of (New) TB Cases by Province, Gender and Age, 2025	20
[Table 4] Number of (New) TB Cases by District, 2025	32
[Table 5] Number of (New) TB Cases by Medical Security and Treatment History, 2025	36
[Table 6] Number of (New) TB Cases by Province and Medical Security, 2025	37
[Figure 3] TB Incidence Rates by Province, 2025	38
[Figure 4] TB Incidence Rates by District, 2025	38
[Figure 5] New TB Incidence Rates by Province, 2025	38
[Figure 6] New TB Incidence Rates by District, 2025	38
[Figure 7] TB Incidence Rates by Gender and Age, 2025	39
[Figure 8] (Age-standardized) TB Incidence Rates by Province, 2025	39

IV

Detailed Statistics on (New) Tuberculosis Cases, 2011–2025

[Table 7] Number and Incidence Rates of (New) TB Cases by Gender and Age, 2011–2025	42
[Table 8] Number and Incidence Rates of (New) TB Cases by Province, 2011–2025	54
[Table 9] Number and Incidence Rates of (New) TB Cases by Site of Disease, 2011–2025	58
[Table 10] Number of (New) TB Cases by Notifying Medical Institution, 2011–2025	60
[Table 11] Number of Foreign (New) TB Cases, 2011–2025	61

V

Drug-Resistant Tuberculosis Cases, 2011–2025

[Table 12] Number of Multidrug-resistant (MDR) TB Cases (2011–2021) and Multidrug/Rifampicin-resistant(MDR/RR) TB (2022–2025) Cases by Gender and Age	64
[Table 13] Number of MDR/RR-TB Cases by Drug Resistance and Treatment History, 2025	68
[Table 14] Number of MDR/RR-TB Cases by Age and Treatment History, 2025	69
[Table 15] Number of MDR/RR-TB Cases by Province and Treatment History, 2025	70

VI

Treatment Outcomes of Tuberculosis Cases


[Table 16] Treatment Outcomes of Drug-susceptible TB Cases, 2024	72
[Table 17] Treatment Outcomes of Drug-susceptible TB Cases aged <65 years, 2024	72
[Table 18] Treatment Outcomes of Drug-susceptible TB Cases aged ≥65 years, 2024	72
[Table 19] Treatment Outcomes of Drug-resistant TB Cases, 2023	73
[Table 20] Treatment Outcomes of Drug-resistant TB Cases <65 years, 2023	73
[Table 21] Treatment Outcomes of Drug-resistant TB Cases ≥65 years, 2023	73

VII

Appendix

1. Number of TB Deaths by Gender and Age, from the Causes of Death Statistics, Statistics Korea, 2014–2024	76
2. Tuberculosis Notification·Reporting Form	78
3. Tuberculosis Case Investigation	81
4. Contact List of Infectious Tuberculosis Patient	84
5. Written Order for (Hospitalization, Quarantine Treatment)	86

**Annual Report
on the Notified Tuberculosis
in the Republic of Korea, 2025**



Overview

1. Purpose
2. Legal Basis
3. History and Publication of Results
4. Overview of Tuberculosis Notification and Reporting
5. Definitions
6. Study Subjects
7. Notes on Data Interpretation

Overview

1 Purpose

This annual report is prepared to analyze data on tuberculosis (“TB”) cases diagnosed or treated at public health centers and medical institutions nationwide, collected through the Korea Tuberculosis Surveillance System (KTB-Surv) within the Korea Tuberculosis Network (KTB-net).

The findings of this report serve as a basis for planning, implementing, and evaluating national TB control policies in the Republic of Korea.

2 Legal Basis

Tuberculosis Prevention Act: Article 6 (Project for Tuberculosis Statistics) and Article 8 (Reporting Obligation of Medical Institutions);

Infectious Disease Control and Prevention Act: Article 11 (Reporting by Physicians), Article 12 (Other Persons Obligated to Report), Article 13 (Reporting by Directors of Public Health Centers), and Article 15 (Detection and Management of Infectious Disease Patients).

3 History and Publication of Results

A History

- 1976: The statistics were approved by Statistics Korea as one of the National Approved Statistics. (Approval No. 11756, *Current State of Nationwide Tuberculosis Patients*)
- 2000: The Korea Tuberculosis Surveillance System (KTBS) was established.
- 2002: The first *Annual Report on the Notified Tuberculosis in Korea* was published.
 - Based on data reported by public health centers and medical institutions nationwide.
- 2005: The *Mycobacterium tuberculosis complex* (MTBC) Examination Management Information System (TBIS) was established.
- 2006: The National Tuberculosis Picture Archiving and Communication System (TB-PACS) was established.

- 2008: The management of the KTBS was transferred from the the Korean Institute of Tuberculosis under the Korean National Tuberculosis Association to the Korea Centers for Disease Control and Prevention (KCDC).
- 2008: The publication frequency of national approved TB statistics was changed from weekly to annually.
- 2009: The Korea Tuberculosis Network (KTB-net) was newly established by integrating the Korea Tuberculosis Surveillance System (KTB-Surv) for TB notification and reporting with the TB testing system at public health centers.
- 2011: The TB-NET, previously operated separately within the KCDC, was merged into the Integrated Disease and Health Management System, which monitors infectious diseases beyond TB.
- 2013: The national statistics approval number was changed. (No. 920007, Current state of Tuberculosis)
- 2019: The national statistics approval number was changed. (No. 117107, Current state of the Notified Tuberculosis Patients)
- (Newly added) [△][Tables 5 and 6] Number of (New) TB Cases by Medical Security Type and Treatment History, and by Province and Medical Security Type; [△][Figures 3, 4, 5 and 6] (New) TB Incidence Rates by Province and District
- 2023: Revision of drug-resistant TB statistics following changes in classification and definitions

Before Revision (2011 to 2021)		After Revision (from 2022)	
Extensively drug-resistant TB	TB that shows resistance to both isoniazid and rifampicin and resistance to at least one of fluoroquinolone* and the three injectable agents**. * *Levofloxacin (Lfx), moxifloxacin (Mfx), ofloxacin (Ofx), gatifloxacin (Gfx) ** Capreomycin (Cm), kanamycin (Km), amikacin (Am)	Changed	Extensively drug-resistant TB TB caused by a strain of <i>Mycobacterium tuberculosis</i> complex that is resistant to rifampicin (and may also be resistant to isoniazid), and that is also resistant to at least one fluoroquinolone* and to at least one other "Group A" drug**. * levofloxacin (Lfx), moxifloxacin (Mfx), ofloxacin (Ofx), or gatifloxacin (Gfx) ** bedaquiline (Bdq) or linezolid (Lzd)
(Newly added)		▶	Pre-extensively drug-resistant TB TB caused by a strain of <i>Mycobacterium tuberculosis</i> complex that is resistant to rifampicin (and may also be resistant to isoniazid), and that is also resistant to at least one fluoroquinolone.
Multidrug-resistant TB	TB caused by a strain of <i>Mycobacterium tuberculosis</i> complex that is resistant to rifampicin and isoniazid.		(Unchanged)
rifampicin-mono-resistant TB	TB caused by a strain of <i>Mycobacterium tuberculosis</i> complex that is resistant to rifampicin. These strains may be susceptible or resistant to isoniazid.		(Unchanged)
(Newly added)			Isoniazid-mono-resistant TB TB caused by a strain of <i>Mycobacterium tuberculosis</i> complex that is resistant to isoniazid but susceptible to rifampicin

- 2025: Expansion of detailed statistical tables from new TB cases only to include all TB cases(after the published Annual TB report in 2024).

Before Revision (Based on the 2023 Annual Report)	After Revision (Since the 2024 Annual Report)
[Figure 7] New TB Incidence Rates by Gender and Age, 2023	[Figure 7] TB Incidence Rates by Gender and Age, 2024
[Figure 8] New TB Incidence Rates by Province, 2023	[Figure 8] (Age-standardized) TB Incidence Rates by Province, 2024
IV. Detailed Statistics on New Tuberculosis (TB) Cases, 2011–2023	IV. Detailed Statistics on (New) Tuberculosis Cases, 2011–2024
[Table 7] Number and Incidence Rates of New TB Cases by Gender and Age, 2011–2023	[Table 7] Number and Incidence Rates of (New) TB Cases by Gender and Age, 2011–2024
[Table 8] Number and Incidence Rates of New TB Cases by Province, 2011–2023	[Table 8] Number and Incidence Rates of (New) TB Cases by Province, 2011–2024
[Table 9] Number and Incidence Rates of New TB Cases by Site of Disease, 2011–2023	[Table 9] Number and Incidence Rates of (New) TB Cases by Site of Disease, 2011–2024
[Table 10] Number of New TB Cases by Notifying Medical Institution, 2011–2023	[Table 10] Number of (New) TB Cases by Notifying Medical Institution, 2011–2024

- 2026: Added the statistic table “ Treatment Outcomes of Tuberculosis Cases”(Since the 2025 Annal Report)
- (New Added) Contents “Treatment Outcomes of Tuberculosis Cases” : △[Table 16–18] Treatment Outcomes in Drug-susceptible TB cases(aged < 65/≥65 years), △[Table 19–21] Treatment Outcomes in Drug-resistant TB cases(aged < 65/≥65 years)

B Data Publication

- ✓ **Publication of nationally approved TB statistics around the end of March (World TB Day) each year.**
- ✓ **Statistical tables available through the Korean Statistical Information Service (KOSIS) of Statistics Korea**
 - ※ Statistics tables from previous years that are not included in the this report can be founded at KOSIS, Statistics Korea
 - <http://kosis.kr> ▶ Domestic Statistics ▶ Statistics by Theme ▶ Health ▶ Tuberculosis Patient Notification Status
 - <http://kosis.kr> ▶ Domestic Statistics ▶ Statistics by Agency ▶ Central Administrative Agencies ▶ Korea Disease Control and Prevention Agency ▶ Tuberculosis Patient Notification Status
- ✓ **Provide microdata through the Microdata Integrated Service (MDIS) of Statistics Korea**
 - <http://mdis.kostat.go.kr> ▶ Data Use ▶ Download Service ▶ Health ▶ Tuberculosis Patient Notification Status
- ✓ **Provide publication files through the TB Zero Website of the KDCA**
 - <http://tbzero.kdca.go.kr> ▶ Statistics and Publications ▶ Publications ▶ Annual Report on the Tuberculosis in the Republic of Korea, 2025

4 Overview of Tuberculosis Notification and Reporting

A Persons Obligated to Report

- ✓ **Applicable laws:** Article 8 (Reporting Obligation of Medical Institutions) of the Tuberculosis Prevention Act; and Article 11 (Reporting by Physicians), Article 12 (Other Persons Obligated to Report), and , Article 13 (Reporting by Directors of Public Health Centers), of the Infectious Disease Control and Prevention Act.

📁 Notification Obligation

- ✓ Where a person diagnoses a suspected or confirmed TB case, or examines the corpse of such a case, they are required to notify the competent authority.
- **Medical Personnel:** The head of a medical institution, physicians, dentists, oriental medical doctors, and other medical workers shall notify the director of the competent public health center.
- **Military Personnel:** A military doctor serving in the Army, Navy, Air Force, or a unit under the direct control of the Ministry of National Defense shall report to the commander of their unit, who shall then notify the director of the competent public health center.
- **Other Persons Obligated to Report:** The following individuals shall request a physician to perform a diagnosis or a postmortem examination, or shall notify the director of the competent public health center:
 - In a household, the cohabiting householder; if the householder is absent, a member of the household.
 - In schools, hospitals, government offices, companies, entertainment venues, places of worship, means of transportation (e.g., vessels, aircraft, trains), business offices, restaurants, hotels, and other locations where many people gather, the manager, executive, or representative.
 - Pharmacists, oriental medicine pharmacists, and pharmacy founders under the Pharmaceutical Affairs Act.

📁 Reporting Obligation

- **Reporting by Directors of Public Health Centers:** The director of a public health center shall report the received notifications to the competent Special Self-Governing City Mayor, Special Self-Governing Province Governor, or the head of the Si/Gun/Gu. The Special Self-Governing City Mayor or Special Self-Governing Province Governor shall then report to the Commissioner of the Korea Disease Control and Prevention Agency (KDCA), while the head of the Si/Gun/Gu shall report to both the KDCA Commissioner and the Mayor/Do Governor.

B Timing of Notification and Reporting: Within 24 hours

- ✓ Notification: (1) When a person diagnoses or treats a suspected or confirmed TB case.
(2) When a suspected or confirmed TB case dies, or when a postmortem inspection is conducted on the body of a person who has died of TB.
- ✓ Report: The treatment outcomes of a suspected or confirmed TB case for whom a report has been filed pursuant to Notification (1).

C Persons Subject to Notification: TB Cases and Suspected TB Cases

- ✓ TB cases: A person infected with *Mycobacterium tuberculosis*, showing clinical symptoms, and who has been bacteriologically confirmed through diagnostic tests.
- ✓ Suspected TB cases: A person suspected to have TB based on clinical, radiological, or histological findings but who has not been bacteriologically confirmed through diagnostic tests

Diagnostic Criteria for Notification

- TB case: A person who shows clinical symptoms consistent with TB and whose infection with *Mycobacterium tuberculosis* has been confirmed according to the diagnostic testing criteria.
 - * Infection with *Mycobacterium bovis* BCG is caused by BCG vaccination and is considered an adverse reaction to immunization; therefore, it is not subject to notification.
- Suspected TB case: A person who shows clinical, radiological, or histological findings consistent with TB but does not meet bacteriological diagnostic criteria.

TB Diagnostic Test Criteria for Diagnosis

- Acid-Fast Bacillus (AFB) smear positive from a specimen (sputum, bronchoalveolar lavage fluid, body fluid, or tissue).
- Isolation and identification of *Mycobacterium tuberculosis* from a specimen (sputum, bronchoalveolar lavage fluid, body fluid, or tissue) via culture.
 - * Especially, *Mycobacterium bovis* must be identified via culture for a definitive diagnosis.
- Detection of TB-specific genes from a specimen (sputum, bronchoalveolar lavage fluid, body fluid, or tissue).

[Public Notification on Diagnostic Criteria for the Notification of Infectious Diseases
(Notification No. 2026-4 of the Korea Disease Control and Prevention Agency, March 29, 2026)]

D Notification Method

- ✓ Notification Authority: Director of the competent public health center
- ✓ Notification Method: Fax or Web (Korea Tuberculosis Network(KTB-net), <http://is.kdca.go.kr> > TB control)
- ✓ Notification Form: Tuberculosis Notification·Reporting Form (Attached Form No. 1 of the *Enforcement Rules of the Tuberculosis Prevention Act*)

5 Definitions

A Classification of Tuberculosis cases

1) Category by Treatment History

Category	Definition
New patient	New patients have never been treated for TB or have taken anti-TB drugs for less than 1 month. ※ If new patients are transferred to another healthcare facility without treatment outcomes (cured, treatment completed, treatment failed, or lost to follow-up), they will be considered new patients.
Previously treated patient	Previously treated patients have received 1 month or more of anti-TB drugs in the past. ※ They are further classified by the outcome of their most recent course of treatment as follows:
Relapse patient	Relapse patients have previously been treated for TB, were declared cured or treatment completed at the end of their most recent course of treatment, and are now diagnosed with a recurrent episode of TB
Treatment after failure patient	Treatment after failure patients are those who have previously been treated for TB and whose treatment failed at the end of their most recent course of treatment.
Treatment after loss to follow-up patient	Treatment after loss to follow-up patients have previously been treated for TB and were declared lost to follow-up at the end of their most recent course of treatment.
Other previously treated patient	Other previously treated patients are those who have previously been treated for TB but whose outcome after their most recent course of treatment is unknown or undocumented.
Patient with unknown previous TB treatment history	Patients with unknown previous TB treatment history do not fit into any of the categories listed above.

* In accordance with the amendment of the *Enforcement Rules of the Tuberculosis Prevention Act* (Jul. 29, 2014), the previous category of "New patient" and "Previously treated patient (Relapse, Treatment after failure, Treatment after loss to follow-up, Transferred-in, Chronic carrier, Other previous treatment)" was revised to "New patient," "Previously treated patient (Relapse, Treatment after failure, Treatment after loss to follow-up, Other previous treatment)" and "Unknown Previous Treatment History".

2) Category by TB Sites

Category	Definition	10 th International Classification of Diseases (ICD-10) (8th Korean Standard Classification of Diseases)
Pulmonary TB	TB involving the lung parenchyma or larynx, trachea or bronchi; or miliary TB	A15.0 Tuberculosis of lung, confirmed by sputum microscopy with or without culture A15.1 Tuberculosis of lung, confirmed by culture only A15.2 Tuberculosis of lung, confirmed histologically A15.3 Tuberculosis of lung, confirmed by unspecified means A15.5 Tuberculosis of larynx, trachea and bronchus, confirmed bacteriologically and histologically A16.0 Tuberculosis of lung, bacteriologically and histologically negative A16.1 Tuberculosis of lung, bacteriological and histological examination not done A16.2 Tuberculosis of lung, without mention of bacteriological or histological confirmation A16.4 Tuberculosis of larynx, trachea and bronchus, without mention of bacteriological or histological confirmation A19 Miliary tuberculosis
Extra-pulmonary TB	TB pleurisy, TB of intrathoracic lymph nodes, TB of the nervous system, TB of bones and joints, genitourinary TB, TB of intestines, peritoneum and mesenteric lymph nodes	A15.4 Tuberculosis of intrathoracic lymph nodes, confirmed bacteriologically and histologically A15.6 Tuberculous pleurisy, confirmed bacteriologically and histologically A15.7 Primary respiratory tuberculosis, confirmed bacteriologically and histologically A15.8 Other respiratory tuberculosis, confirmed bacteriologically and histologically A15.9 Respiratory tuberculosis unspecified, confirmed bacteriologically and histologically A16.3 Tuberculosis of intrathoracic lymph nodes, without mention of bacteriological or histological confirmation A16.5 Tuberculous pleurisy, without mention of bacteriological or histological confirmation A16.7 Primary respiratory tuberculosis without mention of bacteriological or histological confirmation A16.8 Other respiratory tuberculosis, without mention of bacteriological or histological confirmation A16.9 Respiratory tuberculosis unspecified, without mention of bacteriological or histological confirmation A17 Tuberculosis of nervous system A18 Tuberculosis of other organs

* Since the 2012 Annual Report, TB of the larynx, trachea, and bronchi has been classified as pulmonary TB.

3) Category by Sputum Smear Test Results

Category	Definition
Smear-positive	Positive result in an Acid-Fast Bacillus (AFB) sputum smear test among initial TB tests

4) Category by Drug-Resistant TB

Category	Definition
Extensively drug-resistant TB (XDR-TB)	TB caused by a strain of <i>Mycobacterium tuberculosis</i> complex that is resistant to rifampicin (and may also be resistant to isoniazid), and that is also resistant to at least one fluoroquinolone* and to at least one other "Group A" drug**. * levofloxacin (Lfx), moxifloxacin (Mfx), ofloxacin (Ofx), or gatifloxacin (Gfx) ** bedaquiline (Bdq) or linezolid (Lzd)
Pre-extensively drug-resistant TB (Pre-XDR-TB)	TB caused by a strain of <i>Mycobacterium tuberculosis</i> complex that is resistant to rifampicin (and may also be resistant to isoniazid), and that is also resistant to at least one fluoroquinolone.
Multidrug-resistant TB (MDR-TB)	TB caused by a strain of <i>Mycobacterium tuberculosis</i> complex that is resistant to rifampicin and isoniazid.
Rifampicin-resistant TB (RR-TB)	TB caused by a strain of <i>Mycobacterium tuberculosis</i> complex that is resistant to rifampicin. These strains may be susceptible or resistant to isoniazid.

* In accordance with the amendment to Attached Form No. 1 of the Enforcement Rules of the Tuberculosis Prevention Act (effective December 31, 2021), the classification and definitions of drug-resistant TB have been revised as shown above.

5) Definitions of Treatment Outcome

Category	Definition		
Cured	A patient with pulmonary TB with bacteriologically confirmed TB at the beginning of treatment who completed treatment as recommended by the national guideline, with evidence of bacteriological response (bacteriological conversion with no reversion) and no evidence of failure.		
Treatment completed	A patient who completed treatment as recommended by the national guideline but whose outcome does not meet the definition for cured or treatment failed.		
Treatment failed	A patient whose treatment regimen needed to be terminated or permanently changed to a new treatment regimen or strategy.		
Died	A patient who died before starting treatment or during the course of treatment.		
	TB-related death	Primary cause	In cases where TB is listed as the underlying cause of death on the death certificate.
		Other cause	In cases where TB is listed among other causes of death on the death certificate.
	Non-TB-related death		In cases where the cause of death listed on the death certificate does not include TB.
Unknown cause of death		In cases where the death certificate cannot be checked, and the cause of death is therefore unclear.	
Lost to follow-up	A patient who did not start treatment or whose treatment was interrupted for 2 consecutive months or more.		
Not evaluated	A patient to whom none of the following treatment outcomes was assigned: cured, treatment completed, treatment failed, died, or lost to follow-up. This includes cases "transferred out" to another treatment unit with an unknown treatment outcome.		
TB Diagnosis changed	A case in which the diagnosis has been changed to a condition other than tuberculosis (TB).		

^a For reasons including

• No clinical or bacteriological response^a; adverse drug reaction; or acquisition of additional drug-resistance to medicines in the regimen

* Bacteriological response refers to bacteriological conversion with no reversion:

- bacteriological conversion describes a situation in a patient with bacteriologically confirmed TB where at least two consecutive cultures (for drug-susceptible TB and drug-resistant TB) or smears (for drug-susceptible TB only) taken on different occasions at least 7 days apart are negative.
- bacteriological reversion describes a situation where at least two consecutive cultures (for drug-susceptible TB and drug-resistant TB) or smears (for drug-susceptible TB only) taken on different occasions at least 7 days apart are positive either after the bacteriological conversion or in patients without bacteriological confirmation of TB.

B Definition and Calculation of (New) TB Case Notification Rates

1) (New) TB incidence rates

The incidence rate is calculated by dividing the number of (new) TB cases by the reference population and expressing the result per 100,000 population.

- The mid-year resident registration population of the given year is used as the reference population. (Source: Population Trend Survey, Statistics Korea)

$$\frac{\text{Number of (New) TB Cases}}{\text{Mid-year Resident Registration Population of the Given Year}} \times 100,000$$

2) Age-Standardized (New) TB incidence rates

The age-standardized (new) TB incidence rate is calculated by applying the annual (new) TB incidence rate to a standard population to eliminate the effect of age differences within the population on fluctuations in (new) TB incidence rates.

- The 2005 mid-year resident registration population (5-year age groups) is used as the standard population. (Reference: Causes of Death Statistics, Statistics Korea)

$$\frac{\sum ((\text{New) TB Incidence Rate by Age} \times \text{Standard Population by Age Group})}{\text{Standard Population}}$$

6 Study Subjects

A Confirmation of Analysis Subjects

- ✓ Source Data: 24,591 notified or reported TB cases and suspected TB cases from January 1, 2025 to December 31, 2025, as of March 3, 2026

- ✓ Treatment outcomes

- (Drug-susceptible TB) Among the TB cases in 2024 (17,944 cases), 17,228 cases* were classified as having drug-susceptible TB(including Rifampicin-suspetible and isoniazid-resistant TB).

* Excluded: TB cases whose treatment outcomes reported by February 2026 were 'diagnosis changed', 'Lost to follow up(reason: return to home country [foreign national])' or who were diagnosed to multidrug-resistant tuberculosis TB**.

** Extensively drug-resistant tuberculosis (XDR-TB), Pre-extensively drug-resistant tuberculosis (pre-XDR-TB), Multidrug-resistant tuberculosis (MDR-TB), Rifampin-resistant tuberculosis (RR-TB).

- (Drug-resistant TB) Among the 2023 multidrug-resistant TB cases (551 cases), 532 cases were included*.

* Excluded: TB cases whose treatment outcomes reported by February 2026 were 'diagnosis changed', 'Lost to follow up(reason: return to home country [foreign national])'.

B Criteria for Data Cleaning and Classification

✓ Data Cleaning and Removal of Duplicates

- Notifications for cases with at least one treatment outcome reported as "diagnosis changed" were excluded
- If the same TB case was notified multiple times within the relevant year, duplicates were removed after cleaning (reclassification based on past treatment history and site of TB)

✓ Classification Criteria by Treatment History

- TB cases notified multiple times in the same year were classified following a specific hierarchy, prioritizing new cases. The classification order was as follows: New Patient → Previously Treated Patient (Relapse → Treatment after Failure → Treatment after Loss to Follow-up → Other Previously Treated Patient) → Patient with Unknown Previous TB Treatment History.
- If a previously notified patient was mistakenly reported as new or had a delayed notification of over a year, they were categorized as "Other Patients."

✓ Classification Criteria by Sputum Smear Test Result and Site of TB

- If the initial sputum smear test for TB is positive, the case is classified as "smear-positive."
 - If a TB case is notified multiple times, the sputum smear test result is determined in the following order: positive → negative → unknown → not tested.
- TB cases are classified as pulmonary TB or extrapulmonary TB based on ICD-10 codes.
 - In cases where a patient is reported multiple times, pulmonary TB is prioritized over extrapulmonary TB.

✓ Classification of TB Cases by Province and District

- TB cases are classified based on the registered residential address of the patient. If the patient's address is unknown, such as in the case of foreign nationals, classification is determined based on the location of the notifying medical institution.

✓ Classification of Multidrug/Rifampicin-Resistant TB Cases (from 2022)

- Multidrug-resistant or rifampicin-resistant TB (MDR/RR-TB) refers to TB cases notified between January 1 and December 31 of the relevant year, confirmed as MDR/RR-TB according to the "Definition of Drug-Resistant TB" in the Tuberculosis Notification·Reporting Form.
 - ※ For details on the calculation of multidrug-resistant and extensively drug-resistant TB cases (2011-2021), please refer to the 2023 Annual Report on Notified Tuberculosis in the Republic of Korea.

✓ Classification Criteria for Treatment Outcomes

- The treatment outcome of drug-susceptible TB cases is calculated based on treatment outcomes by February 1, two years after the notification year.
 - The treatment outcomes of drug-susceptible TB cases in 2024 were calculated based on the treatment outcomes reported by February 1, 2026, for 17,228 drug-susceptible TB cases.
- The treatment outcome of drug-resistant TB cases is calculated based on treatment outcomes by February 1, three years after the notification year.
 - The treatment outcomes of multidrug-resistant TB cases in 2023 were calculated based on the treatment outcomes reported by February 1, 2026, for 532 multidrug-resistant TB cases.

7 Notes on Data Interpretation

- A. This annual report is based on notified cases from public health centers and medical institutions for the relevant year. The figures in this report may not fully reflect the actual TB burden.
- B. The mid-year resident registration population was used as the reference population to calculate (new) TB incidence rates. Annual reports published before 2010 used projected population data, which may cause differences in statistical values.
- C. For the age-standardized (new) TB incidence rate (Figure 2), the 2005 mid-year resident registration population, used as the standard population in Statistics Korea's Causes of Death Statistics, was applied to adjust for differences in age structure across years.
- D. All statistics include both domestic nationals (i.e., Korean citizens) and foreign nationals, with separate statistics compiled for foreign nationals.
- E. Regarding [Appendix – Table 1], the "Number of TB Deaths" follows the Causes of Death Statistics published by Statistics Korea in late September each year. The number of TB deaths for 2024 is scheduled to be released by Statistics Korea in late September 2025.
- F. Due to changes in the classification and definition of drug-resistant TB (MDR/RR-TB), the number of multidrug-resistant and extensively drug-resistant TB cases (2011–2021) cannot be compared with the number of multidrug-resistant and rifampicin-resistant TB cases (from 2022 onward).
- G. The number of deaths in [Table 16–21], Treatment Outcomes refers to TB (suspected) cases (including foreign nationals) reported to the Korea Tuberculosis Network System(KTB-net) whose treatment outcome was recorded as “death.” Therefore, these figures are not comparable with the number of deaths from tuberculosis (A15–A19) in the cause-of-death statistics, Statistics Korea [Appendix 1].

**Annual Report
on the Notified Tuberculosis
in the Republic of Korea, 2025**



Trends in Tuberculosis Cases, 2001–2025

[Table 1] Number and Incidence Rates of (New) TB Cases, 2001–2025

[Table 2] Number of (New) TB Cases by Treatment History, 2001–2025

[Figure 1] (New) TB Incidence Rates, 2001–2025

[Figure 2] Age-standardized (New) TB Incidence Rates, 2001–2025

Trends in Tuberculosis Cases, 2001–2025

[Table 1] Number and Incidence Rates of (New) TB Cases, 2001–2025

Unit: cases (cases per 100,000 population)

Year	TB Cases		New Cases	
2001	46,082	(96.3)	34,123	(71.3)
2002	43,040	(89.4)	32,010	(66.5)
2003	40,500	(83.8)	30,687	(63.5)
2004	41,735	(86.1)	31,503	(65.0)
2005	46,969	(96.5)	35,269	(72.4)
2006	46,284	(94.7)	35,361	(72.3)
2007	45,597	(92.8)	34,710	(70.6)
2008	44,174	(89.4)	34,157	(69.1)
2009	47,302	(95.3)	35,845	(72.2)
2010	48,101	(96.4)	36,305	(72.8)
2011	50,491	(100.8)	39,557	(78.9)
2012	49,532	(98.4)	39,545	(78.5)
2013	45,292	(89.6)	36,089	(71.4)
2014	43,088	(84.9)	34,869	(68.7)
2015	40,847	(80.2)	32,181	(63.2)
2016	39,245	(76.8)	30,892	(60.4)
2017	36,044	(70.4)	28,161	(55.0)
2018	33,796	(65.9)	26,433	(51.5)
2019	30,304	(59.0)	23,821	(46.4)
2020	25,350	(49.4)	19,933	(38.8)
2021	22,904	(44.6)	18,335	(35.7)
2022	20,383	(39.8)	16,264	(31.7)
2023	19,540	(38.2)	15,640	(30.6)
2024	17,944	(35.2)	14,412	(28.2)
2025	17,070	(33.5)	13,713	(26.9)

[Table 2] Number of (New) TB Cases by Treatment History, 2001–2025


Unit: cases

Year	TB Cases	Treatment History							
		New Cases	Previously treated patients ¹⁾²⁾					Unknown previous treatment history	Other ³⁾
			Sub-total	Relapse	Treatment after failure	Treatment after loss to follow-up	Other previous treatment		
2001	46,082	34,123	11,679	6,742	500	914	–	–	280
2002	43,040	32,010	10,797	6,270	429	772	–	–	233
2003	40,500	30,687	9,647	5,693	359	713	–	–	166
2004	41,735	31,503	9,914	5,691	405	803	–	–	318
2005	46,969	35,269	9,012	5,891	363	711	–	–	2,688
2006	46,284	35,361	8,535	5,558	281	773	–	–	2,388
2007	45,597	34,710	8,299	5,403	314	784	–	–	2,588
2008	44,174	34,157	7,917	5,227	289	734	–	–	2,100
2009	47,302	35,845	8,655	5,624	309	896	–	–	2,802
2010	48,101	36,305	8,794	5,637	267	949	–	–	3,002
2011	50,491	39,557	9,419	5,844	206	1,165	–	–	1,515
2012	49,532	39,545	7,750	5,215	121	836	–	–	2,237
2013	45,292	36,089	8,128	5,490	81	822	–	–	1,075
2014	43,088	34,869	6,254	5,069	98	909	178	252	1,713
2015	40,847	32,181	6,211	4,934	101	829	347	426	2,029
2016	39,245	30,892	6,087	4,981	71	707	328	562	1,704
2017	36,044	28,161	5,637	4,696	49	623	269	610	1,636
2018	33,796	26,433	5,243	4,446	52	517	228	655	1,465
2019	30,304	23,821	4,679	3,999	34	466	180	452	1,352
2020	25,350	19,933	3,709	3,193	39	328	149	388	1,320
2021	22,904	18,335	3,188	2,745	40	246	157	353	1,028
2022	20,383	16,264	2,910	2,526	25	195	164	338	871
2023	19,540	15,640	2,595	2,168	33	233	161	553	752
2024	17,944	14,412	2,256	1,832	32	171	221	554	722
2025	17,070	13,713	2,327	1,881	32	154	260	420	610


1) Following the amendment of the Enforcement Rules of the Tuberculosis Prevention Act (July 29, 2014), the classification of TB cases has been revised as follows: New Cases; Previously Treated Patients (Relapse, Treatment after failure, Treatment after loss to follow-up, Other previous treatment); Unknown Previous Treatment History

2) The previous patient categories of "transferred-in" and "chronic carrier" have been removed. Cases classified as "transferred-in" or "chronic carrier" between 2001 and 2013 have been included in the subtotal of Previously Treated Patients. (For detailed patient numbers of "transferred-in" and "chronic carrier" cases from 2001 to 2013, refer to the 2013 Annual Report.)

3) Among patients notified as New Cases in the relevant year, those with a previous notification history or whose notification was delayed by one year or more were classified as "Other."



[Figure 1] (New) TB Incidence Rates, 2001–2025



[Figure 2] Age-standardized (New) TB Incidence Rates, 2001–2025



Statistics on Tuberculosis Cases, 2025

[Table 3] Number and Incidence Rates of (New) TB Cases by Province, Gender and Age, 2025

[Table 4] Number of (New) TB Cases by District, 2025

[Table 5] Number of (New) TB Cases by Medical Security and Treatment History, 2025

[Table 6] Number of (New) TB Cases by Province and Medical Security, 2025

[Figure 3] TB Incidence Rates by Province, 2025

[Figure 4] TB Incidence Rates by District, 2025

[Figure 5] New TB Incidence Rates by Province, 2025

[Figure 6] New TB Incidence Rates by District, 2025

[Figure 7] TB Incidence Rates by Gender and Age, 2025

[Figure 8] (Age-standardized) TB Incidence Rates by Province, 2025

Statistics on Tuberculosis Cases, 2025

[Table 3] Number and Incidence Rates of (New) TB Cases by Province, Gender and Age, 2025

Province		Age Gender	Total	0-4	5-9	10-14	15-19	20-24	25-29	30-34	35-39
Nation wide	TB cases	Total	17,070 (33.5)	6 (0.5)	1 (0.1)	13 (0.6)	73 (3.2)	243 (9.6)	361 (11.1)	385 (11.0)	414 (13.3)
		Male	10,787 (42.6)	4 (0.6)	1 (0.1)	5 (0.4)	39 (3.3)	126 (9.6)	200 (11.8)	229 (12.4)	242 (15.0)
		Female	6,283 (24.5)	2 (0.3)	0 (0.0)	8 (0.7)	34 (3.0)	117 (9.6)	161 (10.3)	156 (9.4)	172 (11.4)
	New Cases	Total	13,713 (26.9)	6 (0.5)	1 (0.1)	13 (0.6)	66 (2.9)	223 (8.8)	311 (9.5)	325 (9.3)	359 (11.5)
		Male	8,369 (33.0)	4 (0.6)	1 (0.1)	5 (0.4)	34 (2.9)	117 (8.9)	174 (10.2)	192 (10.4)	205 (12.7)
		Female	5,344 (20.9)	2 (0.3)	0 (0.0)	8 (0.7)	32 (2.9)	106 (8.7)	137 (8.8)	133 (8.0)	154 (10.2)
Seoul	TB cases	Total	2,853 (30.9)	0 (0.0)	0 (0.0)	0 (0.0)	17 (4.6)	50 (9.8)	65 (8.5)	64 (8.0)	82 (12.7)
		Male	1,912 (42.9)	0 (0.0)	0 (0.0)	0 (0.0)	7 (3.7)	20 (8.4)	27 (7.5)	29 (7.2)	43 (13.4)
		Female	941 (19.6)	0 (0.0)	0 (0.0)	0 (0.0)	10 (5.5)	30 (11.0)	38 (9.4)	35 (8.8)	39 (12.1)
	New Cases	Total	2,213 (23.9)	0 (0.0)	0 (0.0)	0 (0.0)	17 (4.6)	45 (8.8)	54 (7.0)	57 (7.1)	68 (10.6)
		Male	1,417 (31.8)	0 (0.0)	0 (0.0)	0 (0.0)	7 (3.7)	16 (6.7)	22 (6.1)	25 (6.2)	34 (10.6)
		Female	796 (16.6)	0 (0.0)	0 (0.0)	0 (0.0)	10 (5.5)	29 (10.7)	32 (7.9)	32 (8.0)	34 (10.6)
Busan	TB cases	Total	1,087 (33.5)	0 (0.0)	0 (0.0)	1 (0.7)	7 (5.5)	18 (11.5)	26 (13.6)	19 (9.3)	26 (14.2)
		Male	703 (44.6)	0 (0.0)	0 (0.0)	0 (0.0)	2 (3.0)	5 (6.3)	14 (14.3)	11 (10.4)	11 (11.7)
		Female	384 (23.1)	0 (0.0)	0 (0.0)	1 (1.5)	5 (8.0)	13 (16.9)	12 (12.8)	8 (8.2)	15 (16.8)
	New Cases	Total	860 (26.5)	0 (0.0)	0 (0.0)	1 (0.7)	6 (4.7)	15 (9.6)	23 (12.0)	16 (7.8)	26 (14.2)
		Male	541 (34.3)	0 (0.0)	0 (0.0)	0 (0.0)	2 (3.0)	5 (6.3)	12 (12.3)	10 (9.4)	11 (11.7)
		Female	319 (19.2)	0 (0.0)	0 (0.0)	1 (1.5)	4 (6.4)	10 (13.0)	11 (11.8)	6 (6.1)	15 (16.8)

Unit: cases (cases per 100,000 population)

40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80+	Unknown
532 (14.1)	626 (16.3)	977 (22.5)	1,211 (28.3)	1,559 (37.8)	1,826 (49.4)	1,756 (70.0)	1,989 (108.7)	5,098 (206.6)	0 -
323 (16.8)	402 (20.7)	696 (31.7)	917 (42.8)	1,195 (58.2)	1,332 (74.0)	1,242 (105.1)	1,297 (157.8)	2,537 (291.5)	0 -
209 (11.3)	224 (11.8)	281 (13.1)	294 (13.8)	364 (17.6)	494 (26.0)	514 (38.7)	692 (68.6)	2,561 (160.3)	0 -
442 (11.7)	501 (13.1)	753 (17.4)	946 (22.1)	1,196 (29.0)	1,417 (38.3)	1,355 (54.0)	1,589 (86.8)	4,210 (170.6)	0 -
276 (14.4)	316 (16.3)	536 (24.4)	709 (33.1)	898 (43.7)	990 (55.0)	923 (78.1)	1,000 (121.7)	1,989 (228.5)	0 -
166 (9.0)	185 (9.8)	217 (10.1)	237 (11.1)	298 (14.4)	427 (22.5)	432 (32.5)	589 (58.4)	2,221 (139.0)	0 -
92 (13.3)	109 (16.2)	196 (26.1)	215 (30.4)	289 (42.9)	297 (46.8)	311 (68.7)	322 (94.1)	744 (180.3)	0 -
55 (16.1)	72 (21.8)	142 (38.3)	174 (50.3)	239 (73.9)	226 (76.4)	231 (111.6)	210 (138.5)	437 (271.5)	0 -
37 (10.6)	37 (10.8)	54 (14.2)	41 (11.4)	50 (14.3)	71 (20.9)	80 (32.6)	112 (58.7)	307 (122.0)	0 -
75 (10.9)	79 (11.8)	141 (18.7)	155 (21.9)	198 (29.4)	224 (35.3)	232 (51.2)	253 (73.9)	615 (149.0)	0 -
47 (13.7)	48 (14.6)	99 (26.7)	126 (36.4)	158 (48.8)	162 (54.8)	168 (81.2)	159 (104.9)	346 (215.0)	0 -
28 (8.1)	31 (9.1)	42 (11.0)	29 (8.0)	40 (11.4)	62 (18.3)	64 (26.0)	94 (49.3)	269 (106.9)	0 -
41 (17.9)	35 (15.0)	75 (28.6)	75 (28.1)	124 (44.8)	115 (41.5)	129 (63.3)	130 (89.1)	266 (156.2)	0 -
27 (23.2)	23 (19.5)	53 (40.8)	57 (44.1)	92 (70.2)	82 (63.6)	90 (96.3)	88 (137.1)	148 (237.6)	0 -
14 (12.4)	12 (10.4)	22 (16.7)	18 (13.0)	32 (21.9)	33 (22.2)	39 (35.3)	42 (51.4)	118 (109.2)	0 -
31 (13.5)	31 (13.3)	60 (22.9)	58 (21.7)	96 (34.7)	85 (30.7)	97 (47.6)	104 (71.3)	211 (123.9)	0 -
19 (16.4)	21 (17.8)	40 (30.8)	44 (34.0)	69 (52.7)	56 (43.5)	67 (71.7)	72 (112.1)	113 (181.4)	0 -
12 (10.6)	10 (8.6)	20 (15.1)	14 (10.1)	27 (18.5)	29 (19.5)	30 (27.1)	32 (39.2)	98 (90.7)	0 -

[Table 3] Number and Incidence Rates of (New) TB Cases by Province, Gender and Age, 2025 (continued)

Province		Age Gender	Total	0-4	5-9	10-14	15-19	20-24	25-29	30-34	35-39
Daegu	TB cases	Total	811 (34.5)	0 (0.0)	0 (0.0)	0 (0.0)	3 (2.8)	8 (6.7)	18 (12.8)	12 (8.1)	20 (14.9)
		Male	483 (42.0)	0 (0.0)	0 (0.0)	0 (0.0)	1 (1.8)	6 (9.5)	10 (13.6)	7 (8.8)	10 (14.0)
		Female	328 (27.4)	0 (0.0)	0 (0.0)	0 (0.0)	2 (3.9)	2 (3.5)	8 (12.0)	5 (7.2)	10 (16.0)
	New Cases	Total	693 (29.5)	0 (0.0)	0 (0.0)	0 (0.0)	3 (2.8)	8 (6.7)	15 (10.7)	12 (8.1)	18 (13.4)
		Male	396 (34.4)	0 (0.0)	0 (0.0)	0 (0.0)	1 (1.8)	6 (9.5)	9 (12.2)	7 (8.8)	8 (11.2)
		Female	297 (24.8)	0 (0.0)	0 (0.0)	0 (0.0)	2 (3.9)	2 (3.5)	6 (9.0)	5 (7.2)	10 (16.0)
Incheon	TB cases	Total	928 (30.7)	1 (1.2)	0 (0.0)	1 (0.7)	7 (5.1)	13 (8.8)	14 (7.1)	22 (9.8)	27 (13.5)
		Male	585 (38.8)	1 (2.4)	0 (0.0)	1 (1.4)	5 (7.2)	7 (9.2)	7 (6.9)	13 (11.1)	16 (15.4)
		Female	343 (22.7)	0 (0.0)	0 (0.0)	0 (0.0)	2 (3.0)	6 (8.4)	7 (7.4)	9 (8.5)	11 (11.4)
	New Cases	Total	754 (25.0)	1 (1.2)	0 (0.0)	1 (0.7)	6 (4.4)	13 (8.8)	13 (6.6)	19 (8.5)	25 (12.5)
		Male	466 (30.9)	1 (2.4)	0 (0.0)	1 (1.4)	4 (5.7)	7 (9.2)	7 (6.9)	12 (10.2)	15 (14.4)
		Female	288 (19.0)	0 (0.0)	0 (0.0)	0 (0.0)	2 (3.0)	6 (8.4)	6 (6.3)	7 (6.6)	10 (10.4)
Gwangju	TB cases	Total	368 (26.4)	2 (5.7)	0 (0.0)	1 (1.4)	1 (1.4)	13 (16.0)	9 (9.5)	10 (10.7)	10 (12.5)
		Male	248 (36.0)	1 (5.6)	0 (0.0)	0 (0.0)	1 (2.6)	9 (21.2)	7 (14.2)	7 (14.3)	5 (12.3)
		Female	120 (17.0)	1 (5.8)	0 (0.0)	1 (2.9)	0 (0.0)	4 (10.3)	2 (4.4)	3 (6.8)	5 (12.8)
	New Cases	Total	300 (21.5)	2 (5.7)	0 (0.0)	1 (1.4)	1 (1.4)	12 (14.8)	7 (7.4)	9 (9.6)	10 (12.5)
		Male	201 (29.2)	1 (5.6)	0 (0.0)	0 (0.0)	1 (2.6)	8 (18.9)	6 (12.1)	6 (12.2)	5 (12.3)
		Female	99 (14.0)	1 (5.8)	0 (0.0)	1 (2.9)	0 (0.0)	4 (10.3)	1 (2.2)	3 (6.8)	5 (12.8)

Unit: cases (cases per 100,000 population)

40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80+	Unknown
27 (16.5)	26 (14.9)	38 (18.6)	62 (29.8)	54 (27.0)	74 (42.0)	98 (78.6)	122 (137.6)	249 (215.0)	0 -
19 (23.2)	20 (23.2)	26 (26.0)	44 (43.5)	35 (36.4)	54 (64.9)	69 (122.6)	69 (180.1)	113 (279.3)	0 -
8 (9.7)	6 (6.8)	12 (11.5)	18 (16.8)	19 (18.3)	20 (21.5)	29 (42.4)	53 (105.3)	136 (180.5)	0 -
25 (15.2)	18 (10.3)	31 (15.2)	52 (25.0)	46 (23.0)	64 (36.3)	80 (64.2)	108 (121.9)	213 (183.9)	0 -
17 (20.7)	12 (13.9)	20 (20.0)	37 (36.6)	29 (30.1)	45 (54.1)	55 (97.7)	58 (151.4)	92 (227.4)	0 -
8 (9.7)	6 (6.8)	11 (10.5)	15 (14.0)	17 (16.4)	19 (20.4)	25 (36.5)	50 (99.4)	121 (160.6)	0 -
31 (13.1)	58 (24.8)	49 (19.0)	62 (24.4)	84 (33.4)	131 (61.7)	94 (72.3)	88 (95.3)	246 (210.0)	0 -
19 (15.5)	32 (26.6)	35 (26.9)	38 (30.4)	65 (52.1)	94 (90.6)	66 (106.9)	63 (151.1)	123 (303.1)	0 -
12 (10.4)	26 (22.8)	14 (11.0)	24 (18.5)	19 (15.0)	37 (34.1)	28 (41.0)	25 (49.4)	123 (160.7)	0 -
26 (11.0)	50 (21.3)	39 (15.1)	49 (19.3)	59 (23.5)	105 (49.5)	76 (58.4)	70 (75.8)	202 (172.5)	0 -
17 (13.9)	27 (22.5)	30 (23.1)	30 (24.0)	46 (36.9)	73 (70.3)	51 (82.6)	49 (117.5)	96 (236.5)	0 -
9 (7.8)	23 (20.2)	9 (7.1)	19 (14.7)	13 (10.3)	32 (29.5)	25 (36.6)	21 (41.5)	106 (138.5)	0 -
15 (14.3)	10 (9.0)	26 (21.0)	19 (16.3)	42 (40.7)	43 (48.7)	26 (43.9)	52 (109.7)	89 (151.9)	0 -
7 (13.3)	6 (11.0)	21 (34.1)	16 (27.8)	36 (71.8)	30 (72.2)	11 (41.0)	39 (189.8)	52 (246.7)	0 -
8 (15.4)	4 (7.2)	5 (8.0)	3 (5.1)	6 (11.3)	13 (27.8)	15 (46.3)	13 (48.4)	37 (98.6)	0 -
10 (9.6)	8 (7.2)	22 (17.7)	14 (12.0)	33 (32.0)	33 (37.3)	21 (35.5)	46 (97.0)	71 (121.2)	0 -
6 (11.4)	4 (7.3)	19 (30.9)	12 (20.9)	28 (55.8)	22 (52.9)	9 (33.6)	36 (175.2)	38 (180.3)	0 -
4 (7.7)	4 (7.2)	3 (4.8)	2 (3.4)	5 (9.4)	11 (23.5)	12 (37.0)	10 (37.2)	33 (87.9)	0 -

[Table 3] Number and Incidence Rates of (New) TB Cases by Province, Gender and Age, 2025 (continued)

Province		Age Gender	Total	0-4	5-9	10-14	15-19	20-24	25-29	30-34	35-39
Dae jeon	TB cases	Total	384 (26.8)	0 (0.0)	0 (0.0)	1 (1.5)	4 (5.8)	9 (10.6)	9 (8.6)	8 (7.7)	9 (10.2)
		Male	260 (36.4)	0 (0.0)	0 (0.0)	0 (0.0)	3 (8.4)	5 (11.4)	6 (10.8)	7 (12.6)	5 (10.8)
		Female	124 (17.2)	0 (0.0)	0 (0.0)	1 (3.1)	1 (3.0)	4 (9.6)	3 (6.1)	1 (2.1)	4 (9.7)
	New Cases	Total	293 (20.4)	0 (0.0)	0 (0.0)	1 (1.5)	4 (5.8)	9 (10.6)	8 (7.6)	6 (5.8)	5 (5.7)
		Male	192 (26.9)	0 (0.0)	0 (0.0)	0 (0.0)	3 (8.4)	5 (11.4)	6 (10.8)	5 (9.0)	2 (4.3)
		Female	101 (14.0)	0 (0.0)	0 (0.0)	1 (3.1)	1 (3.0)	4 (9.6)	2 (4.0)	1 (2.1)	3 (7.2)
Ulsan	TB cases	Total	362 (33.2)	0 (0.0)	0 (0.0)	0 (0.0)	1 (1.9)	4 (8.2)	3 (4.6)	13 (18.4)	13 (19.8)
		Male	227 (40.4)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	3 (10.7)	1 (2.7)	10 (25.4)	7 (19.7)
		Female	135 (25.5)	0 (0.0)	0 (0.0)	0 (0.0)	1 (3.9)	1 (4.8)	2 (7.3)	3 (9.7)	6 (19.9)
	New Cases	Total	291 (26.7)	0 (0.0)	0 (0.0)	0 (0.0)	1 (1.9)	4 (8.2)	1 (1.5)	9 (12.8)	12 (18.3)
		Male	178 (31.7)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	3 (10.7)	0 (0.0)	7 (17.7)	6 (16.9)
		Female	113 (21.3)	0 (0.0)	0 (0.0)	0 (0.0)	1 (3.9)	1 (4.8)	1 (3.7)	2 (6.4)	6 (19.9)
Sejong	TB cases	Total	61 (15.6)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	1 (5.2)	3 (10.9)	2 (6.5)
		Male	40 (20.6)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	1 (10.5)	2 (14.8)	2 (13.1)
		Female	21 (10.7)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	1 (7.2)	0 (0.0)
	New Cases	Total	48 (12.3)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	1 (5.2)	2 (7.3)	2 (6.5)
		Male	33 (17.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	1 (10.5)	2 (14.8)	2 (13.1)
		Female	15 (7.6)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)

Unit: cases (cases per 100,000 population)

40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80+	Unknown
10 (9.8)	15 (14.0)	32 (26.0)	31 (26.1)	25 (22.8)	39 (40.2)	37 (57.1)	41 (90.1)	114 (192.4)	0 -
8 (15.5)	7 (13.2)	27 (44.0)	20 (33.9)	16 (29.8)	30 (64.5)	28 (92.5)	32 (156.2)	66 (308.4)	0 -
2 (3.9)	8 (14.8)	5 (8.1)	11 (18.4)	9 (16.1)	9 (17.8)	9 (26.1)	9 (35.9)	48 (126.9)	0 -
8 (7.8)	11 (10.2)	23 (18.7)	26 (21.9)	18 (16.4)	29 (29.9)	28 (43.2)	27 (59.3)	90 (151.9)	0 -
8 (15.5)	5 (9.4)	19 (31.0)	17 (28.9)	11 (20.5)	23 (49.4)	20 (66.0)	19 (92.8)	49 (229.0)	0 -
0 (0.0)	6 (11.1)	4 (6.5)	9 (15.1)	7 (12.5)	6 (11.9)	8 (23.2)	8 (31.9)	41 (108.4)	0 -
12 (14.3)	17 (19.7)	27 (28.0)	34 (32.9)	41 (42.4)	43 (53.7)	40 (79.3)	36 (115.8)	78 (230.1)	0 -
6 (13.8)	11 (24.6)	18 (37.5)	24 (46.3)	32 (64.6)	25 (62.9)	28 (113.8)	25 (168.8)	37 (310.6)	0 -
6 (14.8)	6 (14.4)	9 (18.6)	10 (19.4)	9 (19.1)	18 (44.6)	12 (46.5)	11 (67.6)	41 (186.5)	0 -
11 (13.1)	16 (18.5)	21 (21.8)	28 (27.1)	33 (34.1)	35 (43.7)	33 (65.4)	24 (77.2)	63 (185.8)	0 -
5 (11.5)	10 (22.4)	14 (29.1)	20 (38.6)	26 (52.5)	19 (47.8)	25 (101.6)	16 (108.0)	27 (226.7)	0 -
6 (14.8)	6 (14.4)	7 (14.5)	8 (15.5)	7 (14.8)	16 (39.7)	8 (31.0)	8 (49.2)	36 (163.7)	0 -
2 (5.1)	4 (10.7)	5 (15.1)	3 (12.1)	3 (14.2)	9 (50.5)	5 (44.4)	5 (67.7)	19 (188.0)	0 -
0 (0.0)	2 (10.8)	4 (23.1)	2 (15.6)	2 (18.7)	6 (68.7)	5 (91.3)	3 (86.9)	11 (316.6)	0 -
2 (9.9)	2 (10.6)	1 (6.4)	1 (8.3)	1 (9.5)	3 (33.0)	0 (0.0)	2 (50.8)	8 (120.6)	0 -
2 (5.1)	2 (5.3)	5 (15.1)	2 (8.0)	3 (14.2)	8 (44.9)	4 (35.5)	3 (40.6)	14 (138.5)	0 -
0 (0.0)	1 (5.4)	4 (23.1)	1 (7.8)	2 (18.7)	6 (68.7)	4 (73.1)	2 (57.9)	8 (230.3)	0 -
2 (9.9)	1 (5.3)	1 (6.4)	1 (8.3)	1 (9.5)	2 (22.0)	0 (0.0)	1 (25.4)	6 (90.4)	0 -

[Table 3] Number and Incidence Rates of (New) TB Cases by Province, Gender and Age, 2025 (continued)

Province		Age Gender	Total	0-4	5-9	10-14	15-19	20-24	25-29	30-34	35-39
Gyeonggi	TB cases	Total	3,732 (27.3)	1 (0.3)	0 (0.0)	3 (0.5)	15 (2.3)	49 (7.1)	98 (10.9)	125 (12.6)	134 (14.7)
		Male	2,423 (35.4)	1 (0.5)	0 (0.0)	1 (0.3)	7 (2.1)	28 (7.8)	56 (11.8)	74 (14.0)	87 (18.4)
		Female	1,309 (19.3)	0 (0.0)	0 (0.0)	2 (0.6)	8 (2.5)	21 (6.3)	42 (9.9)	51 (10.9)	47 (10.6)
	New Cases	Total	3,001 (22.0)	1 (0.3)	0 (0.0)	3 (0.5)	12 (1.8)	44 (6.4)	84 (9.3)	100 (10.0)	114 (12.5)
		Male	1,894 (27.6)	1 (0.5)	0 (0.0)	1 (0.3)	5 (1.5)	25 (7.0)	47 (9.9)	60 (11.4)	75 (15.9)
		Female	1,107 (16.3)	0 (0.0)	0 (0.0)	2 (0.6)	7 (2.2)	19 (5.7)	37 (8.7)	40 (8.5)	39 (8.8)
Gangwon	TB cases	Total	703 (46.6)	0 (0.0)	0 (0.0)	0 (0.0)	1 (1.6)	3 (4.2)	7 (8.7)	6 (7.3)	6 (8.0)
		Male	423 (55.8)	0 (0.0)	0 (0.0)	0 (0.0)	1 (3.0)	1 (2.5)	2 (4.4)	2 (4.4)	2 (5.0)
		Female	280 (37.3)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	2 (6.3)	5 (14.2)	4 (10.6)	4 (11.2)
	New Cases	Total	564 (37.4)	0 (0.0)	0 (0.0)	0 (0.0)	1 (1.6)	2 (2.8)	7 (8.7)	6 (7.3)	5 (6.6)
		Male	320 (42.2)	0 (0.0)	0 (0.0)	0 (0.0)	1 (3.0)	1 (2.5)	2 (4.4)	2 (4.4)	1 (2.5)
		Female	244 (32.5)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	1 (3.2)	5 (14.2)	4 (10.6)	4 (11.2)
Chungbuk	TB cases	Total	578 (36.4)	0 (0.0)	0 (0.0)	0 (0.0)	2 (2.8)	7 (9.2)	16 (17.0)	16 (15.8)	6 (6.7)
		Male	353 (43.6)	0 (0.0)	0 (0.0)	0 (0.0)	2 (5.4)	5 (12.1)	9 (17.1)	8 (14.0)	4 (8.3)
		Female	225 (28.8)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	2 (5.8)	7 (16.9)	8 (18.2)	2 (4.8)
	New Cases	Total	471 (29.6)	0 (0.0)	0 (0.0)	0 (0.0)	2 (2.8)	7 (9.2)	14 (14.9)	13 (12.9)	6 (6.7)
		Male	281 (34.7)	0 (0.0)	0 (0.0)	0 (0.0)	2 (5.4)	5 (12.1)	7 (13.3)	6 (10.5)	4 (8.3)
		Female	190 (24.3)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	2 (5.8)	7 (16.9)	7 (15.9)	2 (4.8)

Unit: cases (cases per 100,000 population)

40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80+	Unknown
149 (13.6)	172 (15.8)	250 (20.8)	290 (25.5)	353 (33.6)	422 (48.2)	327 (59.4)	369 (94.0)	975 (186.8)	0 -
94 (16.8)	115 (20.7)	175 (28.8)	216 (38.0)	259 (49.0)	306 (70.7)	238 (90.9)	246 (139.0)	520 (274.6)	0 -
55 (10.3)	57 (10.6)	75 (12.6)	74 (13.0)	94 (18.0)	116 (26.2)	89 (30.9)	123 (57.1)	455 (136.8)	0 -
126 (11.5)	138 (12.6)	196 (16.3)	222 (19.5)	284 (27.0)	323 (36.9)	260 (47.3)	293 (74.7)	801 (153.5)	0 -
84 (15.0)	93 (16.8)	137 (22.6)	160 (28.2)	207 (39.2)	228 (52.7)	181 (69.1)	183 (103.4)	407 (214.9)	0 -
42 (7.9)	45 (8.4)	59 (9.9)	62 (10.9)	77 (14.7)	95 (21.4)	79 (27.4)	110 (51.1)	394 (118.5)	0 -
13 (13.7)	19 (18.6)	26 (20.9)	50 (37.6)	53 (37.6)	83 (60.2)	92 (101.4)	86 (135.1)	258 (254.0)	0 -
5 (10.4)	9 (17.4)	17 (26.4)	38 (55.7)	41 (57.7)	65 (94.6)	65 (148.4)	50 (173.8)	125 (352.5)	0 -
8 (17.3)	10 (19.9)	9 (14.9)	12 (18.5)	12 (17.2)	18 (26.0)	27 (57.5)	36 (103.2)	133 (201.1)	0 -
10 (10.6)	18 (17.6)	15 (12.0)	42 (31.6)	44 (31.2)	58 (42.1)	74 (81.5)	73 (114.7)	209 (205.7)	0 -
3 (6.2)	9 (17.4)	10 (15.5)	31 (45.4)	34 (47.9)	43 (62.6)	49 (111.9)	42 (146.0)	92 (259.4)	0 -
7 (15.1)	9 (17.9)	5 (8.3)	11 (17.0)	10 (14.3)	15 (21.7)	25 (53.2)	31 (88.8)	117 (176.9)	0 -
13 (11.9)	16 (14.1)	28 (21.3)	50 (35.8)	51 (36.8)	64 (50.2)	50 (59.4)	68 (118.7)	191 (214.0)	0 -
7 (12.3)	10 (17.0)	18 (26.5)	40 (56.1)	37 (52.0)	45 (70.4)	39 (95.8)	46 (174.9)	83 (273.8)	0 -
6 (11.5)	6 (11.0)	10 (15.8)	10 (14.6)	14 (20.7)	19 (29.9)	11 (25.3)	22 (71.0)	108 (183.3)	0 -
10 (9.2)	12 (10.6)	19 (14.5)	39 (27.9)	43 (31.0)	50 (39.3)	35 (41.6)	57 (99.5)	164 (183.8)	0 -
7 (12.3)	8 (13.6)	12 (17.7)	33 (46.3)	31 (43.6)	33 (51.7)	27 (66.3)	38 (144.4)	68 (224.3)	0 -
3 (5.7)	4 (7.3)	7 (11.0)	6 (8.8)	12 (17.7)	17 (26.8)	8 (18.4)	19 (61.4)	96 (162.9)	0 -

[Table 3] Number and Incidence Rates of (New) TB Cases by Province, Gender and Age, 2025 (continued)

Province		Age Gender	Total	0-4	5-9	10-14	15-19	20-24	25-29	30-34	35-39
Chung nam	TB cases	Total	919 (43.1)	0 (0.0)	0 (0.0)	1 (1.0)	3 (3.0)	18 (18.0)	22 (19.0)	19 (15.0)	18 (14.4)
		Male	601 (55.0)	0 (0.0)	0 (0.0)	1 (1.9)	3 (5.7)	7 (13.0)	15 (22.9)	11 (15.6)	13 (19.4)
		Female	318 (30.6)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	11 (24.0)	7 (13.9)	8 (14.2)	5 (8.7)
	New Cases	Total	745 (35.0)	0 (0.0)	0 (0.0)	1 (1.0)	2 (2.0)	17 (17.0)	20 (17.2)	17 (13.4)	16 (12.8)
		Male	478 (43.8)	0 (0.0)	0 (0.0)	1 (1.9)	2 (3.8)	7 (13.0)	14 (21.4)	9 (12.7)	12 (17.9)
		Female	267 (25.7)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	10 (21.8)	6 (11.9)	8 (14.2)	4 (7.0)
Jeon buk	TB cases	Total	741 (42.9)	1 (2.8)	0 (0.0)	0 (0.0)	0 (0.0)	8 (9.4)	14 (15.3)	6 (6.6)	9 (11.0)
		Male	462 (53.7)	1 (5.4)	0 (0.0)	0 (0.0)	0 (0.0)	4 (8.7)	8 (16.1)	5 (10.4)	4 (9.5)
		Female	279 (32.2)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	4 (10.3)	6 (14.4)	1 (2.4)	5 (12.6)
	New Cases	Total	603 (34.9)	1 (2.8)	0 (0.0)	0 (0.0)	0 (0.0)	8 (9.4)	11 (12.0)	5 (5.5)	6 (7.3)
		Male	359 (41.8)	1 (5.4)	0 (0.0)	0 (0.0)	0 (0.0)	4 (8.7)	7 (14.1)	4 (8.3)	2 (4.7)
		Female	244 (28.1)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	4 (10.3)	4 (9.6)	1 (2.4)	4 (10.1)
Jeon nam	TB cases	Total	957 (53.8)	1 (2.4)	1 (1.7)	1 (1.3)	1 (1.3)	8 (10.5)	11 (12.6)	13 (14.8)	11 (13.5)
		Male	543 (60.5)	0 (0.0)	1 (3.4)	0 (0.0)	0 (0.0)	3 (7.0)	8 (16.4)	6 (12.6)	8 (18.9)
		Female	414 (46.9)	1 (4.9)	0 (0.0)	1 (2.6)	1 (2.6)	5 (14.8)	3 (7.8)	7 (17.3)	3 (7.7)
	New Cases	Total	770 (43.3)	1 (2.4)	1 (1.7)	1 (1.3)	1 (1.3)	6 (7.8)	10 (11.4)	12 (13.6)	11 (13.5)
		Male	423 (47.1)	0 (0.0)	1 (3.4)	0 (0.0)	0 (0.0)	3 (7.0)	8 (16.4)	6 (12.6)	8 (18.9)
		Female	347 (39.3)	1 (4.9)	0 (0.0)	1 (2.6)	1 (2.6)	3 (8.9)	2 (5.2)	6 (14.8)	3 (7.7)

Unit: cases (cases per 100,000 population)

40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80+	Unknown
32 (20.5)	27 (17.0)	50 (28.3)	61 (34.9)	73 (41.2)	94 (59.0)	75 (67.2)	120 (142.7)	306 (231.5)	0 -
20 (24.1)	20 (23.7)	36 (38.2)	46 (50.0)	60 (65.2)	70 (87.4)	50 (92.8)	85 (216.7)	164 (363.4)	0 -
12 (16.4)	7 (9.4)	14 (17.0)	15 (18.1)	13 (15.3)	24 (30.3)	25 (43.3)	35 (78.1)	142 (163.1)	0 -
28 (18.0)	23 (14.5)	39 (22.1)	49 (28.1)	50 (28.2)	74 (46.4)	53 (47.5)	97 (115.4)	259 (195.9)	0 -
17 (20.5)	16 (19.0)	31 (32.9)	36 (39.1)	38 (41.3)	53 (66.2)	36 (66.8)	68 (173.3)	138 (305.8)	0 -
11 (15.1)	7 (9.4)	8 (9.7)	13 (15.7)	12 (14.1)	21 (26.5)	17 (29.5)	29 (64.7)	121 (139.0)	0 -
18 (16.6)	14 (11.6)	30 (20.2)	38 (25.3)	54 (36.1)	77 (55.2)	87 (85.1)	105 (126.2)	280 (227.0)	0 -
11 (19.9)	6 (9.7)	23 (29.9)	32 (41.1)	42 (55.2)	53 (76.8)	62 (127.3)	78 (209.3)	133 (325.2)	0 -
7 (13.1)	8 (13.5)	7 (9.8)	6 (8.3)	12 (16.3)	24 (34.0)	25 (46.7)	27 (58.8)	147 (178.3)	0 -
17 (15.7)	11 (9.1)	24 (16.2)	35 (23.3)	41 (27.4)	60 (43.0)	69 (67.5)	81 (97.4)	234 (189.7)	0 -
11 (19.9)	6 (9.7)	18 (23.4)	29 (37.2)	31 (40.7)	38 (55.1)	46 (94.5)	58 (155.7)	104 (254.3)	0 -
6 (11.3)	5 (8.5)	6 (8.4)	6 (8.3)	10 (13.6)	22 (31.2)	23 (43.0)	23 (50.1)	130 (157.7)	0 -
12 (11.0)	20 (16.7)	34 (23.3)	52 (32.7)	68 (41.8)	77 (51.0)	90 (82.6)	120 (131.6)	437 (302.1)	0 -
11 (19.1)	11 (17.4)	25 (31.9)	41 (47.9)	50 (58.6)	62 (80.8)	63 (119.6)	78 (190.2)	176 (387.3)	0 -
1 (1.9)	9 (16.0)	9 (13.4)	11 (15.0)	18 (23.3)	15 (20.2)	27 (48.0)	42 (83.7)	261 (263.0)	0 -
10 (9.1)	18 (15.0)	28 (19.2)	43 (27.1)	54 (33.2)	59 (39.1)	65 (59.7)	95 (104.2)	355 (245.4)	0 -
9 (15.6)	10 (15.8)	20 (25.5)	34 (39.7)	40 (46.9)	46 (59.9)	43 (81.6)	59 (143.8)	136 (299.3)	0 -
1 (1.9)	8 (14.2)	8 (11.9)	9 (12.3)	14 (18.1)	13 (17.5)	22 (39.1)	36 (71.8)	219 (220.7)	0 -

[Table 3] Number and Incidence Rates of (New) TB Cases by Province, Gender and Age, 2025 (continued)

Province		Age Gender	Total	0-4	5-9	10-14	15-19	20-24	25-29	30-34	35-39
Gyeongbuk	TB cases	Total	1,289 (51.3)	0 (0.0)	0 (0.0)	1 (0.9)	6 (5.5)	11 (10.3)	16 (13.2)	23 (17.9)	12 (9.6)
		Male	729 (57.4)	0 (0.0)	0 (0.0)	1 (1.8)	5 (8.8)	6 (9.9)	9 (12.9)	18 (25.0)	8 (11.9)
		Female	560 (45.1)	0 (0.0)	0 (0.0)	0 (0.0)	1 (2.0)	5 (10.8)	7 (13.7)	5 (8.8)	4 (7.0)
	New Cases	Total	1,065 (42.4)	0 (0.0)	0 (0.0)	1 (0.9)	6 (5.5)	10 (9.4)	15 (12.4)	18 (14.0)	10 (8.0)
		Male	584 (46.0)	0 (0.0)	0 (0.0)	1 (1.8)	5 (8.8)	6 (9.9)	8 (11.5)	14 (19.5)	7 (10.4)
		Female	481 (38.7)	0 (0.0)	0 (0.0)	0 (0.0)	1 (2.0)	4 (8.7)	7 (13.7)	4 (7.1)	3 (5.2)
Gyeongnam	TB cases	Total	1,076 (33.5)	0 (0.0)	0 (0.0)	2 (1.3)	3 (1.9)	19 (13.7)	27 (17.0)	21 (12.1)	23 (13.5)
		Male	654 (40.5)	0 (0.0)	0 (0.0)	1 (1.2)	2 (2.5)	14 (17.8)	18 (20.2)	16 (17.0)	15 (16.8)
		Female	422 (26.5)	0 (0.0)	0 (0.0)	1 (1.3)	1 (1.3)	5 (8.4)	9 (13.0)	5 (6.3)	8 (9.9)
	New Cases	Total	873 (27.2)	0 (0.0)	0 (0.0)	2 (1.3)	2 (1.3)	18 (13.0)	25 (15.8)	20 (11.6)	19 (11.2)
		Male	501 (31.0)	0 (0.0)	0 (0.0)	1 (1.2)	1 (1.2)	13 (16.6)	16 (18.0)	15 (16.0)	11 (12.3)
		Female	372 (23.4)	0 (0.0)	0 (0.0)	1 (1.3)	1 (1.3)	5 (8.4)	9 (13.0)	5 (6.3)	8 (9.9)
Jeju	TB cases	Total	221 (33.3)	0 (0.0)	0 (0.0)	1 (2.8)	2 (5.9)	5 (15.9)	5 (13.8)	5 (12.5)	6 (16.3)
		Male	141 (42.5)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	3 (17.5)	2 (10.5)	3 (14.5)	2 (10.9)
		Female	80 (24.1)	0 (0.0)	0 (0.0)	1 (5.7)	2 (12.2)	2 (14.0)	3 (17.4)	2 (10.3)	4 (21.7)
	New Cases	Total	169 (25.5)	0 (0.0)	0 (0.0)	1 (2.8)	2 (5.9)	5 (15.9)	3 (8.3)	4 (10.0)	6 (16.3)
		Male	105 (31.7)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	3 (17.5)	2 (10.5)	2 (9.6)	2 (10.9)
		Female	64 (19.3)	0 (0.0)	0 (0.0)	1 (5.7)	2 (12.2)	2 (14.0)	1 (5.8)	2 (10.3)	4 (21.7)

Unit: cases (cases per 100,000 population)

40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80+	Unknown
22 (13.5)	24 (13.8)	30 (14.3)	68 (30.0)	111 (47.0)	133 (59.8)	145 (89.8)	186 (163.9)	501 (285.7)	0 -
10 (11.8)	16 (17.6)	19 (17.5)	53 (45.3)	90 (74.4)	97 (87.4)	93 (120.7)	105 (201.8)	199 (351.2)	0 -
12 (15.4)	8 (9.6)	11 (11.0)	15 (13.7)	21 (18.2)	36 (32.3)	52 (61.6)	81 (131.8)	302 (254.4)	0 -
20 (12.3)	20 (11.5)	28 (13.4)	55 (24.3)	92 (39.0)	111 (49.9)	110 (68.1)	153 (134.8)	416 (237.2)	0 -
9 (10.6)	13 (14.3)	19 (17.5)	44 (37.6)	72 (59.5)	80 (72.1)	66 (85.6)	83 (159.5)	157 (277.1)	0 -
11 (14.1)	7 (8.4)	9 (9.0)	11 (10.0)	20 (17.4)	31 (27.8)	44 (52.2)	70 (113.9)	259 (218.2)	0 -
32 (13.8)	47 (19.0)	57 (20.0)	75 (25.6)	109 (38.3)	107 (41.5)	131 (74.8)	124 (101.8)	299 (177.4)	0 -
17 (14.2)	31 (24.4)	40 (27.3)	58 (38.9)	78 (54.3)	74 (57.9)	88 (104.8)	71 (129.2)	131 (244.4)	0 -
15 (13.3)	16 (13.3)	17 (12.2)	17 (11.8)	31 (22.0)	33 (25.4)	43 (47.1)	53 (79.3)	168 (146.1)	0 -
27 (11.6)	37 (14.9)	43 (15.1)	56 (19.1)	83 (29.1)	84 (32.6)	104 (59.4)	96 (78.8)	257 (152.4)	0 -
15 (12.5)	24 (18.9)	30 (20.5)	41 (27.5)	60 (41.7)	53 (41.4)	64 (76.2)	53 (96.4)	104 (194.0)	0 -
12 (10.6)	13 (10.8)	13 (9.3)	15 (10.4)	23 (16.3)	31 (23.9)	40 (43.8)	43 (64.3)	153 (133.1)	0 -
11 (21.7)	13 (24.8)	24 (39.6)	26 (45.2)	25 (47.7)	18 (40.5)	19 (66.2)	15 (66.1)	46 (137.4)	0 -
7 (27.7)	11 (41.2)	17 (54.4)	18 (60.4)	21 (78.6)	13 (59.1)	16 (117.8)	9 (88.3)	19 (168.1)	0 -
4 (15.7)	2 (7.8)	7 (23.8)	8 (28.9)	4 (15.5)	5 (22.2)	3 (19.8)	6 (48.0)	27 (121.7)	0 -
6 (11.8)	9 (17.2)	19 (31.3)	21 (36.5)	19 (36.2)	15 (33.7)	14 (48.8)	9 (39.7)	36 (107.5)	0 -
2 (7.9)	9 (33.7)	14 (44.8)	14 (47.0)	16 (59.9)	10 (45.4)	12 (88.3)	5 (49.1)	14 (123.8)	0 -
4 (15.7)	0 (0.0)	5 (17.0)	7 (25.3)	3 (11.7)	5 (22.2)	2 (13.2)	4 (32.0)	22 (99.2)	0 -

[Table 4] Number of (New) TB Cases by District, 2025

Province	District	TB Cases	New Cases	Province	District	TB Cases	New Cases
Nationwide	Total	17,070	13,713				
Seoul	Sub-total	2,853	2,213	Busan	Buk-gu	79	57
	Gangnam-gu	97	84		Sasang-gu	82	61
	Gangdong-gu	140	115		Saha-gu	93	69
	Gangbuk-gu	124	92		Seo-gu	31	22
	Gangseo-gu	185	150		Suyeong-gu	58	48
	Gwanak-gu	170	121		Yeonje-gu	77	67
	Gwangjin-gu	93	73		Yeongdo-gu	40	34
	Guro-gu	155	122		Jung-gu	17	16
	Geumcheon-gu	110	91		Haeundae-gu	102	78
	Nowon-gu	155	120	Daegu	Sub-total	811	693
	Dobong-gu	115	94		Gunwi-gun	65	52
	Dongdaemun-gu	141	110		Nam-gu	179	160
	Dongjak-gu	99	74		Dalseo-gu	96	83
	Mapo-gu	73	57		Dalseong-gun	125	109
	Seodaemun-gu	70	58		Dong-gu	118	104
	Seocho-gu	66	51		Buk-gu	82	72
	Seongdong-gu	51	37		Seo-gu	89	67
	Seongbuk-gu	129	98		Suseong-gu	28	23
	Songpa-gu	131	102		Jung-gu	29	23
Incheon	Yangcheon-gu	136	107	Incheon	Sub-total	928	754
	Yeongdeungpo-gu	141	110		Ganghwa-gun	34	28
	Yongsan-gu	54	31		Gyeyang-gu	92	77
	Eunpyeong-gu	125	100		Namdong-gu	131	106
	Jongno-gu	66	47		Dong-gu	16	11
	Jung-gu	57	43		Michuhol-gu	126	104
	Jungnang-gu	170	126		Bupyeong-gu	192	151
					Seo-gu	194	158
					Yeonsu-gu	74	58
					Ongjin-gun	15	11
Busan	Sub-total	1,087	860	Gwangju	Jung-gu	54	50
	Gangseo-gu	31	21		Sub-total	368	300
	Geungjeong-gu	69	57		Gwangsan-gu	85	70
	Gijang-gun	51	36		Nam-gu	62	55
	Nam-gu	95	82		Dong-gu	37	29
	Dong-gu	36	26		Buk-gu	125	99
	Dongnae-gu	87	74				
	Busanjin-gu	139	112				

단위 : 명

Province	District	TB Cases	New Cases	Province	District	TB Cases	New Cases
Gwangju	Seo-gu	59	47	Gyeonggi	Suwonsi Yeongtonggu	65	53
Daejeon	Sub-total	384	293		Suwonsi Jangangu	77	61
	Daedeok-gu	59	41		Suwonsi Paldalgu	75	57
	Dong-gu	78	66		Siheung-si	210	166
	Seo-gu	108	81		Ansansi Danwongu	271	218
	Yuseong-gu	73	55		Ansansi Sangnokgu	143	118
	Jung-gu	66	50		Anseong-si	128	100
Ulsan	Sub-total	362	291		Anyang-si Dongangu	61	46
	Nam-gu	98	78		Anyang-si Manangu	141	115
	Dong-gu	38	28		Yangju-si	59	51
	Buk-gu	67	56		Yangpyeonggun	82	64
	Ulju-gun	80	67		Yeoju-si	78	62
	Jung-gu	79	62		Yeoncheongun	52	37
Sejong	Sejong-city	61	48		Osansi	48	39
Gyeonggi	Sub-total	3,732	3,001		Yonginsu Giheunggu	26	23
	Gapyeong-gun	29	26		Yonginsu Sujigu	61	53
	Goyang-si	231	193		Yonginsu Cheoin-gu	196	147
	Deokyang-gu,	111	98		Uiwang-si	73	51
	Ilсандong-gu,	62	46		Uijeongbu-si	48	34
	Ilсанseo-gu,	58	49		Icheon-si	75	62
	Gwacheon-si	16	14		Paju-si	35	29
	Gwangmyeong-si	91	67		Pyeongtaek-si	170	135
	Gwangju-si	97	83		Pocheon-si	64	54
	Guri-si	47	35		Hanamsi	137	111
	Gunpo-si	56	47		Hwaseong-si	152	112
	Gimpo-si	126	104		Pocheon-si	67	62
	Namyangju-si	164	136		Hanamsi	59	50
	Dongducheon-si	29	27		Hwaseong-si	222	171
	Bucheon-si	250	204	Gangwon	Sub-total	703	564
	Seongnam-si	237	184		Gangneung-si	107	95
	Bundang-gu,	71	53		Goseonggun	16	12
	Sujeong-gu,	86	67		Donghaesi	49	42
	Jungwon-gu,	80	64		Samcheoksi	58	40
	Sumwon-si	309	251		Sokchosi	32	19
	Kwonseon-gu, Sumwon-si	92	80		Yanggugun	6	2

[Table 4] Number of (New) TB Cases by District, 2025 (continued)

Province	District	TB Cases	New Cases	Province	District	TB Cases	New Cases
Gangwon	Yanggugun	12	10	Chungnam	Buyeogun	38	33
	Yeongwolgun	32	25		Seosansi	94	74
	Wonjusi	104	87		Seocheongun	25	22
	Injegun	17	14		Asansi	122	99
	Jeongseongun	27	19		Yesangun	46	40
	Cheorwongun	16	14		Cheonansi	200	161
	Chuncheonsi	84	68		Cheonansi Dongnamgu	96	79
	Taebaeksi	36	31		Cheonansi Seobukgu	104	82
	Pyeongchanggun	34	28		Cheongyanggun	18	13
	Hongcheongun	36	27		Taeangun	38	33
	Hwacheongun	8	7		Hongseonggun	45	32
	Hoengseonggun	29	24		Sub-total	741	603
Chungbuk	Sub-total	578	471	Jeonbuk	Gochanggun	42	37
	Goesangun	32	27		Gunsansi	81	65
	Danyanggun	21	19		Gimjesi	60	51
	Boeungun	29	27		Namwonsi	25	18
	Yeongdonggun	33	26		Mujugun	23	20
	Okcheongun	25	21		Buangun	43	39
	Eumseonggun	46	36		Sunchanggun	23	18
	Jecheonsi	67	53		Wanjugun	56	50
	Jeungpyeonggun	16	14		Iksansi	92	73
	Jincheongun	36	28		Imsilgun	18	12
	Cheongjusi	205	167		Jangsugun	12	8
	Cheongjusi Sangdanggu	53	41		Jeonjusi	174	143
	Cheongjusi Seowongu	57	43		Jeonjusi Deogjingu	84	72
	Cheongjusi Cheongwongu	42	34		Jeonjusi Wansangu	90	71
	Cheongjusi Hwangdeokgu	53	49		Jeongeupsi	81	60
	Chungjusi	68	53		Jinangun	11	9
Chungnam	Sub-total	919	745	Jeonnam	Sub-total	957	770
	Gyeryongsi	4	4		Gangjingun	32	27
	Gongjusi	47	39		Goheunggun	41	30
	Geumsangun	29	24		Gokseonggun	20	16
	Nonsansi	66	54		Gwangyangsi	40	33
	Dangjinnsi	79	63		Guryegun	19	17
	Boryeongsi	68	54		Najusi	59	49

Unit: cases

Province	District	TB Cases	New Cases	Province	District	TB Cases	New Cases
Jeonnam	Damyanggun	23	18	Gyeongbuk	Cheongdogun	29	21
	Mokposi	97	83		Cheongsonggun	40	33
	Muangun	68	46		Chilgokgun	50	43
	Boseonggun	21	15		Pohangsi	226	177
	Suncheonsi	68	58		Pohangsi Namgu	96	71
	Sinangun	45	38		Pohangsi Bukgu	130	106
	Yeosusi	110	82		Sub-total	1,076	873
	Yeonggwanggun	28	23	Gyeongnam	Geojesi	57	44
	Yeongamgun	35	31		Geochanggun	25	18
	Wandogun	46	40		Goseonggun	30	20
	Jangseonggun	17	14		Gimhaesi	146	109
	Jangheunggun	24	16		Namhaegun	14	14
	Jindogun	24	16		Miryangsi	56	48
	Hampyeonggun	29	23		Sacheonsi	38	36
	Haenamgun	69	60		Sancheonggun	19	14
	Hwasungun	42	35		Yangsansi	92	73
Gyeongbuk	Sub-total	1,289	1,065		Uiryeonggun	19	15
	Gyeongsansi	95	83		Jinjusi	125	111
	Gyeongjusi	126	106		Changnyeonggun	35	27
	Goryeonggun	26	21		Changwonsi	286	231
	Gumisi	106	83		Changwonsi MasanHappogu	69	60
	Gimcheonsi	57	46		Changwonsi MasanHoewongu	75	56
	Mungyeongsi	35	32		Changwonsi Seongsangu	44	28
	Bonghwagun	18	17		Changwonsi Uichanggu	57	48
	Sangjusi	64	55		Changwonsi Jinhaegu	41	39
	Seongjugun	18	16		Tongyeongsi	40	31
	Andongsi	93	79		Hadonggun	20	18
	Yeongdeokgun	38	26		Hamangun	27	23
	Yeongyanggun	17	13		Hamyanggun	17	14
	Yeongjusi	40	37		Hapcheongun	30	27
	Yeongcheonsi	85	73	Jeju	Sub-total	221	169
	Yecheongun	35	31		Seogwiposi	62	42
	Ulleunggun	3	3		Jejusi	159	127
	Uljinun	30	22				
	Uiseonggun	58	48				

[Table 5] Number of (New) TB Cases by Medical Security and Treatment History, 2025

Unit: cases

Health security	TB Cases	Treatment history							
		New Cases	Previously treated patients					Unknown previous treatment history	Other
			Sub-total	Relapse	Treatment after failure	Treatment after loss to follow-up	Other previously treated		
Total cases	17,070	13,713	2,327	1,881	32	154	260	420	610
Health Security	16,868	13,534	2,312	1,870	32	153	257	415	607
NHI ¹⁾	14,858	12,102	1,906	1,532	27	113	234	357	493
I.W. ¹⁾	8,186	6,757	978	799	7	51	121	187	264
S.E. ¹⁾	6,672	5,345	928	733	20	62	113	170	229
Medical Aid	2,010	1,432	406	338	5	40	23	58	114
Unknown ²⁾	202	179	15	11	0	1	3	5	3

1) NHI (National Health Insurance); I.W. (industrial workers); S.E. (self-employees)

2) In cases where there is no history of medical coverage eligibility before December 31, 2024:

- This refers to the status of medical coverage eligibility as of December 31, 2024. If eligibility was lost due to reasons such as death, disappearance, loss of nationality, registration as having an unknown residence, or immigration, classification is based on the date of the final loss of eligibility.

[Table 6] Number of (New) TB Cases by Province and Medical Security, 2025


Unit: cases

Province		Total	Medical Security					Unknown ²⁾
			Sub-total	NHI ¹⁾			Medical Aid	
				Sub-total	I.W. ¹⁾	S.E. ¹⁾		
Nationwide	Total Cases	17,070	16,868	14,858	8,186	6,672	2,010	202
	New Cases	13,713	13,534	12,102	6,757	5,345	1,432	179
Seoul	Total Cases	2,853	2,828	2,423	1,353	1,070	405	25
	New Cases	2,213	2,192	1,921	1,100	821	271	21
Busan	Total Cases	1,087	1,078	934	552	382	144	9
	New Cases	860	851	753	459	294	98	9
Daegu	Total Cases	811	801	675	387	288	126	10
	New Cases	693	684	583	341	242	101	9
Incheon	Total Cases	928	918	796	428	368	122	10
	New Cases	754	745	650	356	294	95	9
Gwangju	Total Cases	368	361	307	171	136	54	7
	New Cases	300	293	259	147	112	34	7
Daejeon	Total Cases	384	375	332	177	155	43	9
	New Cases	293	286	261	142	119	25	7
Ulsan	Total Cases	362	360	328	201	127	32	2
	New Cases	291	289	266	157	109	23	2
Sejong	Total Cases	61	59	52	31	21	7	2
	New Cases	48	46	42	25	17	4	2
Gyeonggi	Total Cases	3,732	3,687	3,334	1,825	1,509	353	45
	New Cases	3,001	2,963	2,704	1,486	1,218	259	38
Gangwon	Total Cases	703	701	611	318	293	90	2
	New Cases	564	562	494	261	233	68	2
Chungbuk	Total Cases	578	567	491	259	232	76	11
	New Cases	471	460	406	218	188	54	11
Chungnam	Total Cases	919	903	802	441	361	101	16
	New Cases	745	731	657	362	295	74	14
Jeonbuk	Total Cases	741	736	654	378	276	82	5
	New Cases	603	600	542	323	219	58	3
Jeonnam	Total Cases	957	944	851	440	411	93	13
	New Cases	770	759	688	366	322	71	11
Gyeongbuk	Total Cases	1,289	1,279	1,141	605	536	138	10
	New Cases	1,065	1,055	957	508	449	98	10
Gyeongnam	Total Cases	1,076	1,056	939	522	417	117	20
	New Cases	873	855	777	430	347	78	18
Jeju	Total Cases	221	215	188	98	90	27	6
	New Cases	169	163	142	76	66	21	6


1) NHI (National Health Insurance); I.W. (industrial workers); S.E. (self-employees)

2) In cases where there is no history of medical coverage eligibility before December 31, 2024:


- This refers to the status of medical coverage eligibility as of December 31, 2024. If eligibility was lost due to reasons such as death, disappearance, loss of nationality, registration as having an unknown residence, or immigration, classification is based on the date of the final loss of eligibility




[Figure 3] TB Incidence Rates by Province, 2025




[Figure 4] TB Incidence Rates by District, 2025




[Figure 5] New TB Incidence Rates by Province, 2025



[Figure 6] New TB Incidence Rates by District, 2025



[Figure 7] TB Incidence Rates by Gender and Age, 2025



[Figure 8] (Age-standardized) TB Incidence Rates by Province, 2025



Detailed Statistics on (New) Tuberculosis Cases, 2011–2025

[Table 7] Number and Incidence Rates of (New) TB Cases by Gender and Age, 2011–2025

[Table 8] Number and Incidence Rates of (New) TB Cases by Province, 2011–2025

[Table 9] Number and Incidence Rates of (New) TB cases by Site of Disease, 2011–2025

[Table 10] Number of (New) TB Cases by Notifying Medical Institution, 2011–2025

[Table 11] Number of Foreign (New) TB cases, 2011–2025

Detailed Statistics on (New) Tuberculosis Cases, 2011–2025

[Table 7] Number and Incidence Rates of (New) TB Cases by Gender and Age, 2011–2025

Category	Year	Age Gender	Total	0–4	5–9	10–14	15–19	20–24	25–29	30–34	35–39
TB Cases	2011	Total	50,491 (100.8)	62 (2.7)	40 (1.7)	320 (10.0)	2,202 (62.1)	2,950 (93.3)	3,751 (104.2)	3,541 (89.6)	3,344 (78.2)
		Male	29,811 (118.9)	31 (2.6)	24 (1.9)	138 (8.3)	1,378 (73.2)	1,508 (90.8)	1,905 (102.8)	1,931 (95.8)	2,007 (92.2)
		Female	20,680 (82.6)	31 (2.8)	16 (1.4)	182 (11.9)	824 (49.6)	1,442 (96.2)	1,846 (105.7)	1,610 (83.2)	1,337 (63.8)
	2012	Total	49,532 (98.4)	64 (2.8)	47 (2.0)	212 (7.0)	1,756 (50.0)	2,764 (85.0)	3,447 (101.7)	3,300 (82.3)	3,052 (74.0)
		Male	29,501 (117.1)	39 (3.3)	24 (2.0)	101 (6.4)	1,111 (59.7)	1,439 (84.0)	1,794 (102.6)	1,789 (87.4)	1,834 (87.5)
		Female	20,031 (79.6)	25 (2.2)	23 (2.0)	111 (7.6)	645 (39.1)	1,325 (86.1)	1,653 (100.7)	1,511 (77.0)	1,218 (60.1)
	2013	Total	45,292 (89.6)	45 (1.9)	26 (1.1)	160 (5.6)	1,382 (40.1)	2,424 (72.4)	2,906 (90.1)	2,984 (73.8)	2,643 (66.5)
		Male	26,960 (106.6)	26 (2.2)	9 (0.7)	75 (5.0)	817 (44.9)	1,309 (73.9)	1,547 (92.8)	1,601 (77.6)	1,558 (77.1)
		Female	18,332 (72.5)	19 (1.7)	17 (1.5)	85 (6.2)	565 (34.7)	1,115 (70.6)	1,359 (87.2)	1,383 (69.9)	1,085 (55.5)
	2014	Total	43,088 (84.9)	41 (1.8)	23 (1.0)	120 (4.4)	1,207 (35.9)	2,288 (66.6)	2,596 (82.4)	2,542 (64.0)	2,348 (60.6)
		Male	25,723 (101.4)	25 (2.1)	12 (1.0)	50 (3.5)	753 (42.6)	1,258 (69.1)	1,334 (81.6)	1,404 (69.2)	1,350 (68.4)
		Female	17,365 (68.4)	16 (1.4)	11 (1.0)	70 (5.4)	454 (28.4)	1,030 (63.9)	1,262 (83.2)	1,138 (58.6)	998 (52.4)
	2015	Total	40,847 (80.2)	26 (1.1)	19 (0.8)	134 (5.2)	1,092 (33.3)	1,919 (54.7)	2,282 (72.9)	2,206 (58.1)	2,146 (55.3)
		Male	24,625 (96.7)	19 (1.6)	13 (1.1)	79 (5.9)	675 (39.3)	1,069 (57.4)	1,208 (74.1)	1,187 (61.1)	1,254 (63.5)
		Female	16,222 (63.6)	7 (0.6)	6 (0.5)	55 (4.5)	417 (26.7)	850 (51.6)	1,074 (71.6)	1,019 (55.0)	892 (46.8)
	2016	Total	39,245 (76.8)	18 (0.8)	13 (0.6)	106 (4.4)	806 (25.3)	1,636 (46.3)	2,047 (64.8)	1,854 (51.5)	1,895 (48.1)
		Male	23,668 (92.7)	8 (0.7)	7 (0.6)	42 (3.4)	499 (30.0)	838 (44.7)	1,080 (65.4)	1,009 (54.7)	1,075 (53.6)
		Female	15,577 (60.9)	10 (0.9)	6 (0.5)	64 (5.5)	307 (20.2)	798 (48.1)	967 (64.1)	845 (48.2)	820 (42.4)

Unit: cases (cases per 100,000 population)

40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80+	Unknown
3,702 (82.4)	3,958 (93.9)	4,471 (108.0)	3,742 (123.3)	3,176 (140.2)	3,453 (183.1)	4,082 (256.6)	3,718 (344.1)	3,979 (410.7)	0 -
2,365 (103.8)	2,687 (124.6)	3,059 (146.7)	2,555 (169.5)	2,134 (192.6)	2,184 (249.3)	2,334 (339.8)	1,898 (463.3)	1,673 (600.3)	0 -
1,337 (60.4)	1,271 (61.7)	1,412 (68.7)	1,187 (77.7)	1,042 (90.0)	1,269 (125.7)	1,748 (193.3)	1,820 (271.3)	2,306 (334.2)	0 -
3,579 (78.4)	3,839 (92.6)	4,420 (103.0)	3,883 (119.6)	3,156 (134.8)	3,224 (171.8)	4,266 (252.1)	4,064 (352.4)	4,410 (425.2)	49
2,295 (99.1)	2,683 (126.5)	3,113 (144.1)	2,711 (167.7)	2,162 (188.7)	2,011 (228.6)	2,459 (333.2)	2,068 (464.4)	1,834 (610.3)	34
1,284 (57.1)	1,156 (57.0)	1,307 (61.4)	1,172 (71.8)	994 (83.2)	1,213 (121.6)	1,807 (189.4)	1,996 (281.9)	2,576 (349.7)	15
3,306 (72.5)	3,489 (83.2)	4,118 (95.0)	3,649 (105.8)	2,926 (120.8)	2,865 (149.2)	3,905 (220.3)	3,776 (308.9)	4,681 (419.5)	7
2,097 (90.4)	2,416 (113.3)	2,867 (131.0)	2,558 (148.6)	1,995 (168.1)	1,871 (206.1)	2,325 (298.4)	1,927 (401.8)	1,958 (598.1)	4
1,209 (54.0)	1,073 (52.0)	1,251 (58.2)	1,091 (63.1)	931 (75.3)	994 (98.2)	1,580 (159.1)	1,849 (249.0)	2,723 (345.4)	3
3,022 (67.0)	3,249 (75.5)	3,873 (89.6)	3,791 (103.1)	2,875 (114.0)	2,749 (136.8)	3,680 (206.2)	3,856 (297.5)	4,828 (400.1)	0 -
1,906 (83.0)	2,240 (102.8)	2,748 (125.8)	2,658 (144.8)	1,982 (160.3)	1,791 (186.9)	2,172 (275.1)	1,963 (380.4)	2,077 (577.3)	0 -
1,116 (50.4)	1,009 (47.5)	1,125 (52.6)	1,133 (61.5)	893 (69.5)	958 (91.2)	1,508 (151.5)	1,893 (242.6)	2,751 (324.8)	0 -
2,626 (59.5)	2,925 (66.9)	3,614 (84.7)	3,664 (94.4)	2,929 (107.9)	2,719 (128.9)	3,416 (192.2)	3,945 (291.4)	5,185 (395.2)	0 -
1,675 (74.6)	2,077 (93.8)	2,636 (122.0)	2,604 (134.4)	2,081 (156.3)	1,779 (176.0)	2,017 (254.7)	2,012 (368.6)	2,240 (562.2)	0 -
951 (43.9)	848 (39.3)	978 (46.4)	1,060 (54.5)	848 (61.3)	940 (85.6)	1,399 (142.0)	1,933 (239.3)	2,945 (322.3)	0 -
2,375 (55.8)	2,874 (64.4)	3,352 (80.3)	3,660 (89.8)	2,964 (100.0)	2,848 (130.3)	3,106 (175.9)	3,875 (275.2)	5,816 (409.1)	0 -
1,555 (71.9)	2,012 (89.2)	2,420 (114.1)	2,681 (131.8)	2,138 (147.1)	1,934 (184.4)	1,860 (234.1)	2,015 (350.5)	2,495 (567.3)	0 -
820 (39.2)	862 (39.1)	932 (45.4)	979 (48.0)	826 (54.6)	914 (80.4)	1,246 (128.3)	1,860 (223.2)	3,321 (338.2)	0 -

[Table 7] Number and Incidence Rates of (New) TB Cases by Gender and Age, 2011–2025 (continued)

Category	Year	Age Gender	Total	0–4	5–9	10–14	15–19	20–24	25–29	30–34	35–39
TB Cases	2017	Total	36,044 (70.4)	16 (0.7)	8 (0.3)	80 (3.4)	667 (22)	1,323 (37.8)	1,676 (51.5)	1,530 (45.1)	1,718 (43)
		Male	21,645 (84.6)	8 (0.7)	5 (0.4)	39 (3.2)	410 (25.9)	691 (37.3)	847 (49.7)	864 (49.6)	971 (47.7)
		Female	14,399 (56.1)	8 (0.8)	3 (0.3)	41 (3.6)	257 (17.7)	632 (38.4)	829 (53.6)	666 (40.4)	747 (38.1)
	2018	Total	33,796 (65.9)	27 (1.3)	8 (0.3)	44 (1.9)	468 (16.3)	1,050 (30.6)	1,411 (42.1)	1,365 (42.3)	1,449 (35.9)
		Male	20,454 (79.9)	13 (1.3)	4 (0.3)	19 (1.6)	288 (19.2)	580 (32.0)	751 (42.6)	736 (44.3)	813 (39.6)
		Female	13,342 (51.9)	14 (1.4)	4 (0.4)	25 (2.2)	180 (13.1)	470 (28.9)	660 (41.6)	629 (40.2)	636 (32.2)
	2019	Total	30,304 (59.0)	18 (0.9)	6 (0.3)	56 (2.4)	361 (13.2)	847 (25.3)	1,225 (35.7)	1,080 (34.3)	1,287 (32.5)
		Male	18,470 (72.1)	10 (1.0)	4 (0.3)	28 (2.4)	217 (15.3)	462 (26.3)	685 (37.8)	594 (36.5)	710 (35.2)
		Female	11,834 (46.0)	8 (0.9)	2 (0.2)	28 (2.5)	144 (11.0)	385 (24.1)	540 (33.3)	486 (31.9)	577 (29.7)
	2020	Total	25,350 (49.4)	9 (0.5)	11 (0.5)	35 (1.5)	248 (9.7)	661 (20.2)	968 (27.6)	925 (29.5)	1,010 (26.7)
		Male	15,400 (60.1)	4 (0.4)	6 (0.5)	16 (1.3)	143 (10.8)	343 (20.1)	531 (28.7)	511 (31.5)	569 (29.4)
		Female	9,950 (38.7)	5 (0.6)	5 (0.4)	19 (1.7)	105 (8.6)	318 (20.4)	437 (26.4)	414 (27.5)	441 (23.8)
	2021	Total	22,904 (44.6)	5 (0.3)	6 (0.3)	26 (1.1)	172 (7.2)	489 (15.4)	781 (22.1)	773 (24.4)	793 (22.1)
		Male	13,893 (54.3)	3 (0.4)	3 (0.3)	14 (1.2)	95 (7.6)	256 (15.5)	419 (22.5)	410 (24.9)	458 (24.9)
		Female	9,011 (35.0)	2 (0.3)	3 (0.3)	12 (1.1)	77 (6.7)	233 (15.3)	362 (21.7)	363 (23.9)	335 (19.1)
	2022	Total	20,383 (39.8)	6 (0.4)	2 (0.1)	19 (0.8)	128 (5.5)	302 (10.0)	546 (15.6)	629 (19.3)	639 (18.9)
		Male	12,520 (49.0)	4 (0.5)	2 (0.2)	14 (1.2)	70 (5.8)	153 (9.7)	287 (15.6)	349 (20.5)	369 (21.3)
		Female	7,863 (30.6)	2 (0.3)	0 (0.0)	5 (0.4)	58 (5.1)	149 (10.3)	259 (15.7)	280 (18.0)	270 (16.4)

Unit: cases (cases per 100,000 population)

40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80+	Unknown
2,033 (49.5)	2,512 (55.4)	2,838 (69.1)	3,523 (83.4)	3,021 (95.1)	2,587 (114.4)	2,847 (161.2)	3,733 (247.8)	5,932 (387.2)	0 -
1,279 (61.4)	1,681 (73.3)	2,025 (97)	2,560 (121.3)	2,156 (138.1)	1,725 (158.7)	1,758 (218.8)	2,042 (327.6)	2,584 (535.3)	0 -
754 (37.3)	831 (37.1)	813 (40.3)	963 (45.6)	865 (53.6)	862 (73.4)	1,089 (113.2)	1,691 (191.5)	3,348 (319.1)	0 -
1,629 (41.1)	2,258 (49.8)	2,628 (63.2)	3,246 (76.0)	2,931 (86.8)	2,501 (106.6)	2,626 (144.7)	3,862 (243.6)	6,293 (382.8)	0 -
986 (49.1)	1,550 (67.4)	1,879 (89.4)	2,379 (111.2)	2,113 (126.9)	1,727 (153.0)	1,653 (198.0)	2,153 (324.8)	2,810 (533.0)	0 -
643 (33.0)	708 (31.7)	749 (36.5)	867 (40.6)	818 (47.8)	774 (63.6)	973 (99.4)	1,709 (185.3)	3,483 (311.9)	0 -
1,368 (35.5)	1,910 (42.6)	2,318 (54.4)	2,871 (67.4)	2,764 (76.7)	2,269 (92.8)	2,431 (127.8)	3,320 (207.1)	6,173 (348.9)	0 -
871 (44.4)	1,323 (58.2)	1,652 (76.9)	2,148 (100.5)	2,045 (115.0)	1,585 (134.6)	1,583 (179.1)	1,828 (270.5)	2,725 (472.1)	0 -
497 (26.2)	587 (26.6)	666 (31.5)	723 (34.1)	719 (39.4)	684 (54.0)	848 (83.3)	1,492 (160.9)	3,448 (289.2)	0 -
1,069 (27.7)	1,572 (35.9)	1,899 (43.8)	2,254 (53.6)	2,387 (62.7)	2,006 (76.1)	2,060 (103.0)	2,734 (170.6)	5,502 (290.2)	0 -
643 (32.8)	1,058 (47.6)	1,370 (62.7)	1,637 (77.4)	1,767 (94.0)	1,401 (110.2)	1,363 (145.9)	1,580 (231.6)	2,458 (391.5)	0 -
426 (22.4)	514 (23.8)	529 (24.6)	617 (29.5)	620 (32.2)	605 (44.4)	697 (65.4)	1,154 (125.4)	3,044 (240.1)	0 -
955 (24.3)	1,280 (30.3)	1,735 (39.2)	1,937 (47.0)	2,282 (57.1)	1,893 (65.7)	2,071 (99.8)	2,438 (152.6)	5,268 (260.4)	0 -
555 (27.8)	848 (39.5)	1,231 (55.2)	1,438 (69.1)	1,679 (85.0)	1,332 (95.8)	1,362 (140.4)	1,415 (205.5)	2,375 (349.6)	0 -
400 (20.7)	432 (20.7)	504 (23.0)	499 (24.5)	603 (29.8)	561 (37.6)	709 (64.2)	1,023 (112.5)	2,893 (215.3)	0 -
803 (20.2)	999 (24.5)	1,432 (31.9)	1,594 (39.3)	1,986 (47.9)	1,866 (60.4)	1,927 (89.7)	2,271 (141.6)	5,234 (241.1)	0 -
476 (23.5)	647 (31.3)	1,017 (44.9)	1,218 (59.4)	1,481 (72.2)	1,339 (89.6)	1,304 (129.6)	1,363 (194.6)	2,427 (327.4)	0 -
327 (16.7)	352 (17.5)	415 (18.6)	376 (18.8)	505 (24.1)	527 (33.1)	623 (54.6)	908 (100.4)	2,807 (196.4)	0 -

[Table 7] Number and Incidence Rates of (New) TB Cases by Gender and Age, 2011–2025 (continued)

Category	Year	Age Gender	Total	0–4	5–9	10–14	15–19	20–24	25–29	30–34	35–39
TB Cases	2023	Total	19,540 (23.6)	1 (0.0)	4 (0.1)	15 (0.3)	96 (2.1)	247 (4.4)	502 (7.7)	508 (8.6)	563 (10.1)
		Male	12,078 (29.3)	0 (0.1)	3 (0.1)	7 (0.7)	50 (3.8)	127 (8.1)	265 (13.2)	289 (12.5)	326 (14.3)
		Female	7,462 (76.1)	1 (0.1)	1 (0.4)	8 (1.3)	46 (8.5)	120 (18.0)	237 (30.8)	219 (31.9)	237 (35.9)
	2024	Total	17,944 (35.2)	4 (0.3)	6 (0.3)	18 (0.8)	104 (4.5)	229 (8.4)	402 (12.0)	475 (13.9)	474 (15.1)
		Male	11,210 (44.1)	1 (0.1)	5 (0.5)	8 (0.7)	57 (4.8)	120 (8.5)	214 (12.2)	278 (15.4)	280 (17.3)
		Female	6,734 (26.3)	3 (0.5)	1 (0.1)	10 (0.9)	47 (4.2)	109 (8.4)	188 (11.8)	197 (12.1)	194 (12.7)
	2025	Total	17,070 (33.5)	6 (0.5)	1 (0.1)	13 (0.6)	73 (3.2)	243 (9.6)	361 (11.1)	385 (11.0)	414 (13.3)
		Male	10,787 (42.6)	4 (0.6)	1 (0.1)	5 (0.4)	39 (3.3)	126 (9.6)	200 (11.8)	229 (12.4)	242 (15.0)
		Female	6,283 (24.5)	2 (0.3)	0 (0.0)	8 (0.7)	34 (3.0)	117 (9.6)	161 (10.3)	156 (9.4)	172 (11.4)

Unit: cases (cases per 100,000 population)

40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80+	미상
726 (11.1)	868 (14.9)	1,242 (19.1)	1,483 (27.0)	1,976 (35.2)	1,940 (43.2)	1,877 (57.1)	2,077 (77.7)	5,415 (111.6)	0 -
447 (13.7)	585 (14.2)	859 (16.9)	1,105 (18.3)	1,477 (24.0)	1,419 (32.7)	1,272 (57.9)	1,284 (108.5)	2,563 (358.7)	0 -
279 (36.8)	283 (44.7)	383 (56.0)	378 (72.7)	499 (93.5)	521 (114.9)	605 (158.6)	793 (225.1)	2,852 (360.4)	0 -
621 (15.8)	706 (18.4)	1,190 (26.8)	1,391 (33.1)	1,790 (42.8)	1,882 (53.7)	1,812 (78.0)	1,936 (111.4)	4,904 (205.1)	0 -
363 (18.1)	437 (22.5)	835 (37.2)	1,019 (48.4)	1,348 (64.9)	1,392 (81.7)	1,250 (114.4)	1,219 (157.0)	2,384 (285.6)	0 -
258 (13.3)	269 (14.2)	355 (16.2)	372 (17.7)	442 (21.0)	490 (27.2)	562 (45.6)	717 (74.6)	2,520 (161.9)	0 -
532 (14.1)	626 (16.3)	977 (22.5)	1,211 (28.3)	1,559 (37.8)	1,826 (49.4)	1,756 (70.0)	1,989 (108.7)	5,098 (206.6)	0 -
323 (16.8)	402 (20.7)	696 (31.7)	917 (42.8)	1,195 (58.2)	1,332 (74.0)	1,242 (105.1)	1,297 (157.8)	2,537 (291.5)	0 -
209 (11.3)	224 (11.8)	281 (13.1)	294 (13.8)	364 (17.6)	494 (26.0)	514 (38.7)	692 (68.6)	2,561 (160.3)	0 -

[Table 7] Number and Incidence Rates of (New) TB Cases by Gender and Age, 2011–2025 (continued)

Category	Year	Age Gender	Total	0–4	5–9	10–14	15–19	20–24	25–29	30–34	35–39
New Cases	2011	Total	39,557 (78.9)	59 (2.6)	38 (1.6)	305 (9.6)	2,030 (57.3)	2,496 (79.0)	3,127 (86.9)	2,852 (72.2)	2,620 (61.3)
		Male	22,371 (89.2)	30 (2.5)	24 (1.9)	132 (7.9)	1,285 (68.3)	1,241 (74.7)	1,577 (85.1)	1,528 (75.8)	1,526 (70.1)
		Female	17,186 (68.7)	29 (2.6)	14 (1.2)	173 (11.3)	745 (44.8)	1,255 (83.7)	1,550 (88.7)	1,324 (68.4)	1,094 (52.2)
	2012	Total	39,545 (78.5)	59 (2.5)	42 (1.8)	199 (6.5)	1,630 (46.5)	2,365 (72.7)	2,895 (85.4)	2,659 (66.3)	2,422 (58.7)
		Male	22,705 (90.1)	35 (2.9)	23 (1.9)	96 (6.1)	1,027 (55.2)	1,212 (70.7)	1,490 (85.2)	1,439 (70.3)	1,447 (69.1)
		Female	16,840 (66.9)	24 (2.1)	19 (1.7)	103 (7.1)	603 (36.6)	1,153 (74.9)	1,405 (85.6)	1,220 (62.2)	975 (48.1)
	2013	Total	36,089 (71.4)	40 (1.7)	25 (1.1)	155 (5.4)	1,281 (37.2)	2,099 (62.7)	2,465 (76.4)	2,442 (60.4)	2,070 (52.1)
		Male	20,665 (81.7)	23 (1.9)	8 (0.7)	72 (4.8)	770 (42.3)	1,125 (63.5)	1,296 (77.7)	1,292 (62.6)	1,194 (59.1)
		Female	15,424 (61.0)	17 (1.5)	17 (1.5)	83 (6.0)	511 (31.4)	974 (61.7)	1,169 (75.0)	1,150 (58.1)	876 (44.8)
	2014	Total	34,869 (68.7)	40 (1.7)	21 (0.9)	115 (4.2)	1,131 (33.6)	1,988 (57.9)	2,218 (70.4)	2,092 (52.7)	1,935 (49.9)
		Male	19,974 (78.7)	25 (2.1)	12 (1.0)	46 (3.2)	710 (40.2)	1,075 (59.0)	1,135 (69.4)	1,130 (55.7)	1,091 (55.3)
		Female	14,895 (58.7)	15 (1.3)	9 (0.8)	69 (5.3)	421 (26.4)	913 (56.6)	1,083 (71.4)	962 (49.5)	844 (44.4)
	2015	Total	32,181 (63.2)	23 (1.0)	16 (0.7)	128 (5.0)	1,014 (30.9)	1,671 (47.6)	1,928 (61.6)	1,794 (47.3)	1,689 (43.5)
		Male	18,695 (73.4)	17 (1.5)	11 (0.9)	76 (5.7)	630 (36.7)	907 (48.7)	1,029 (63.1)	958 (49.3)	963 (48.8)
		Female	13,486 (52.9)	6 (0.5)	5 (0.4)	52 (4.2)	384 (24.5)	764 (46.4)	899 (59.9)	836 (45.1)	726 (38.1)
	2016	Total	30,892 (60.4)	17 (0.8)	13 (0.6)	102 (4.2)	750 (23.5)	1,419 (40.1)	1,760 (55.7)	1,548 (43.0)	1,533 (38.9)
		Male	17,865 (70.0)	8 (0.7)	7 (0.6)	41 (3.3)	463 (27.8)	698 (37.2)	927 (56.1)	841 (45.6)	860 (42.9)
		Female	13,027 (50.9)	9 (0.8)	6 (0.5)	61 (5.3)	287 (18.8)	721 (43.4)	833 (55.2)	707 (40.3)	673 (34.8)

Unit: cases (cases per 100,000 population)

40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80+	Unknown
2,812 (62.6)	2,915 (69.1)	3,320 (80.2)	2,761 (91.0)	2,363 (104.3)	2,603 (138.1)	3,130 (196.7)	2,926 (270.8)	3,200 (330.3)	0 -
1,723 (75.6)	1,904 (88.3)	2,189 (105.0)	1,815 (120.4)	1,517 (136.9)	1,550 (177.0)	1,678 (244.3)	1,391 (339.6)	1,261 (452.4)	0 -
1,089 (49.2)	1,011 (49.1)	1,131 (55.0)	946 (61.9)	846 (73.1)	1,053 (104.3)	1,452 (160.6)	1,535 (228.8)	1,939 (281.0)	0 -
2,785 (61.0)	2,907 (70.1)	3,324 (77.5)	2,976 (91.6)	2,452 (104.8)	2,505 (133.4)	3,394 (200.6)	3,263 (282.9)	3,636 (350.6)	32 -
1,738 (75.0)	1,992 (93.9)	2,288 (105.9)	2,010 (124.4)	1,596 (139.3)	1,482 (168.5)	1,826 (247.4)	1,560 (350.3)	1,423 (473.5)	21 -
1,047 (46.6)	915 (45.1)	1,036 (48.7)	966 (59.2)	856 (71.6)	1,023 (102.6)	1,568 (164.3)	1,703 (240.6)	2,213 (300.4)	11 -
2,608 (57.2)	2,650 (63.2)	3,107 (71.6)	2,758 (79.9)	2,227 (91.9)	2,240 (116.7)	3,060 (172.7)	3,008 (246.1)	3,849 (345.0)	5 -
1,603 (69.1)	1,783 (83.6)	2,082 (95.2)	1,860 (108.0)	1,463 (123.3)	1,403 (154.5)	1,717 (220.4)	1,440 (300.3)	1,531 (467.6)	3 -
1,005 (44.9)	867 (42.0)	1,025 (47.7)	898 (52.0)	764 (61.8)	837 (82.7)	1,343 (135.2)	1,568 (211.1)	2,318 (294.0)	2 -
2,450 (54.3)	2,546 (59.2)	2,978 (68.9)	2,916 (79.3)	2,228 (88.4)	2,163 (107.7)	2,971 (166.4)	3,131 (241.5)	3,946 (327.0)	0 -
1,499 (65.3)	1,698 (77.9)	2,033 (93.1)	1,962 (106.8)	1,485 (120.1)	1,334 (139.2)	1,650 (209.0)	1,484 (287.6)	1,605 (446.1)	0 -
951 (43.0)	848 (40.0)	945 (44.2)	954 (51.8)	743 (57.8)	829 (78.9)	1,321 (132.7)	1,647 (211.1)	2,341 (276.4)	0 -
2,078 (47.1)	2,211 (50.6)	2,699 (63.3)	2,785 (71.7)	2,207 (81.3)	2,069 (98.1)	2,665 (149.9)	3,071 (226.9)	4,133 (315.0)	0 -
1,287 (57.3)	1,539 (69.5)	1,903 (88.1)	1,911 (98.6)	1,515 (113.8)	1,289 (127.5)	1,490 (188.1)	1,483 (271.7)	1,687 (423.4)	0 -
791 (36.5)	672 (31.1)	796 (37.8)	874 (44.9)	692 (50.0)	780 (71.0)	1,175 (119.2)	1,588 (196.6)	2,446 (267.7)	0 -
1,863 (43.8)	2,165 (48.5)	2,448 (58.7)	2,719 (66.7)	2,227 (75.1)	2,176 (99.6)	2,402 (136.1)	3,057 (217.1)	4,693 (330.1)	0 -
1,198 (55.4)	1,493 (66.2)	1,719 (81.0)	1,940 (95.4)	1,556 (107.0)	1,404 (133.9)	1,346 (169.4)	1,471 (255.9)	1,893 (430.4)	0 -
665 (31.8)	672 (30.5)	729 (35.5)	779 (38.2)	671 (44.4)	772 (67.9)	1,056 (108.8)	1,586 (190.3)	2,800 (285.2)	0 -

[Table 7] Number and Incidence Rates of (New) TB Cases by Gender and Age, 2011–2025 (continued)

Category	Year	Age Gender	Total	0–4	5–9	10–14	15–19	20–24	25–29	30–34	35–39
New Cases	2017	Total	28,161 (55.0)	16 (0.7)	8 (0.3)	75 (3.2)	622 (20.5)	1,135 (32.4)	1,429 (43.9)	1,244 (36.7)	1,379 (34.5)
		Male	16,147 (63.1)	8 (0.7)	5 (0.4)	36 (3.0)	386 (24.4)	581 (31.4)	711 (41.7)	686 (39.4)	759 (37.3)
		Female	12,014 (46.8)	8 (0.8)	3 (0.3)	39 (3.5)	236 (16.3)	554 (33.6)	718 (46.4)	558 (33.8)	620 (31.6)
	2018	Total	26,433 (51.5)	27 (1.3)	7 (0.3)	43 (1.8)	431 (15.0)	897 (26.1)	1,215 (36.3)	1,101 (34.1)	1,173 (29.1)
		Male	15,313 (59.8)	13 (1.3)	4 (0.3)	19 (1.6)	272 (18.2)	482 (26.6)	649 (36.8)	587 (35.3)	637 (31.0)
		Female	11,120 (43.3)	14 (1.4)	3 (0.3)	24 (2.1)	159 (11.6)	415 (25.5)	566 (35.7)	514 (32.8)	536 (27.1)
	2019	Total	23,821 (46.4)	18 (0.9)	6 (0.3)	55 (2.4)	327 (12.0)	745 (22.2)	1,058 (30.8)	903 (28.7)	1,025 (25.9)
		Male	13,847 (54.1)	10 (1.0)	4 (0.3)	28 (2.4)	198 (14.0)	403 (22.9)	577 (31.9)	483 (29.7)	559 (27.7)
		Female	9,974 (38.8)	8 (0.9)	2 (0.2)	27 (2.4)	129 (9.9)	342 (21.4)	481 (29.7)	420 (27.6)	466 (24.0)
	2020	Total	19,933 (38.8)	9 (0.5)	10 (0.4)	32 (1.4)	220 (8.6)	579 (17.7)	820 (23.4)	766 (24.5)	827 (21.8)
		Male	11,608 (45.3)	4 (0.4)	5 (0.4)	15 (1.3)	124 (9.4)	296 (17.3)	449 (24.2)	415 (25.6)	469 (24.3)
		Female	8,325 (32.3)	5 (0.6)	5 (0.4)	17 (1.5)	96 (7.8)	283 (18.1)	371 (22.5)	351 (23.3)	358 (19.3)
	2021	Total	18,335 (35.7)	5 (0.3)	6 (0.3)	26 (1.1)	155 (6.5)	431 (13.6)	690 (19.5)	652 (20.6)	670 (18.7)
		Male	10,639 (41.6)	3 (0.4)	3 (0.3)	14 (1.2)	87 (7.0)	224 (13.5)	371 (19.9)	349 (21.2)	378 (20.6)
		Female	7,696 (29.9)	2 (0.3)	3 (0.3)	12 (1.1)	68 (5.9)	207 (13.6)	319 (19.2)	303 (20.0)	292 (16.6)
	2022	Total	16,264 (31.7)	6 (0.4)	2 (0.1)	18 (0.8)	120 (5.1)	264 (8.7)	470 (13.5)	531 (16.3)	530 (15.7)
		Male	9,578 (37.5)	4 (0.5)	2 (0.2)	14 (1.2)	65 (5.4)	128 (8.1)	246 (13.4)	303 (17.8)	304 (17.5)
		Female	6,686 (26.0)	2 (0.3)	0 (0.0)	4 (0.3)	55 (4.9)	136 (9.4)	224 (13.6)	228 (14.7)	226 (13.7)

Unit: cases (cases per 100,000 population)

40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80+	Unknown
1,602 (39.0)	1,902 (41.9)	2,088 (50.9)	2,623 (62.1)	2,240 (70.5)	1,972 (87.2)	2,196 (124.4)	2,919 (193.8)	4,711 (307.5)	0 -
981 (47.1)	1,210 (52.7)	1,433 (68.6)	1,837 (87.1)	1,534 (98.3)	1,271 (116.9)	1,268 (157.8)	1,507 (241.8)	1,934 (400.7)	0 -
621 (30.7)	692 (30.9)	655 (32.5)	786 (37.2)	706 (43.7)	701 (59.7)	928 (96.4)	1,412 (159.9)	2,777 (264.7)	0 -
1,273 (32.1)	1,716 (37.9)	1,963 (47.2)	2,381 (55.7)	2,177 (64.5)	1,918 (81.8)	2,001 (110.3)	3,044 (192.0)	5,066 (308.1)	0 -
756 (37.6)	1,165 (50.7)	1,361 (64.8)	1,682 (78.6)	1,506 (90.4)	1,268 (112.3)	1,191 (142.7)	1,581 (238.5)	2,140 (405.9)	0 -
517 (26.5)	551 (24.7)	602 (29.3)	699 (32.8)	671 (39.2)	650 (53.4)	810 (82.7)	1,463 (158.6)	2,926 (262.0)	0 -
1,084 (28.1)	1,438 (32.1)	1,766 (41.5)	2,121 (49.8)	2,057 (57.1)	1,711 (70.0)	1,869 (98.3)	2,634 (164.3)	5,004 (282.8)	0 -
685 (35.0)	964 (42.4)	1,211 (56.4)	1,539 (72.0)	1,476 (83.0)	1,142 (96.9)	1,148 (129.9)	1,370 (202.7)	2,050 (355.1)	0 -
399 (21.0)	474 (21.5)	555 (26.3)	582 (27.4)	581 (31.9)	569 (44.9)	721 (70.8)	1,264 (136.3)	2,954 (247.8)	0 -
865 (22.4)	1,171 (26.7)	1,425 (32.9)	1,655 (39.3)	1,772 (46.6)	1,538 (58.4)	1,622 (81.1)	2,177 (135.8)	4,445 (234.5)	0 -
524 (26.7)	758 (34.1)	1,014 (46.4)	1,163 (55.0)	1,269 (67.5)	1,025 (80.6)	1,032 (110.5)	1,195 (175.2)	1,851 (294.8)	0 -
341 (17.9)	413 (19.2)	411 (19.1)	492 (23.5)	503 (26.1)	513 (37.6)	590 (55.3)	982 (106.7)	2,594 (204.6)	0 -
777 (19.8)	969 (22.9)	1,350 (30.5)	1,460 (35.4)	1,738 (43.5)	1,451 (50.3)	1,618 (78.0)	1,956 (122.4)	4,381 (216.6)	0 -
451 (22.6)	619 (28.9)	926 (41.6)	1,046 (50.3)	1,251 (63.3)	975 (70.1)	1,018 (104.9)	1,074 (156.0)	1,850 (272.3)	0 -
326 (16.9)	350 (16.8)	424 (19.3)	414 (20.3)	487 (24.1)	476 (31.9)	600 (54.3)	882 (97.0)	2,531 (188.4)	0 -
664 (16.7)	768 (18.8)	1,105 (24.6)	1,222 (30.1)	1,495 (36.1)	1,428 (46.3)	1,522 (70.8)	1,829 (114.0)	4,290 (197.6)	0 -
395 (19.5)	486 (23.5)	768 (33.9)	911 (44.5)	1,091 (53.2)	991 (66.3)	996 (99.0)	1,037 (148.1)	1,837 (247.8)	0 -
269 (13.8)	282 (14.0)	337 (15.1)	311 (15.5)	404 (19.3)	437 (27.4)	526 (46.1)	792 (87.6)	2,453 (171.6)	0 -

[Table 7] Number and Incidence Rates of (New) TB Cases by Gender and Age, 2011–2025 (continued)

Category	Year	Age Gender	Total	0–4	5–9	10–14	15–19	20–24	25–29	30–34	35–39
New Cases	2023	Total	15,640 (30.6)	1 (0.1)	3 (0.1)	15 (0.6)	92 (3.9)	221 (7.7)	444 (12.9)	432 (12.9)	469 (14.6)
		Male	9,302 (36.5)	0 (0.0)	3 (0.3)	7 (0.6)	48 (4.0)	113 (7.6)	234 (13.0)	236 (13.5)	273 (16.5)
		Female	6,338 (24.7)	1 (0.1)	0 (0.0)	8 (0.7)	44 (3.9)	108 (7.9)	210 (12.9)	196 (12.3)	196 (12.5)
	2024	Total	14,412 (28.2)	4 (0.3)	6 (0.3)	17 (0.7)	98 (4.3)	207 (7.6)	357 (10.7)	407 (11.9)	400 (12.7)
		Male	8,690 (34.2)	1 (0.1)	5 (0.5)	8 (0.7)	56 (4.7)	106 (7.5)	193 (11.0)	241 (13.4)	235 (14.5)
		Female	5,722 (22.3)	3 (0.5)	1 (0.1)	9 (0.8)	42 (3.8)	101 (7.7)	164 (10.3)	166 (10.2)	165 (10.8)
	2025	Total	13,713 (26.9)	6 (0.5)	1 (0.1)	13 (0.6)	66 (2.9)	223 (8.8)	311 (9.5)	325 (9.3)	359 (11.5)
		Male	8,369 (33.0)	4 (0.6)	1 (0.1)	5 (0.4)	34 (2.9)	117 (8.9)	174 (10.2)	192 (10.4)	205 (12.7)
		Female	5,344 (20.9)	2 (0.3)	0 (0.0)	8 (0.7)	32 (2.9)	106 (8.7)	137 (8.8)	133 (8.0)	154 (10.2)

Unit: cases (cases per 100,000 population)

40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80+	Unknown
590 (14.7)	677 (17.2)	960 (21.4)	1,136 (27.7)	1,518 (36.2)	1,474 (44.9)	1,462 (65.6)	1,663 (100.6)	4,483 (195.1)	0 -
364 (17.8)	456 (22.9)	661 (29.1)	834 (40.5)	1,112 (53.5)	1,048 (65.7)	950 (90.9)	961 (131.5)	2,002 (251.8)	0 -
226 (11.5)	221 (11.4)	299 (13.5)	302 (14.8)	406 (19.2)	426 (25.2)	512 (43.3)	702 (76.1)	2,481 (165.1)	0 -
498 (12.6)	557 (14.5)	918 (20.7)	1,059 (25.2)	1,393 (33.3)	1,440 (41.1)	1,424 (61.3)	1,567 (90.2)	4,060 (169.8)	0 -
292 (14.6)	347 (17.9)	631 (28.1)	764 (36.3)	1,035 (49.9)	1,028 (60.4)	937 (85.8)	943 (121.5)	1,868 (223.8)	0 -
206 (10.6)	210 (11.1)	287 (13.1)	295 (14.1)	358 (17.0)	412 (22.9)	487 (39.5)	624 (64.9)	2,192 (140.9)	0 -
442 (11.7)	501 (13.1)	753 (17.4)	946 (22.1)	1,196 (29.0)	1,417 (38.3)	1,355 (54.0)	1,589 (86.8)	4,210 (170.6)	0 -
276 (14.4)	316 (16.3)	536 (24.4)	709 (33.1)	898 (43.7)	990 (55.0)	923 (78.1)	1,000 (121.7)	1,989 (228.5)	0 -
166 (9.0)	185 (9.8)	217 (10.1)	237 (11.1)	298 (14.4)	427 (22.5)	432 (32.5)	589 (58.4)	2,221 (139.0)	0 -

[Table 8] Number and Incidence Rates of (New) TB Cases by Province, 2011–2025

Year		Nationwide	Seoul	Busan	Daegu	Incheon	Gwangju	Daejeon	Ulsan
2011	TB Cases	50,491 (100.8)	10,086 (99.7)	4,366 (124.2)	2,754 (110.8)	2,540 (92.4)	1,260 (86.9)	1,158 (77.3)	1,171 (104.3)
	New Cases	39,557 (78.9)	8,028 (79.4)	3,357 (95.5)	2,211 (88.9)	1,997 (72.6)	948 (65.4)	959 (64.0)	966 (86.0)
2012	TB Cases	49,532 (98.4)	10,184 (101.2)	4,142 (118.2)	2,645 (106.4)	2,641 (94.5)	1,283 (88.1)	1,112 (73.7)	1,004 (88.5)
	New Cases	39,545 (78.5)	8,261 (82.1)	3,278 (93.6)	2,150 (86.5)	1,983 (71.0)	1,072 (73.6)	884 (58.6)	792 (69.8)
2013	TB Cases	45,292 (89.6)	9,258 (92.5)	3,603 (103.1)	2,323 (93.6)	2,401 (84.7)	1,089 (74.5)	1,034 (68.1)	984 (85.9)
	New Cases	36,089 (71.4)	7,389 (73.8)	2,766 (79.2)	1,882 (75.8)	1,908 (67.3)	887 (60.7)	829 (54.6)	820 (71.6)
2014	TB Cases	43,088 (84.9)	8,419 (84.4)	3,240 (93.0)	2,266 (91.5)	2,168 (75.7)	1,006 (68.7)	1,048 (68.9)	895 (77.5)
	New Cases	34,869 (68.7)	6,831 (68.5)	2,548 (73.1)	1,881 (75.9)	1,766 (61.7)	817 (55.8)	859 (56.5)	738 (63.9)
2015	TB Cases	40,847 (80.2)	7,605 (76.8)	3,046 (87.6)	1,899 (76.8)	2,110 (73.1)	1,000 (68.3)	913 (60.3)	777 (66.8)
	New Cases	32,181 (63.2)	6,011 (60.7)	2,386 (68.6)	1,518 (61.4)	1,646 (57.0)	803 (54.8)	730 (48.2)	634 (54.5)
2016	TB Cases	39,245 (76.8)	7,360 (75.0)	2,859 (82.5)	1,865 (75.6)	2,028 (69.8)	908 (62.1)	844 (56.1)	802 (68.8)
	New Cases	30,892 (60.4)	5,769 (58.8)	2,221 (64.1)	1,466 (59.4)	1,635 (56.3)	737 (50.4)	677 (45.0)	651 (55.8)
2017	TB Cases	36,044 (70.4)	6,663 (68.5)	2,462 (71.4)	1,652 (67.1)	1,865 (63.9)	856 (58.7)	846 (56.5)	695 (59.8)
	New Cases	28,161 (55.0)	5,226 (53.7)	1,861 (54.0)	1,333 (54.2)	1,472 (50.5)	703 (48.2)	681 (45.5)	556 (47.8)
2018	TB Cases	33,796 (65.9)	6,153 (63.8)	2,243 (65.6)	1,491 (60.9)	1,699 (58.1)	805 (55.4)	751 (50.6)	735 (63.7)
	New Cases	26,433 (51.5)	4,747 (49.2)	1,764 (51.6)	1,219 (49.8)	1,373 (47.0)	653 (45.0)	583 (39.2)	585 (50.7)
2019	TB Cases	30,304 (59.0)	5,450 (56.9)	2,064 (60.9)	1,331 (54.7)	1,640 (56.0)	706 (48.7)	664 (45.1)	583 (50.9)
	New Cases	23,821 (46.4)	4,259 (44.5)	1,642 (48.4)	1,061 (43.6)	1,313 (44.9)	578 (39.9)	515 (35.0)	470 (41.0)
2020	TB Cases	25,350 (49.4)	4,442 (46.6)	1,658 (49.2)	1,208 (50.1)	1,303 (44.6)	595 (41.2)	547 (37.5)	472 (41.5)
	New Cases	19,933 (38.8)	3,486 (36.6)	1,270 (37.7)	977 (40.5)	1,005 (34.4)	493 (34.1)	426 (29.2)	370 (32.6)

Unit: cases (cases per 100,000 population)

Sejong	Gyeonggi	Gangwon	Chungbuk	Chungnam	Jeonbuk	Jeonnam	Gyeongbuk	Gyeongnam	Jeju
–	9,792	1,842	1,502	1,980	1,968	2,279	3,761	3,402	630
–	(83.3)	(121.3)	(97.2)	(95.5)	(105.9)	(119.8)	(140.6)	(103.8)	(110.9)
–	7,761	1,420	1,126	1,492	1,534	1,700	2,970	2,610	478
–	(66.0)	(93.5)	(72.9)	(72.0)	(82.5)	(89.4)	(111.0)	(79.7)	(84.1)
87	9,735	1,806	1,530	1,871	1,723	2,443	3,423	3,281	622
(84.2)	(81.7)	(118.5)	(98.7)	(93.2)	(92.6)	(128.7)	(127.7)	(99.7)	(108.2)
72	7,818	1,413	1,187	1,476	1,345	1,942	2,789	2,585	498
(69.6)	(65.6)	(92.7)	(76.6)	(73.5)	(72.3)	(102.3)	(104.0)	(78.5)	(86.6)
85	9,384	1,690	1,277	1,760	1,591	2,130	3,119	3,055	509
(72.8)	(77.8)	(110.7)	(81.9)	(86.9)	(85.5)	(112.4)	(116.3)	(92.4)	(87.1)
72	7,523	1,371	1,018	1,374	1,224	1,677	2,536	2,405	408
(61.7)	(62.4)	(89.8)	(65.3)	(67.9)	(65.8)	(88.5)	(94.6)	(72.8)	(69.9)
89	8,860	1,935	1,242	1,815	1,604	2,130	3,050	2,880	441
(64.4)	(72.6)	(126.5)	(79.3)	(88.9)	(86.2)	(112.5)	(113.7)	(86.7)	(74.0)
71	7,177	1,555	998	1,506	1,304	1,676	2,472	2,295	375
(51.3)	(58.8)	(101.6)	(63.7)	(73.8)	(70.1)	(88.5)	(92.2)	(69.1)	(62.9)
101	8,637	1,762	1,242	1,827	1,542	2,149	2,962	2,804	471
(55.3)	(70.0)	(114.9)	(79.1)	(88.9)	(83.0)	(113.5)	(110.4)	(84.0)	(77.0)
80	6,782	1,368	986	1,455	1,206	1,657	2,328	2,217	374
(43.8)	(55.0)	(89.2)	(62.8)	(70.8)	(64.9)	(87.5)	(86.7)	(66.4)	(61.2)
126	8,312	1,647	1,254	1,892	1,619	1,903	2,859	2,556	411
(55.8)	(66.4)	(107.2)	(79.5)	(91.3)	(87.3)	(100.5)	(106.5)	(76.3)	(65.4)
103	6,577	1,298	977	1,483	1,281	1,515	2,214	1,977	311
(45.6)	(52.6)	(84.5)	(61.9)	(71.5)	(69.1)	(80.0)	(82.5)	(59.0)	(49.5)
137	7,818	1,502	1,154	1,720	1,352	1,914	2,527	2,395	486
(52.6)	(61.6)	(97.7)	(72.9)	(82.2)	(73.2)	(101.4)	(94.4)	(71.4)	(75.5)
92	6,130	1,165	844	1,359	1,025	1,503	1,978	1,853	380
(35.3)	(48.3)	(75.8)	(53.3)	(65.0)	(55.5)	(79.6)	(73.9)	(55.2)	(59.0)
132	7,311	1,431	1,108	1,620	1,307	1,831	2,420	2,303	456
(44.6)	(56.8)	(93.3)	(69.8)	(76.9)	(71.3)	(97.5)	(90.7)	(68.6)	(69.4)
99	5,666	1,154	862	1,278	1,006	1,419	1,854	1,798	373
(33.4)	(44.1)	(75.3)	(54.3)	(60.6)	(54.9)	(75.6)	(69.5)	(53.6)	(56.8)
98	6,683	1,287	940	1,408	1,207	1,607	2,259	1,977	400
(30.0)	(51.2)	(84.2)	(59.1)	(66.7)	(66.5)	(86.2)	(85.1)	(59.0)	(60.3)
71	5,231	1,010	677	1,122	937	1,295	1,786	1,532	322
(21.8)	(40.1)	(66.1)	(42.6)	(53.2)	(51.6)	(69.5)	(67.3)	(45.8)	(48.5)
118	5,491	1,050	800	1,280	1,041	1,353	1,882	1,773	337
(34.0)	(41.5)	(68.7)	(50.3)	(60.7)	(57.8)	(73.2)	(71.4)	(53.2)	(50.5)
93	4,343	850	616	1,019	821	1,044	1,495	1,356	269
(26.8)	(32.9)	(55.6)	(38.7)	(48.3)	(45.6)	(56.5)	(56.7)	(40.7)	(40.3)

[Table 8] Number and Incidence Rates of (New) TB Cases by Province, 2011–2025 (continued)

Year		Nationwide	Seoul	Busan	Daegu	Incheon	Gwangju	Daejeon	Ulsan
2021	TB Cases	22,904 (44.6)	3,854 (40.8)	1,623 (48.5)	1,095 (45.9)	1,185 (40.6)	541 (37.6)	504 (34.8)	448 (39.9)
	New Cases	18,335 (35.7)	3,067 (32.4)	1,266 (37.9)	898 (37.6)	953 (32.6)	434 (30.2)	404 (27.9)	352 (31.3)
2022	TB Cases	20,383 (39.8)	3,424 (36.5)	1,340 (40.4)	928 (39.2)	1,037 (35.3)	438 (30.6)	450 (31.2)	365 (32.8)
	New Cases	16,264 (31.7)	2,756 (29.4)	1,038 (31.3)	787 (33.3)	827 (28.1)	352 (24.6)	368 (25.5)	290 (26.1)
2023	TB Cases	19,540 (38.2)	3,351 (35.9)	1,285 (39.0)	953 (40.2)	1,017 (34.3)	453 (31.9)	407 (28.3)	317 (28.7)
	New Cases	15,640 (30.6)	2,655 (28.4)	1,002 (30.4)	795 (33.5)	829 (27.9)	372 (26.2)	311 (21.6)	267 (24.2)
2024	TB Cases	17,944 (35.2)	3,012 (32.4)	1,141 (34.9)	899 (38.1)	950 (31.7)	404 (28.7)	369 (25.7)	366 (33.3)
	New Cases	14,412 (28.2)	2,383 (25.7)	904 (27.7)	767 (32.5)	787 (26.3)	332 (23.6)	299 (20.8)	297 (27.1)
2025	TB Cases	17,070 (33.5)	2,853 (30.9)	1,087 (33.5)	811 (34.5)	928 (30.7)	368 (26.4)	384 (26.8)	362 (33.2)
	New Cases	13,713 (26.9)	2,213 (23.9)	860 (26.5)	693 (29.5)	754 (25.0)	300 (21.5)	293 (20.4)	291 (26.7)

Unit: cases (cases per 100,000 population)

Sejong	Gyeonggi	Gangwon	Chungbuk	Chungnam	Jeonbuk	Jeonnam	Gyeongbuk	Gyeongnam	Jeju
100 (27.6)	5,111 (38.1)	954 (62.3)	758 (47.6)	1,094 (51.9)	883 (49.4)	1,286 (70.2)	1,684 (64.3)	1,527 (46.1)	257 (38.3)
80 (22.0)	4,137 (30.9)	771 (50.4)	609 (38.3)	860 (40.8)	725 (40.6)	1,015 (55.4)	1,368 (52.2)	1,189 (35.9)	207 (30.8)
75 (19.9)	4,570 (33.8)	899 (58.7)	633 (39.8)	1,044 (49.4)	812 (45.8)	1,183 (65.0)	1,610 (61.8)	1,322 (40.2)	253 (37.6)
56 (14.9)	3,626 (26.9)	704 (46.0)	498 (31.3)	842 (39.8)	653 (36.8)	917 (50.4)	1,315 (50.5)	1,039 (31.6)	196 (29.1)
82 (21.3)	4,339 (32.0)	788 (51.6)	651 (41.0)	1,017 (48.0)	788 (44.8)	1,047 (57.9)	1,554 (60.7)	1,254 (38.5)	237 (35.2)
62 (16.1)	3,440 (25.4)	629 (41.2)	528 (33.2)	852 (40.2)	640 (36.4)	828 (45.8)	1,252 (48.9)	988 (30.3)	190 (28.2)
58 (15.0)	4,073 (30.0)	728 (48.0)	605 (38.1)	873 (41.1)	731 (42.0)	1,007 (56.2)	1,403 (55.3)	1,087 (33.7)	238 (35.6)
39 (10.1)	3,205 (23.6)	577 (38.0)	489 (30.8)	702 (33.0)	608 (34.9)	818 (45.6)	1,143 (45.1)	867 (26.8)	195 (29.1)
61 (15.6)	3,732 (27.3)	703 (46.6)	578 (36.4)	919 (43.1)	741 (42.9)	957 (53.8)	1,289 (51.3)	1,076 (33.5)	221 (33.3)
48 (12.3)	3,001 (22.0)	564 (37.4)	471 (29.6)	745 (35.0)	603 (34.9)	770 (43.3)	1,065 (42.4)	873 (27.2)	169 (25.5)

[Table 9] Number and Incidence Rates of (New) TB Cases by Site of Disease, 2011–2025

Year		Total	Pulmonary TB ¹⁾		Extrapulmonary TB							
			Sub-to tal	Smear-positive	Sub-to tal ²⁾	Pleural	Lymph atic	Abdomi nal	Bone-Joint	CNS	Genito urinary	Other
2011 ³⁾	TB Cases	50,491 (100.8)	39,135 (78.1)	15,742 (31.4)	11,356 (22.7)	3,659	2,496	1,349	651	419	282	2,500
	New Cases	39,557 (78.9)	30,100 (60.1)	11,531 (23.4)	9,457 (18.9)	3,167	1,993	1,155	520	337	240	2,045
2012	TB Cases	49,532 (98.4)	39,602 (78.7)	16,006 (31.8)	9,930 (19.7)	3,206	2,165	1,315	657	375	271	1,941
	New Cases	39,545 (78.5)	31,075 (61.7)	12,137 (24.1)	8,470 (16.8)	2,873	1,739	1,174	544	335	235	1,570
2013	TB Cases	45,292 (89.6)	36,516 (72.2)	14,368 (28.4)	8,776 (17.4)	2,546	2,289	1,333	536	405	247	1,420
	New Cases	36,089 (71.4)	28,720 (56.8)	11,100 (22.0)	7,369 (14.6)	2,258	1,826	1,161	441	344	212	1,127
2014	TB Cases	43,088 (84.9)	35,057 (69.1)	13,175 (26.0)	8,031 (15.8)	2,857	2,186	1,253	522	324	216	731
	New Cases	34,869 (68.7)	27,906 (55.0)	10,446 (20.6)	6,963 (13.7)	2,568	1,780	1,133	418	288	192	636
2015	TB Cases	40,847 (80.2)	33,013 (64.8)	11,997 (23.5)	7,834 (15.4)	3,089	1,927	1,164	565	385	199	556
	New Cases	32,181 (63.2)	25,550 (50.1)	9,309 (18.3)	6,631 (13.0)	2,685	1,526	1,041	456	323	173	473
2016	TB Cases	39,245 (76.8)	31,859 (62.3)	11,141 (21.8)	7,386 (14.5)	2,908	1,759	1,156	499	307	220	589
	New Cases	30,892 (60.4)	24,696 (48.3)	8,812 (17.2)	6,196 (12.1)	2,492	1,362	1,040	380	265	192	512
2017 ⁴⁾	TB Cases	36,044 (70.4)	29,102 (56.8)	9,859 (19.2)	6,942 (13.6)	2,686	1,529	1,094	467	350	184	689
	New Cases	28,161 (55.0)	22,314 (43.6)	7,701 (15.0)	5,847 (11.4)	2,337	1,176	949	363	310	169	591

1) If a case was diagnosed with and notified both pulmonary and extrapulmonary TB, it was classified as pulmonary TB.

2) The subtotal of extrapulmonary TB case counts may not match the sum of case counts by extrapulmonary TB lesion sites due to cases with multiple reported lesion sites from 2014.

3) The number of pulmonary–smear positive new TB cases in 2011, 2018 and The number of genitourinary new TB cases were found to be incorrect and were corrected in the 2024 annual report.

4) The number of pleural TB cases in 2017 was found to be incorrect and was corrected in the 2018 annual report.

5) The number of new TB cases by site of disease was found to be incorrect and was corrected in the 2022 annual report.

Unit: cases (cases per 100,000 population)

Year		Total	Pulmonary TB ¹⁾		Extrapulmonary TB							
			Sub-to tal	Smear- positive	Sub-to tal ²⁾	Pleural	Lymph atic	Abdomi nal	Bone- Joint	CNS	Genito urinary	Other
2018 ³⁾	TB Cases	33,796 (65.9)	27,137 (52.9)	9,195 (17.9)	6,659 (13.0)	2,671	1,498	1,037	495	305	168	535
	New Cases	26,433 (51.5)	20,883 (40.7)	7,321 (14.3)	5,550 (10.8)	2,335	1,132	906	376	264	143	433
2019	TB Cases	30,304 (59.0)	24,302 (47.3)	8,116 (15.8)	6,002 (11.7)	2,431	1,299	864	425	274	167	593
	New Cases	23,821 (46.4)	18,765 (36.6)	6,497 (12.7)	5,056 (9.8)	2,125	1,007	756	331	239	138	501
2020	TB Cases	25,350 (49.4)	19,724 (38.4)	6,657 (13.0)	5,626 (11.0)	2,353	1,224	722	414	233	175	540
	New Cases	19,933 (38.8)	15,221 (29.6)	5,379 (10.5)	4,712 (9.2)	2,047	945	636	326	195	148	444
2021 ^{3/5)}	TB Cases	22,904 (44.6)	17,858 (34.8)	6,316 (12.3)	5,046 (9.8)	1,978	1,068	764	382	261	153	478
	New Cases	18,335 (35.7)	14,100 (27.5)	5,170 (10.1)	4,235 (8.3)	1,714	841	658	309	224	130	390
2022	TB Cases	20,383 (39.8)	15,746 (30.7)	5,722 (11.2)	4,637 (9.0)	2,007	901	604	322	266	113	451
	New Cases	16,264 (31.7)	12,406 (24.2)	4,669 (9.1)	3,858 (7.5)	1,715	698	518	247	229	97	381
2023	TB Cases	19,540 (38.2)	15,391 (30.1)	5,305 (10.4)	4,149 (8.1)	1,840	755	572	256	226	110	426
	New Cases	15,640 (30.6)	12,121 (23.7)	4,321 (8.4)	3,519 (6.9)	1,602	583	503	205	198	96	363
2024	TB Cases	17,944 (35.2)	14,095 (27.6)	4,740 (9.3)	3,849 (7.5)	1,720	714	475	290	173	102	390
	New Cases	14,412 (28.2)	11,158 (21.9)	3,849 (7.5)	3,254 (6.4)	1,487	546	416	244	142	92	339
2025	TB Cases	17,070 (33.5)	13,371 (26.2)	4,332 (8.5)	3,699 (7.3)	1,699	717	426	258	135	102	393
	New Cases	13,713 (26.9)	10,587 (20.8)	3,558 (7.0)	3,126 (6.1)	1,483	553	375	199	117	86	341

[Table 10] Number of (New) TB Cases by Notifying Medical Institution, 2011–2025

Unit: cases (%)*

Year		Total	Public Health Center	Medical Institution			
				Sub-total	General Hospital	Hospital	Clinic
2011	TB Cases	50,491 (100.0)	5,807 (11.5)	44,684 (88.5)	36,741 (72.8)	5,137 (10.2)	2,806 (5.6)
	NewCases	39,557 (100.0)	4,461 (11.3)	35,096 (88.7)	29,207 (73.8)	3,704 (9.4)	2,185 (5.5)
2012	TB Cases	49,532 (100.0)	4,966 (10.0)	44,566 (90.0)	35,889 (72.5)	5,552 (11.2)	3,125 (6.3)
	NewCases	39,545 (100.0)	3,779 (9.6)	35,766 (90.4)	29,335 (74.2)	4,121 (10.4)	2,310 (5.8)
2013	TB Cases	45,292 (100.0)	4,295 (9.5)	40,997 (90.5)	33,998 (75.1)	5,014 (11.1)	1,985 (4.4)
	NewCases	36,089 (100.0)	3,269 (9.1)	32,820 (90.9)	27,565 (76.4)	3,743 (10.4)	1,512 (4.2)
2014	TB Cases	43,088 (100.0)	3,942 (9.1)	39,146 (90.9)	33,288 (77.3)	4,473 (10.4)	1,385 (3.2)
	NewCases	34,869 (100.0)	2,994 (8.6)	31,875 (91.4)	27,502 (78.9)	3,310 (9.5)	1,063 (3.0)
2015	TB Cases	40,847 (100.0)	3,210 (7.9)	37,637 (92.1)	31,893 (78.1)	4,372 (10.7)	1,372 (3.4)
	NewCases	32,181 (100.0)	2,320 (7.2)	29,861 (92.8)	25,919 (80.5)	3,012 (9.4)	930 (2.9)
2016	TB Cases	39,245 (100.0)	3,260 (8.3)	35,985 (91.7)	31,162 (79.4)	3,746 (9.5)	1,077 (2.7)
	NewCases	30,892 (100.0)	2,405 (7.8)	28,487 (92.2)	25,175 (81.5)	2,556 (8.3)	756 (2.4)
2017	TB Cases	36,044 (100.0)	2,154 (6.0)	33,890 (94.0)	29,625 (82.2)	3,373 (9.4)	892 (2.5)
	NewCases	28,161 (100.0)	1,516 (5.4)	26,645 (94.6)	23,730 (84.3)	2,282 (8.1)	633 (2.2)
2018	TB Cases	33,796 (100.0)	1,548 (4.6)	32,248 (95.4)	28,599 (84.6)	2,968 (8.8)	681 (2.0)
	NewCases	26,433 (100.0)	1,069 (4.0)	25,364 (96.0)	22,931 (86.8)	1,968 (7.4)	465 (1.8)
2019	TB Cases	30,304 (100.0)	1,127 (3.7)	29,177 (96.3)	26,274 (86.7)	2,335 (7.7)	568 (1.9)
	NewCases	23,821 (100.0)	742 (3.1)	23,079 (96.9)	21,163 (88.8)	1,521 (6.4)	395 (1.7)
2020	TB Cases	25,350 (100.0)	506 (2.0)	24,844 (98.0)	22,434 (88.5)	1,930 (7.6)	480 (1.9)
	NewCases	19,933 (100.0)	264 (1.3)	19,669 (98.7)	18,191 (91.3)	1,161 (5.8)	317 (1.6)
2021	TB Cases	22,904 (100.0)	286 (1.2)	22,618 (98.8)	20,689 (90.3)	1,525 (6.7)	404 (1.8)
	NewCases	18,335 (100.0)	155 (0.8)	18,180 (99.2)	16,935 (92.4)	959 (5.2)	286 (1.6)
2022	TB Cases	20,383 (100.0)	258 (1.3)	20,125 (98.7)	18,441 (90.5)	1,360 (6.7)	324 (1.6)
	NewCases	16,264 (100.0)	133 (0.8)	16,131 (99.2)	14,971 (92.0)	920 (5.7)	240 (1.5)
2023	TB Cases	19,540 (100.0)	239 (1.2)	19,301 (98.8)	17,757 (90.9)	1,267 (6.5)	277 (1.4)
	NewCases	15,640 (100.0)	160 (1.0)	15,480 (99.0)	14,416 (92.2)	861 (5.5)	203 (1.3)
2024	TB Cases	17,944 (100.0)	220 (1.2)	17,724 (98.8)	16,202 (90.3)	1,244 (6.9)	278 (1.5)
	NewCases	14,412 (100.0)	136 (0.9)	14,276 (99.1)	13,225 (91.8)	840 (5.8)	211 (1.5)
2025	TB Cases	17,070 (100.0)	155 (0.9)	16,915 (99.1)	15,470 (90.6)	1,194 (7.0)	251 (1.5)
	NewCases	13,713 (100.0)	83 (0.6)	13,630 (99.4)	12,626 (92.1)	818 (6.0)	186 (1.4)

* Percentage based on the total, Totals may not equal the sum of components due to roundings.

[Table 11] Number of Foreign (New) TB Cases, 2011–2025

Unit: cases

Year	TB Cases				New Cases			
	Sub-total	Pulmonary TB	(Smear -positive)	Extra pulmonary TB	Sub-total	Pulmonary TB	(Smear -positive)	Extra pulmonary TB
2011 ¹⁾	1,213	918	(318)	295	1,007	748	(248)	259
2012	1,510	1,191	(423)	319	1,227	956	(320)	271
2013 ¹⁾	1,735	1,383	(435)	352	1,418	1,117	(338)	301
2014 ²⁾	1,858	1,522	(457)	336	1,561	1,257	(336)	304
2015	1,944	1,602	(497)	342	1,589	1,287	(398)	302
2016	2,569	2,210	(572)	359	2,123	1,810	(452)	313
2017	2,045	1,719	(449)	326	1,632	1,355	(353)	277
2018 ¹⁾	1,801	1,441	(409)	360	1,398	1,104	(315)	294
2019	1,597	1,258	(368)	339	1,287	995	(294)	292
2020	1,316	985	(314)	331	1,076	796	(254)	280
2021	1,242	906	(299)	336	1,029	728	(248)	301
2022	1,072	809	(272)	263	877	643	(221)	234
2023	1,107	852	(258)	255	919	694	(216)	225
2024	1,077	788	(242)	289	916	663	(213)	253
2025	1,049	774	(253)	275	897	659	(215)	238

1) The number of foreign pulmonary–smear positive new TB cases in 2011, 2018 and the number of foreign (New) TB cases in 2013 were found to be incorrect and were corrected in the 2024 annual report.

2) The number of foreign new TB cases in 2014 was found to be incorrect and was corrected in the 2018 annual report.

**Annual Report
on the Notified Tuberculosis
in the Republic of Korea, 2025**



Drug-resistant Tuberculosis Cases, 2011–2025

[Table 12] Number of Multidrug-resistant (MDR) TB Cases (2011–2021) and Multidrug/Rifampicin-resistant (MDR/RR) TB (2022–2025) Cases by Gender and Age

[Table 13] Number of Multidrug/Rifampicin-resistant Tuberculosis (MDR/RR-TB) Cases by Drug Resistance and Treatment History, 2025

[Table 14] Number of Multidrug/Rifampicin-resistant Tuberculosis (MDR/RR-TB) Cases by Age and Treatment History, 2025

[Table 15] Number of Multidrug/Rifampicin-resistant Tuberculosis (MDR/RR-TB) Cases by Province and Treatment History, 2025

Drug-resistant Tuberculosis Cases, 2011–2025

[Table 12] Number of Multidrug-resistant (MDR) TB Cases (2011–2021) and Multidrug/Rifampicin-resistant (MDR/RR) TB (2022–2025) Cases by Gender and Age

Year	Age Gender	Total	0–4	5–9	10–14	15–19	20–24	25–29	30–34	35–39
2011	Total	975	0	0	0	23	54	96	106	77
	Male	701	0	0	0	14	24	51	61	56
	Female	274	0	0	0	9	30	45	45	21
2012 ¹⁾	Total	1,212	0	0	1	34	74	102	94	113
	Male	818	0	0	0	17	40	51	59	79
	Female	394	0	0	1	17	34	51	35	34
2013 ¹⁾	Total	951	0	0	3	16	68	81	89	74
	Male	626	0	0	1	11	30	35	40	46
	Female	325	0	0	2	5	38	46	49	28
2014	Total	856	0	1	2	20	49	80	89	62
	Male	575	0	1	1	11	29	38	53	37
	Female	281	0	0	1	9	20	42	36	25
2015	Total	787	0	0	0	16	67	78	75	54
	Male	538	0	0	0	12	38	42	42	36
	Female	249	0	0	0	4	29	36	33	18
2016	Total	852	0	0	2	17	52	69	68	56
	Male	552	0	0	0	10	31	38	41	35
	Female	300	0	0	2	7	21	31	27	21
2017 ²⁾	Total	681	0	1	0	11	30	39	47	56
	Male	459	0	1	0	6	18	23	32	41
	Female	222	0	0	0	5	12	16	15	15
2018	Total	618	0	0	0	7	27	38	41	42
	Male	418	0	0	0	3	13	20	25	21
	Female	200	0	0	0	4	14	18	16	21
2019	Total	580	0	0	2	8	17	35	50	33
	Male	395	0	0	1	4	6	20	27	22
	Female	185	0	0	1	4	11	15	23	11
2020	Total	399	0	0	2	5	17	23	37	26
	Male	258	0	0	0	2	6	17	19	16
	Female	141	0	0	2	3	11	6	18	10

Unit: cases

40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80+
112	100	110	89	64	55	34	35	20
91	81	92	76	52	43	25	25	10
21	19	18	13	12	12	9	10	10
129	135	137	113	87	57	57	45	33
94	98	110	83	72	40	39	22	13
35	37	27	30	15	17	18	23	20
84	101	110	100	49	51	49	40	35
55	83	92	82	36	36	36	24	18
29	18	18	18	13	15	13	16	17
83	74	81	78	60	43	43	44	47
56	60	71	64	47	34	29	26	18
27	14	10	14	13	9	14	18	29
71	73	84	72	54	46	40	23	34
52	64	68	58	43	31	30	14	8
19	9	16	14	11	15	10	9	26
70	74	103	81	64	42	39	47	68
47	58	75	66	52	30	20	28	21
23	16	28	15	12	12	19	19	47
59	56	70	75	58	42	41	39	57
39	45	57	58	42	33	21	22	21
20	11	13	17	16	9	20	17	36
52	56	60	70	53	42	36	43	51
38	41	47	60	42	34	25	26	23
14	15	13	10	11	8	11	17	28
42	49	58	71	58	36	32	21	68
29	37	45	59	47	30	22	15	31
13	12	13	12	11	6	10	6	37
25	36	29	35	40	31	26	19	48
19	27	27	28	30	20	17	10	20
6	9	2	7	10	11	9	9	28

[Table 12] Number of Multidrug-resistant (MDR) TB Cases (2011–2021) and Multidrug/Rifampicin-resistant (MDR/RR) TB (2022–2025) Cases by Gender and Age (continued)

Year	Gender \ Age	Total	0–4	5–9	10–14	15–19	20–24	25–29	30–34	35–39
2021	Total	371	0	0	0	4	12	14	22	20
	Male	262	0	0	0	2	6	11	19	11
	Female	109	0	0	0	2	6	3	3	9
2022	Total	560	0	0	0	5	16	26	24	32
	Male	388	0	0	0	4	11	15	13	26
	Female	172	0	0	0	1	5	11	11	6
2023	Total	551	0	0	0	2	8	18	18	22
	Male	379	0	0	0	1	3	9	11	18
	Female	172	0	0	0	1	5	9	7	4
2024	Total	461	0	0	0	4	3	14	18	23
	Male	336	0	0	0	2	1	6	11	19
	Female	125	0	0	0	2	2	8	7	4
2025	Total	445	0	0	0	6	3	13	13	19
	Male	313	0	0	0	4	1	7	9	12
	Female	132	0	0	0	2	2	6	4	7

※ The calculation method of the number of multidrug-resistant TB (MDR/TB) and extensively drug-resistant tuberculosis (XDR-TB) refer to the 2023 annual report.

- (2011–2021) MDR-TB: TB resistant to both rifampicin and isoniazid.
- (From 2022) MDR/RR-TB: TB resistant to rifampicin alone or to both rifampicin and isoniazid.

1) In 2012, one person with unknown age (1 male); in 2013, one person with unknown age (1 male)

2) The calculation of the number of MDR-TB cases in 2017 was found to be incorrect and was corrected in the 2018 Annual Report.

단위 : 명

40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80+
21	28	49	39	45	27	24	23	43
14	22	39	30	38	22	17	13	18
7	6	10	9	7	5	7	10	25
24	54	49	61	55	48	32	42	92
16	41	39	49	49	42	24	20	39
8	13	10	12	6	6	8	22	53
32	57	49	59	65	52	46	37	86
16	42	39	47	58	42	33	25	35
16	15	10	12	7	10	13	12	51
26	29	45	56	56	48	39	32	68
18	23	37	46	48	43	32	17	33
8	6	8	10	8	5	7	15	35
28	25	33	50	50	44	35	44	82
20	15	29	38	44	41	25	31	37
8	10	4	12	6	3	10	13	45

[Table 13] Number of Multidrug/Rifampicin-resistant Tuberculosis (MDR/RR-TB) Cases by Drug Resistance and Treatment History, 2025

Unit: cases

Category		TB Cases	Treatment History						
			New Cases	Previously treated patients				Unknown previous treatment history	Other
				Sub-total	Relapse	Treatment after failure	Treatment after loss to follow-up		
Total		17,070	13,713	2,327	1,881	32	154	260	610
MDR/RR-TB		445	259	155	109	12	14	20	17
Drug Resistance	Extensively drug-resistant tuberculosis (XDR-TB)	2	0	2	0	2	0	0	0
	Pre-extensively drug-resistant tuberculosis (Pre-XDR-TB)	60	36	22	14	4	1	3	1
	Multidrug-resistant tuberculosis (MDR-TB)	247	142	89	66	5	8	10	8
	Rifampicin-resistant tuberculosis (RR-TB)	136	81	42	29	1	5	7	8

※ As of January 1, 2022, the definitions of “(26) Type of drug-resistant TB” in the “Tuberculosis Notification · Reporting Form” have been revised.

[Table 14] Number of Multidrug/Rifampicin-resistant Tuberculosis (MDR/RR-TB) Cases by Age and Treatment History, 2025

Unit: cases

Category		TB Cases	Treatment History						
			New Cases	Previously treated patients				Unknown previous treatment history	Other
				Sub-total	Relapse	Treatment after failure	Treatment after loss to follow-up		
Total		17,070	13,713	2,327	1,881	32	154	260	420
MDR/RR-TB		445	259	155	109	12	14	20	17
Age	0-4	0	0	0	0	0	0	0	0
	5-9	0	0	0	0	0	0	0	0
	10-14	0	0	0	0	0	0	0	0
	15-19	6	4	1	1	0	0	0	1
	20-24	3	1	2	0	0	1	1	0
	25-29	13	10	2	1	0	0	1	1
	30-34	13	7	5	4	0	0	1	0
	35-39	19	14	4	4	0	0	0	1
	40-44	28	16	11	8	1	0	2	1
	45-49	25	16	7	3	1	2	1	2
	50-54	33	13	19	6	7	2	4	1
	55-59	50	28	16	11	1	2	2	2
	60-64	50	26	20	14	1	3	2	2
	65-69	44	23	16	14	0	1	1	3
	70-74	35	18	16	15	0	0	1	0
	75-79	44	23	18	15	0	0	3	1
	80+	82	60	18	13	1	3	1	2

[Table 15] Number of Multidrug/Rifampicin-resistant Tuberculosis (MDR/RR-TB) Cases by Province and Treatment History, 2024

Unit: cases

Category		TB Cases	Treatment History							
			New Cases	Previously treated patients					Unknown previous treatment history	Other
				Sub-total	Relapse	Treatment after failure	Treatment after loss to follow-up	Other previous treatment		
Total		17,070	13,713	2,327	1,881	32	154	260	420	610
MDR/RR-TB		445	259	155	109	12	14	20	14	17
Province	Seoul	90	50	36	23	4	3	6	2	2
	Busan	32	15	16	11	2	1	2	0	1
	Daegu	15	8	6	4	0	0	2	0	1
	Incheon	30	16	12	10	0	1	1	1	1
	Gwangju	6	3	3	1	2	0	0	0	0
	Daejeon	5	2	3	3	0	0	0	0	0
	Ulsan	12	7	4	4	0	0	0	0	1
	Sejong	0	0	0	0	0	0	0	0	0
	Gyeonggi	103	66	26	17	2	3	4	4	7
	Gangwon	10	5	5	4	0	1	0	0	0
	Chungbuk	15	10	3	2	0	0	1	1	1
	Chungnam	24	10	13	9	0	3	1	1	0
	Jeonbuk	11	10	0	0	0	0	0	1	0
	Jeonnam	21	15	5	5	0	0	0	1	0
	Gyeongbuk	28	18	8	4	1	1	2	1	1
	Gyeongnam	38	23	12	11	1	0	0	1	2
	Jeju	5	1	3	1	0	1	1	1	0



Treatment Outcomes of Tuberculosis Cases

[Table 16] Treatment Outcomes of Drug-susceptible TB Cases, 2024

[Table 17] Treatment Outcomes of Drug-susceptible TB Cases aged <65 years, 2024

[Table 18] Treatment Outcomes of Drug-susceptible TB Cases aged ≥ 65 years, 2024

[Table 19] Treatment Outcomes of Drug-resistant TB Cases, 2023

[Table 20] Treatment Outcomes of Drug-resistant TB Cases <65 years, 2023

[Table 21] Treatment Outcomes of Drug-resistant TB Cases ≥ 65 years, 2023

Treatment Outcomes of Tuberculosis Cases

1 Treatment Outcomes of Drug-susceptible TB Cases

[Table 16] Treatment Outcomes of Drug-susceptible TB Cases, 2024

Unit: Cases (%)

Year	Total	Treatment success			Treatment Lost to Follow up	Treatment Failure	Death			Not Evaluated
		Sub-total	Cured	Treatment completed			Sub-total	TB-related death	Non-TB-related death*	
2024	17,228	13,758	3,988	9,770	394	4	2,816	596	2,220	256
	(100.0)	(79.9)	(23.1)	(56.7)	(2.3)	(0.1)	(16.3)	(3.5)	(12.9)	(1.5)

* Non-TB-related death includes Unknown cause of death (The death cause could not be determined)

[Table 17] Treatment Outcomes of Drug-susceptible TB Cases aged < 65 years, 2024

Unit: Cases (%)

Year	Total	Treatment success			Treatment Lost to Follow up	Treatment Failure	Death			Not Evaluated
		Sub-total	Cured	Treatment completed			Sub-total	TB-related death	Non-TB-related death*	
2024	6,964	6,325	1,724	4,601	159	0	332	89	243	148
	(100.0)	(90.8)	(24.8)	(66.1)	(2.3)	(0.0)	(4.8)	(1.3)	(3.5)	(2.1)

* Non-TB-related death includes Unknown cause of death (The death cause could not be determined)

[Table 18] Treatment Outcomes of Drug-susceptible TB Cases aged < 65 years, 2024

Unit: Cases (%)

Year	Total	Treatment success			Treatment Lost to Follow up	Treatment Failure	Death			Not Evaluated
		Sub-total	Cured	Treatment completed			Sub-total	TB-related death	Non-TB-related death*	
2024	10,264	7,433	2,264	5,169	235	4	2,484	507	1,977	108
	(100.0)	(72.4)	(22.1)	(50.4)	(2.3)	(0.1)	(24.2)	(4.9)	(19.3)	(1.1)

* Non-TB-related death includes Unknown cause of death (The death cause could not be determined)

2 Treatment Outcomes of Drug-resistant TB Cases

[Table 19] Treatment Outcomes of Drug-resistant TB Cases, 2023

Unit: Cases (%)

Year	Total	Treatment success			Treatment Lost to Follow up	Treatment Failure	Death			Not Evaluated
		Sub-total	Cured	Treatment completed			Sub-total	TB-related death	Non-TB-related death*	
2023	532	384	227	157	23	0	114	36	78	11
	(100.0)	(72.2)	(42.7)	(29.5)	(4.3)	(0.0)	(21.4)	(6.8)	(14.7)	(2.1)

* Non-TB-related death includes Unknown cause of death (The death cause could not be determined)

[Table 20] Treatment Outcomes of Drug-resistant TB Cases < 65 years, 2023

Unit: Cases (%)

Year	Total	Treatment success			Treatment Lost to Follow up	Treatment Failure	Death			Not Evaluated
		Sub-total	Cured	Treatment completed			Sub-total	TB-related death	Non-TB-related death*	
2023	313	255	157	98	12	0	37	19	18	9
	(100.0)	(81.5)	(50.2)	(31.3)	(3.8)	(0.0)	(11.8)	(6.1)	(5.8)	(2.9)

* Non-TB-related death includes Unknown cause of death (The death cause could not be determined)

[Table 21] Treatment Outcomes of Drug-resistant TB Cases ≥ 65 years, 2023

Unit: Cases (%)

Year	Total	Treatment success			Treatment Lost to Follow up	Treatment Failure	Death			Not Evaluated
		Sub-total	Cured	Treatment completed			Sub-total	TB-related death	Non-TB-related death*	
2023	219	129	70	59	11	0	77	17	60	2
	(100.0)	(58.9)	(32.0)	(26.9)	(5.0)	(0.0)	(35.2)	(7.8)	(27.4)	(0.9)

* Non-TB-related death includes Unknown cause of death (The death cause could not be determined)

**Annual Report
on the Notified Tuberculosis
in the Republic of Korea, 2025**



Appendix

1. Number of TB Deaths by Gender and Age, from the Causes of Death Statistics, Statistics Korea, 2015–2024
2. Tuberculosis Notification·Reporting Form
3. Tuberculosis Case Investigation
4. Contact List of Infectious Tuberculosis Patient
5. Written Order for (Hospitalization, Quarantine Treatment)

Appendix

1. Number of TB Deaths by Gender and Age, from the Causes of Death Statistics, Statistics Korea, 2015–2024

Year	Age Gender	Total	0–4	5–9	10–14	15–19	20–24	25–29	30–34	35–39
2015	Total	2,209	0	0	0	0	0	8	18	15
	Male	1,390	0	0	0	0	0	3	11	10
	Female	819	0	0	0	0	0	5	7	5
2016	Total	2,186	0	0	0	0	5	3	6	16
	Male	1,349	0	0	0	0	2	1	5	11
	Female	837	0	0	0	0	3	2	1	5
2017	Total	1,816	0	0	0	0	2	4	2	10
	Male	1,107	0	0	0	0	2	3	1	9
	Female	709	0	0	0	0	0	1	1	1
2018	Total	1,800	0	0	0	0	0	4	6	4
	Male	1,120	0	0	0	0	0	3	4	4
	Female	680	0	0	0	0	0	1	2	0
2019	Total	1,610	0	0	0	0	1	2	4	6
	Male	977	0	0	0	0	1	1	2	5
	Female	633	0	0	0	0	0	1	2	1
2020	Total	1,356	0	0	0	0	2	3	1	14
	Male	842	0	0	0	0	0	2	0	8
	Female	514	0	0	0	0	2	1	1	6
2021	Total	1,430	0	0	0	0	2	3	1	5
	Male	854	0	0	0	0	1	3	1	3
	Female	576	0	0	0	0	1	0	0	2
2022	Total	1,322	0	0	0	0	0	0	5	1
	Male	791	0	0	0	0	0	0	5	1
	Female	531	0	0	0	0	0	0	0	0
2023	Total	1,331	0	0	0	0	0	2	2	3
	Male	830	0	0	0	0	0	2	2	1
	Female	501	0	0	0	0	0	0	0	2
2024	Total	1,347	0	0	0	0	0	1	0	4
	Male	803	0	0	0	0	0	1	0	1
	Female	544	0	0	0	0	0	0	0	3

※ The number of TB deaths by gender and age is based on the 'Causes of Death Statistics' published annually by Statistics Korea around late September (The number of TB deaths in 2025 will be addressed by Statistics Korea at the end of September, 2026)(Source: Cause of Death Statistics, Statistics Korea)

Unit : person

40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80+	Unknown
37	66	113	117	98	141	201	371	1,023	1
32	56	92	101	86	119	134	242	503	1
5	10	21	16	12	22	67	129	520	0
27	64	87	95	97	120	177	369	1,120	0
22	51	74	81	83	97	132	232	558	0
5	13	13	14	14	23	45	137	562	0
21	47	65	81	88	84	146	290	976	0
20	44	59	71	76	65	111	202	444	0
1	3	6	10	12	19	35	88	532	0
13	47	58	109	76	77	132	313	960	1
12	43	58	93	72	62	93	217	459	0
1	4	0	16	4	15	39	96	501	1
11	35	50	78	88	67	121	224	923	0
6	31	44	63	76	60	95	148	445	0
5	4	6	15	12	7	26	76	478	0
18	32	44	54	68	71	90	206	752	1
14	28	40	46	56	65	76	133	373	1
4	4	4	8	12	6	14	73	379	0
14	24	52	59	91	74	96	191	818	0
11	20	44	51	83	53	73	127	384	0
3	4	8	8	8	21	23	64	434	0
15	21	40	42	67	72	87	154	818	0
12	14	35	34	54	53	67	104	412	0
3	7	5	8	13	19	20	50	406	0
10	21	40	37	56	76	82	175	827	0
8	17	38	32	43	63	61	130	433	0
2	4	2	5	13	13	21	45	394	0
3	14	29	39	65	69	123	137	863	0
3	12	24	35	54	56	93	99	425	0
0	2	5	4	11	13	30	38	438	0

2. Tuberculosis Notification·Reporting Form

■ Enforcement Rules of the Tuberculosis Prevention Act [Attached Form No. 1] (Amended on Sep. 30, 2024)

Tuberculosis Notification·Reporting Form

(Page 1 of 3)

※ The shaded fields are mandatory for notification and reporting and must be filled out.

※ Please refer to the instructions on page 2 for notification methods and how to complete this form, and place a check mark (✓) in the [] boxes where applicable.

Recipient: Director of _____ Public Health Center

Fax Number: _____

1. Notification: [] Diagnosis or treatment of a tuberculosis (hereinafter, "TB") patient or suspected case
[] Death or postmortem examination of a TB patient or suspected case (Date of death: [MM.DD.YYYY.])
[] TB-related death ([] primary cause [] other cause) [] Non-TB-related death [] Unknown cause of death

A. Personal Information

(1) Name:	(2) Resident (Foreign) Registration No.:
(3) Age:	(4) Sex: [] Male [] Female
(5) Medical Coverage: [] National Health Insurance ([] Reduced copayment recipient) [] Medical Aid [] Veterans and other beneficiaries [] Other () [] N/A	
(6) Nationality (for foreign nationals only):	(7) Most recent date of entry (for foreign nationals only: [MM.DD.YYYY.])
(8) Telephone:	(9) Mobile:
(10) Address:	
(11) Occupation: [] School staff [] Healthcare worker [] Student [] Soldier [] Barber, Hairdresser, or related worker [] Food service worker [] Seafarer (deep-sea) [] Aircraft cabin crew [] Livestock Industry Worker or related field [] Other occupation () [] Unemployed	
(12) Facility name (workplace, school, care facility, etc.):	
(13) Facility address (workplace, school, care facility, etc.):	

B. Examination, Diagnosis and Treatment Information

[Initial TB Tests] ※ Please place a check mark (✓) in the applicable fields.

(14) Type of initial test	(15) Test state and result				(16) Date of specimen collection (or date of test)	(17) Type of Specimen
	Not performed	Test in progress	Test completed Positive Cavity	Test completed Negative NTM Not interpretable		
Chest X-ray					[MM.DD.YYYY.]	
Smear test					[MM.DD.YYYY.]	[] Sputum, [] Other: _____
Culture test					[MM.DD.YYYY.]	[] Sputum, [] Other: _____
Nucleic acid amplification test (TB-PCR)					[MM.DD.YYYY.]	[] Sputum, [] Other: _____
Xpert MTB/RIF test, etc.					[MM.DD.YYYY.]	[] Sputum, [] Other: _____
Biopsy					[MM.DD.YYYY.]	

[Diagnosis and Initial Treatment Drugs]

(18) ICD-10 code: [] [] [] [] []	(19) Date of diagnosis: [MM.DD.YYYY.]	(21) TB patient category: [] New patient [] Previously treated patient [] Relapse patient, [] Treatment after failure patient, [] Treatment after loss to follow-up patient, [] Other previously treated patient [] Patient with unknown previous TB treatment history
(20) Site of TB [] Pulmonary TB (TB involving the lung parenchyma or larynx, trachea or bronchi; or miliary TB) [] Extrapulmonary TB (site: _____) [] Both pulmonary and extrapulmonary TB (site: _____)		
(22) Whether this medical institution provides treatment: [] Treatment (start or scheduled date: [MM.DD.YYYY.]) [] Not treatment		
(23) Treatment drugs: [] H [] R [] E [] Z [] RFB [] RPT [] Km [] Am [] Cm [] S [] Lfx [] Mfx [] Ofx [] Gfx [] Pto [] Cs [] PAS [] Eto [] Trd [] PAS-Na [] Lzd [] Clr [] Bdq [] Dlm [] Cfz [] Mpm [] Amx/Clv [] IpM/ClN [] high dose H [] JT [] Pa [] Other drugs ()		

[Drug-resistant TB Diagnosis and Treatment Drugs]

(24) Drug susceptibility test result: [] Not performed [] Test in progress [] Test completed ([] No resistance [] Resistance)	
(25) Drug susceptibility test method: [] Conventional susceptibility test [] Rapid susceptibility test [] Real-time PCR test (Xpert MTB/RIF test, etc.)	
(26) Anti-TB drug-resistant drugs: [] H [] R [] E [] Z [] RFB [] RPT [] Km [] Am [] Cm [] S [] Lfx [] Mfx [] Ofx [] Gfx [] Pto [] Cs [] PAS [] Eto [] Trd [] PAS-Na [] Lzd [] Clr [] Bdq [] Dlm [] Cfz [] Mpm [] Amx/Clv [] IpM/ClN [] high dose H [] JT [] Pa [] Other drugs ()	
(27) Type of drug-resistant TB: [] Extensively drug-resistant TB [] Pre-extensively drug-resistant TB [] Multidrug-resistant TB [] Rifampicin-resistant TB [] Isoniazid-resistant TB	
(28) Date of specimen collection: [MM.DD.YYYY.]	
(29) Whether this medical institution provides treatment for drug-resistant TB: [] Treatment (start or scheduled date: [MM.DD.YYYY.]) [] Not treatment	
(30) Drug-resistant TB treatment drugs: [] H [] R [] E [] Z [] RFB [] RPT [] Km [] Am [] Cm [] S [] Lfx [] Mfx [] Ofx [] Gfx [] Pto [] Cs [] PAS [] Eto [] Trd [] PAS-Na [] Lzd [] Clr [] Bdq [] Dlm [] Cfz [] Mpm [] Amx/Clv [] IpM/ClN [] high dose H [] JT [] Pa [] Other drugs ()	

2. Treatment Outcome Report

(31) Treatment outcome: [] Cured [] Treatment completed [] Treatment failed [] Died ([] TB-related death ([] Primary cause, [] Other cause) [] Non-TB-related death [] Unknown cause of death [] Lost to follow-up [] Not evaluated [] TB Diagnosis changed ([] NTM [] Tumor [] Other disease)	
(32) Date of outcome determination: [MM.DD.YYYY.]	(33) Date of treatment completion: [MM.DD.YYYY.]
(34) Remarks:	

210mm×297mm[White Paper 80/m²]

[Notifier - Reporter]

(35) Date of notification or reporting: [MM.DD.YYYY.]

(36) No. of notifying institution: Name of notifying institution: Tel. of notifying institution:

(37) Name of diagnosing physician: (signature or seal) Medical license No.: Medical specialty: Name of head of notifying institution:

In accordance with Article 8 of the *Tuberculosis Prevention Act* and Article 3 of the *Enforcement Rules* thereof, the TB patient or suspected case is hereby notified · reported as described above.**Methods of Notification**

1. TB is classified as a Class 2 infectious disease under the Infectious Disease Control and Prevention Act. If a TB patient or suspected case is diagnosed or treated in accordance with the Standards for the Diagnosis of Infectious Diseases as determined and announced by the Commissioner of the Korea Disease Control and Prevention Agency, or if a tuberculosis patient or suspected case dies or undergoes a postmortem examination, a TB Notification · Reporting Form must be submitted to the director of the competent public health center within 24 hours.
2. If, at the time of notification, diagnostic tests have not been conducted or are still in progress, only the identifiable items may be completed, and a supplemental notification must be submitted once the test results become available.
3. If a notified TB patient or suspected case has been treated, the treatment outcome must be reported to the director of the competent public health center.
4. Notification can be made via fax or through the information system [Korea Tuberculosis Network System (<https://is.kdca.go.kr>)].

Instructions for Completion**1. Notification****A. Personal Information**

- (1) **Name:** Write the name in Korean without special characters or spaces (for a foreign national, write the English name as indicated on the foreign registration card, and if the person does not have a foreign registration card, write the name as indicated on the passport.)
- (2) **Resident (Foreign) Registration No.:** Write the 13-digit resident registration number (for a foreign national, write the foreign registration number, and if the person does not have a foreign registration card, write the date of birth and passport number as indicated on the passport)
※ If the resident (foreign) registration number of the patient (or deceased person) cannot be identified, write only what can be identified and fill the remaining part with an asterisk (*).
- (5) **Medical Coverage:** Place a check mark (✓) in the applicable field. If the person is not enrolled in any medical coverage, place a check mark (✓) in the "N/A" field.
- (11) **Occupation:** Place a check mark (✓) in the applicable occupation field, and if the person has more than one occupation, list all applicable occupations.
※ Livestock or related field: Livestock-related workers and zoo-related workers
 - ① Livestock-related workers: Livestock farm workers, veterinarians, livestock artificial insemination technicians, quarantine officers for livestock, government officials responsible for livestock quarantine, slaughterhouse workers, livestock manure handlers, drivers of vehicles entering livestock farms, etc.
 - ② Zoo-related workers: Zoo employees (caretakers, veterinarians, staff, etc.)
- (12) · (13) **Facility name and address:** Write the name and address of the facility such as a workplace, school, care facility, etc. If the person has more than one occupation, list each facility name and address for each occupation.

B. Examination, Diagnosis and Treatment Information**[Initial TB Tests]**

- (14) **Type of initial test:** Initial tests must always be performed, and if a test has not yet been performed or is still in progress, submit a supplemental notification once the test results are available.
- (15) **Test state and result:** For chest X-ray, if the result indicates a suspicion of TB, place a check mark (✓) in the "Positive" field.
- (17) **Type of Specimen:** If the specimen is not sputum, place a check mark (✓) in the "Other" and specify the type of specimen.

[Diagnosis and Initial Treatment Drugs]

- (18) **ICD-10 code:** Write the relevant sub-class code for TB, and if the sub-class code is unknown or not applicable, write the class code.
- (19) **Date of diagnosis:** Write the date when the patient was first diagnosed as a TB patient or suspected case by the notifying medical institution.
- (20) **Site of TB:** If the diagnosis is extrapulmonary TB, specify the anatomical site of TB.
- (21) **TB Patient category:** Refer to page 3 for the definitions of TB patient category and place a check mark (✓) in the applicable field.
- (22) **Whether this medical institution provides treatment:** If the patient was diagnosed and not treated at the relevant medical institution and referred to another institution for treatment, place a check mark (✓) in the "Not treatment" field.
- (23) **Treatment drugs:** Write the drug ingredients initially prescribed by the notifying medical institution after diagnosing the TB patient or suspected case.

※ Drug ingredients (Abbreviations)

isoniazid(H), rifampicin(R), ethambutol(E), pyrazinamide(Z), rifabutin(RFB), rifapentine(RPT), kanamycin(Km), amikacin(Am), capreomycin(Cm), streptomycin(S), levofloxacin(Lfx), moxifloxacin(Mfx), ofloxacin(Ofx), gatifloxacin(Gfx), prothionamide(Pto), cycloserine(Cs), p-aminosalicylic acid(PAS), ethionamide(Eto), terizidone(Trd), sodium p-aminosalicylic acid(PAS-Na), linezolid(Lzd), clarithromycin(Clr), bedaquiline(Bdq), delamanid(Dlm), clofazimine(Cfz), meropenem(Mpm), amoxicillin/clavulanate(Amx/Civ), imipenem/cilastatin(lpm/Cln), high dose isoniazid(high dose H), thioacetazone(T), pretomanid(Pa)

[Drug-resistant TB Diagnosis and Treatment Drugs]

- (24) ~ (28): Whenever a drug susceptibility test is conducted, submit a supplemental notification.
- (27) **Type of drug-resistant TB:** Refer to page 3 for definitions of drug-resistant TB and place a check mark (✓) in the applicable field.
- (28) **Date of specimen collection:** Write the date the specimen for the drug susceptibility test was collected from the patient, even if the test is still in progress.
- (29) **Whether this medical institution provides treatment for drug-resistant TB:** If the patient was referred to another institution after being diagnosed with drug-resistant TB [when (27) Type of drug-resistant TB is marked] without receiving treatment, place a check mark (✓) in the "Not treatment" field.
- (30) **Drug-resistant TB treatment drugs:** Write the names of the drug-resistant TB treatment drugs initially prescribed by the notifying medical institution after the patient is diagnosed with drug-resistant TB [For the names of the drug-resistant TB treatment drugs, refer to (23) Treatment drugs].

2. Treatment Outcome Report

- (31) **Treatment outcome:** Refer to the definitions of treatment outcome on page 3, and place a check mark (✓) in the applicable field.
- (32) **Date of outcome determination:** Write the date when the treatment outcome was determined, and if the patient was transferred to another medical institution for continued treatment, write the date of the last visit at the relevant medical institution.
- (33) **Date of treatment completion:** Write the date when treatment (medication) ended at the relevant medical institution.
- (34) **Remarks:** Provide any important information not already included in the notification and report form, such as the patient's actual place of residence, previously used treatment drugs, amendments or supplemental details or other relevant information when the patient has been transferred to another medical institution for continued treatment.

[Notifier · Reporter]

- (35) **Date of notification or report:** Write the date on which the notifier or reporter first notified the competent public health center (If the notification was submitted by fax, write the date the fax was sent; if submitted via the information system, write the date on which the data was entered into the system.)

Definitions by TB Patient Category	
Category	Definition
New patient	New patients have never been treated for TB or have taken anti-TB drugs for less than 1 month. ※ If new patients are transferred to another healthcare facility without treatment outcomes (cured, treatment completed, treatment failed, or lost to follow-up), they will be considered new patients.
Previously treated patient	Previously treated patients have received 1 month or more of anti-TB drugs in the past. ※ They are further classified by the outcome of their most recent course of treatment as follows:
Relapse patient	Relapse patients have previously been treated for TB, were declared cured or treatment completed at the end of their most recent course of treatment, and are now diagnosed with a recurrent episode of TB
Treatment after failure patient	Treatment after failure patients are those who have previously been treated for TB and whose treatment failed at the end of their most recent course of treatment.
Treatment after loss to follow-up patient	Treatment after loss to follow-up patients have previously been treated for TB and were declared lost to follow-up at the end of their most recent course of treatment.
Other previously treated patient	Other previously treated patients are those who have previously been treated for TB but whose outcome after their most recent course of treatment is unknown or undocumented.
※ Definitions of treatment outcome (cured, treatment completed, treatment failed, lost to follow-up) are provided below.	
Patient with unknown previous TB treatment history	Patients with unknown previous TB treatment history do not fit into any of the categories listed above.

Definitions of TB Treatment Outcome									
Category	Definition								
Cured	A patient with pulmonary TB with bacteriologically confirmed TB at the beginning of treatment who completed treatment as recommended by the national guideline, with evidence of bacteriological response (bacteriological conversion with no reversion) and no evidence of failure.								
Treatment completed	A patient who completed treatment as recommended by the national guideline but whose outcome does not meet the definition for cured or treatment failed.								
Treatment failed	A patient whose treatment regimen needed to be terminated or permanently changed ^a to a new treatment regimen or strategy.								
Died	A patient who died before starting treatment or during the course of treatment.								
	<table> <tr> <td>Primary cause</td><td>In cases where TB is listed as the underlying cause of death on the death certificate.</td></tr> <tr> <td>Other cause</td><td>In cases where TB is listed among other causes of death on the death certificate.</td></tr> <tr> <td>Non-TB-related death</td><td>In cases where the cause of death listed on the death certificate does not include TB.</td></tr> <tr> <td>Unknown cause of death</td><td>In cases where the death certificate cannot be checked, and the cause of death is therefore unclear.</td></tr> </table>	Primary cause	In cases where TB is listed as the underlying cause of death on the death certificate.	Other cause	In cases where TB is listed among other causes of death on the death certificate.	Non-TB-related death	In cases where the cause of death listed on the death certificate does not include TB.	Unknown cause of death	In cases where the death certificate cannot be checked, and the cause of death is therefore unclear.
Primary cause	In cases where TB is listed as the underlying cause of death on the death certificate.								
Other cause	In cases where TB is listed among other causes of death on the death certificate.								
Non-TB-related death	In cases where the cause of death listed on the death certificate does not include TB.								
Unknown cause of death	In cases where the death certificate cannot be checked, and the cause of death is therefore unclear.								
Lost to follow-up	A patient who did not start treatment or whose treatment was interrupted for 2 consecutive months or more.								
Not evaluated	A patient to whom none of the following treatment outcomes was assigned: cured, treatment completed, treatment failed, died, or lost to follow-up. This includes cases "transferred out" to another treatment unit with an unknown treatment outcome.								
TB Diagnosis changed	A case in which the diagnosis has been changed to a condition other than tuberculosis (TB).								

^a For reasons including

• No clinical or bacteriological response^{*}; adverse drug reaction; or acquisition of additional drug-resistance to medicines in the regimen

^{*} Bacteriological response refers to bacteriological conversion with no reversion:

- bacteriological conversion describes a situation in a patient with bacteriologically confirmed TB where at least two consecutive cultures (for drug-susceptible TB and drug-resistant TB) or smears (for drug-susceptible TB only) taken on different occasions at least 7 days apart are negative.
- bacteriological reversion describes a situation where at least two consecutive cultures (for drug-susceptible TB and drug-resistant TB) or smears (for drug-susceptible TB only) taken on different occasions at least 7 days apart are positive either after the bacteriological conversion or in patients without bacteriological confirmation of TB.

Definitions of Drug-resistant TB	
Category	Definition
Extensively drug-resistant TB	TB caused by a strain of <i>Mycobacterium tuberculosis</i> complex that is resistant to rifampicin (and may also be resistant to isoniazid), and that is also resistant to at least one fluoroquinolone [*] and to at least one other "Group A" drug ^{**} . * levofloxacin (Lfx), moxifloxacin (Mfx), ofloxacin (Ofx), or gatifloxacin (Gfx) ** bedaquiline (Bdq) or linezolid (Lzd)
Pre-extensively drug-resistant TB	TB caused by a strain of <i>Mycobacterium tuberculosis</i> complex that is resistant to rifampicin (and may also be resistant to isoniazid), and that is also resistant to at least one fluoroquinolone.
Multidrug-resistant TB	TB caused by a strain of <i>Mycobacterium tuberculosis</i> complex that is resistant to rifampicin and isoniazid.
Rifampin-resistant TB	TB caused by a strain of <i>Mycobacterium tuberculosis</i> complex that is resistant to rifampicin. These strains may be susceptible or resistant to isoniazid.
Isoniazid-resistant TB	TB caused by a strain of <i>Mycobacterium tuberculosis</i> complex that is resistant to isoniazid but susceptible to rifampicin

210mm × 297mm [White Paper 80/m²]

3. Tuberculosis Case Investigation

■ Enforcement Rules of the Tuberculosis Prevention Act [Attached Form No. 2] (Amended on Sep. 30, 2024)

(Page 1 of 3)

Tuberculosis Case Investigation

※ Place a check mark(✓) in [] where applicable.

A. Personal Information						
(1) Name		(2) Date of birth	/ / [MM/DD/YYYY]	(5) Contact	Home:	
(3) Sex	☐ M ☐ F	(4) Age			Work:	
					Mobile:	
(6) Medical coverage	☐ National Health Insurance (☐ Reduced copayment recipient) ☐ Medical Aid ☐ Veterans and other beneficiaries ☐ Other () ☐ N/A					
(7) Address						
(8) through (10) are for foreign nationals only.						
(8) Nationality		(9) Visa status				
(10) Date of entry						
(11) Occupation	☐ School staff ☐ Healthcare worker (☐ Doctor ☐ Nurse ☐ Nursing assistant ☐ Radiologic technologist ☐ Clinical laboratory technologist ☐ Physical therapist ☐ Other () ☐ Student ☐ Soldier (☐ Career soldier ☐ Active duty soldier ☐ Social service worker) ☐ Barber, Hairdresser, or related worker ☐ Food service worker ☐ Seafarer (deep-sea) ☐ Aircraft cabin crew ☐ Livestock or related field (☐ Livestock-related worker ☐ Zoo worker) ☐ Other occupation () ☐ Unemployed					
(12) Facility name (workplace, school, care facility, etc.)						
(13) Facility category	☐ School ☐ Medical institution ☐ Military unit ☐ Police station ☐ Correctional facility ☐ Social welfare facility ☐ Business establishment ☐ Other facility ()					
(14) Facility address						
(15) through (20) apply only to infants and toddlers up to 24 months of age only.						
(15) Name of birth hospital						
(16) Address of birth hospital						
(17) Delivery method	☐ Vaginal Birth ☐ Cesarean section					
(18) Use of postnatal care center	☐ Used ☐ Not used					
(19) Name of postnatal care center						
(20) Address of postnatal care center						
B. Information on Contacts						
(21) Type of residence	☐ Household with two or more person ☐ Single-person household ☐ Dormitory ☐ Facility (care facility, welfare facility, etc.)					
(22) History of Exposure to a Tuberculosis (TB) Patient	☐ Yes ☐ No ☐ Unknown					
	※ Complete the following only if "Yes"					
	Order	Relationship			Treatment state	
	1	☐ Grandfather ☐ Father ☐ Mother ☐ Spouse ☐ Sibling ☐ Child ☐ Grandchild ☐ Relative ☐ Other cohabitant			☐ Untreated ☐ Treatment in progress ☐ Treatment completed ☐ Unknown	
	2	☐ Grandfather ☐ Father ☐ Mother ☐ Spouse ☐ Sibling ☐ Child ☐ Grandchild ☐ Relative ☐ Other cohabitant			☐ Untreated ☐ Treatment in progress ☐ Treatment completed ☐ Unknown	
3	☐ Grandfather ☐ Father ☐ Mother ☐ Spouse ☐ Sibling ☐ Child ☐ Grandchild ☐ Relative ☐ Other cohabitant			☐ Untreated ☐ Treatment in progress ☐ Treatment completed ☐ Unknown		
(23) Household Members and Close Contacts	Order	Relationship	Name	Age	Sex	Contact
	1					
	2					
	3					
	4					
	5					

C. Matters Regarding Examination, Diagnosis and Treatment									
(24) Symptoms experienced by the TB patient (Please check all that apply)	☐ None		☐ Cough		☐ Sputum (phlegm)		☐ Chest pain		☐ Dyspnea
	☐ Weight loss		☐ Night sweats		☐ Fever		☐ Hemoptysis		☐ Other symptoms ()
(25) Date of Symptom Onset	[]/[]/[] [MM/DD/YYYY]								
(26) Height and weight	cm, kg								
(27) Initial test results	Initial test type		Chest X-ray	Smear test	Culture test	Nucleic acid amplification test (TB-PCR test)	Xpert MTB/RIF test, etc.	Biopsy	
	Test state and result	Not performed							
		Test in progress							
		Test completed	☐ Suspicious of TB (☐ Joint)	☐ Positive (☐ trace ☐ ++ ☐ +++ ☐ ++++)	☐ Positive (☐ + ☐ ++ ☐ +++ ☐ ++++)	☐ Positive	☐ Positive	☐ Positive	
			☐ Normal	☐ Negative	☐ Negative (☐ NTM)	☐ Negative (☐ NTM)	☐ Negative	☐ Negative	
		☐ Not interpretable	☐ Not interpretable	☐ Not interpretable	☐ Not interpretable	☐ Not interpretable	☐ Not interpretable	☐ Not interpretable	
	Specimen type		☐ Sputum ☐ Non-sputum:		☐ Sputum ☐ Non-sputum:		☐ Sputum ☐ Non-sputum:		
	Culture medium		☐ Solid ☐ Liquid						
	Date of specimen collection (or date of test)		[]/[]/[] [MM/DD/YYYY]	[]/[]/[] [MM/DD/YYYY]	[]/[]/[] [MM/DD/YYYY]	[]/[]/[] [MM/DD/YYYY]	[]/[]/[] [MM/DD/YYYY]	[]/[]/[] [MM/DD/YYYY]	
	Date of result confirmation		[]/[]/[] [MM/DD/YYYY]	[]/[]/[] [MM/DD/YYYY]	[]/[]/[] [MM/DD/YYYY]	[]/[]/[] [MM/DD/YYYY]	[]/[]/[] [MM/DD/YYYY]	[]/[]/[] [MM/DD/YYYY]	
(28) Drug susceptibility test	Result		☐ Not performed ☐ Test in progress ☐ Test completed (☐ No resistance ☐ Resistance)						
	Test method		☐ Conventional susceptibility test ☐ Rapid susceptibility test ☐ Real-time PCR test (Xpert MTB/RIF test, etc.)						
	Anti-TB drug-resistant drugs		☐ H ☐ Am ☐ Pto ☐ Lzd ☐ Amx/Civ ☐ Other drugs ()	☐ R ☐ Cm ☐ Cs ☐ Clr ☐ Ipml/Cln ☐ high dose H	☐ E ☐ S ☐ PAS ☐ Bdq ☐ Dlm	☐ Z ☐ Lfx ☐ Eto ☐ Dlm ☐ Cfz ☐ T	☐ RFB ☐ Mfx ☐ Trd ☐ CFZ ☐ Pa	☐ RPT ☐ Ofx ☐ PAS-Na ☐ Mpm	☐ Km ☐ Gfx
	Type of drug-resistant TB		☐ Extensively drug-resistant TB ☐ Rifampin-resistant TB ☐ Pre-extensively drug-resistant TB ☐ Isoniazid-resistant TB ☐ Multidrug-resistant TB						
	Date of specimen collection		[] / [] / [] [MM/DD/YYYY]						
	Date of result confirmation		[] / [] / [] [MM/DD/YYYY]						
	(29) Treatment outcome		☐ Cured ☐ Completed ☐ Failed ☐ Lost to follow-up ☐ Died (☐ TB-related death (☐ Primary cause ☐ Other cause) ☐ Death from a cause other than TB ☐ Unknown cause of death ☐ Not evaluated ☐ TB Diagnosis changed (☐ NTM ☐ Tumor ☐ Other disease)						
	(30) Reason for treatment failure		☐ Absence of clinical response ☐ Absence of bacteriological response ☐ Drug side effects ☐ Acquisition of additional resistance ☐ Other reason ()						
(31) Reason for treatment discontinuation		☐ Lost ☐ Side effect of anti-TB drugs ☐ Lack of awareness of illness ☐ Return to home country (for foreigners) ☐ Difficulty visiting hospital (distance, work, etc.) ☐ Burden of taking medication ☐ Financial reason ☐ Improvement of symptoms ☐ Other reason ()							

D. Matters Regarding Past Medical History and Treatment History			
(32) History of TB infection		☐ No ☐ Yes ☐ Unknown ※ Complete the following only if "Yes." - Number of previous TB treatment: ☐ Untreated ☐ Once ☐ Twice or more - Year of diagnosis () - Duration of previous TB treatment (or medication use): ☐ Untreated ☐ Less than 1 month ☐ 1 month or more ☐ Unknown	
(33) History of latent TB infection		☐ No ☐ Yes ☐ Unknown ※ Complete the following only if "Yes." - Year of diagnosis () - Treatment outcome (☐ Untreated ☐ Under treatment ☐ Treatment completed)	
Risk Factors	(34) Underlying disease	☐ No ☐ Yes ※ Complete the following only if "Yes." ☐ Silicosis ☐ Gastrectomy, etc. ☐ Cancer ☐ Chronic renal failure ☐ HIV ☐ Alcohol abuse ☐ Steroid use ☐ Diabetes ☐ Immunosuppressant use ☐ TNF antagonist use ☐ Pregnant ☐ Other disease ()	
	(35) Smoking status	☐ Non-smoker ☐ Former Smoker (Quit) ☐ Current smoker	
(36) BCG vaccination status (Applicable only to those under 15 years of age)		☐ No ☐ Yes ☐ Unknown ※ Complete the following only if "Yes." ☐ Intradermal ☐ Percutaneous ☐ Unknown	
(37) Reason for medical consultation		☐ Patient visit (☐ Due to TB symptoms ☐ Due to other illness ☐ Other reason) ☐ Health examination by the National Health Insurance Service ☐ Personal health examination ☐ Student health examination ☐ Issuance of health examination certificate (formerly health card) ☐ Visa issuance for foreign nationals ☐ Family contact examination ☐ Epidemiological investigation ☐ Other reason ()	
E. Others to Note			
Record details of residence or regular activities within communal living or group facilities, etc.			

Date of investigation	[/ /] [MM/DD/YYYY]		
Investigating agency	☐ Public Health Center (Name of center:)	Investigator	Name:
	☐ Medical Institution (Name of institution:)		Contact:

4. Contact List of Infectious Tuberculosis Patient

■ Enforcement Rules of the Tuberculosis Prevention Act [Attached Form No. 3] (Amended on Dec. 1, 2023)

Contact List of Infectious Tuberculosis Patient

※ Place a check mark (✓) in [] where applicable

(Page 1 of 2)

1. Contact List													
(1) Index Patient Information			(2) Contact Information										
			Personal Information					Initial Test		Follow-up Test		Treatment	
Name	Resident (Foreign) Reg. No.	Organization	Name	Relationship	Resident (Foreign) Reg. No.	Organization Name or Home Address	Phone Number	Type	Result	Type	Result	Regimen	Outcome

2. Detailed Information for Each Contact Person	
A. Pre-Screening Assessment	
(3) TB Symptoms	☐ None ☐ Cough ☐ Sputum (Phlegm) ☐ Chest Pain ☐ Dyspnea ☐ Weight Loss ☐ Night Sweats ☐ Fever ☐ Hemoptysis ☐ Other Symptoms
(4) History of TB Treatment	☐ No ☐ Yes ☐ Unknown ※ If "Yes," complete the following: - Year of Diagnosis () - Treatment Outcome ☐ Cured ☐ Discontinued ☐ Unknown
(5) History of Latent TB Infection	☐ No ☐ Yes ☐ Unknown ※ If "Yes," complete the following: - Year of Diagnosis () - Treatment Outcome ☐ Cured ☐ Discontinued ☐ Unknown
(6) Pregnancy Status	☐ No ☐ Yes
(7) History of Live Vaccine Administration in the Past 4 Weeks	☐ No ☐ Yes (Date of Vaccination: [MM.DD.YYYY.]) ☐ Unknown [Type of live vaccines: MMR, chickenpox, shingles, yellow fever, live influenza (spray), live Japanese encephalitis vaccine, etc.]
(8) BCG Vaccination Status	☐ No ☐ Yes ☐ Unknown ※ If "Yes," complete the following: ☐ Within 1 year of birth ☐ After 1 year of birth ☐ Unknown (Generally given within four weeks of birth according to national immunization programs)
(9) Keloid Prone Condition	☐ No ☐ Yes ☐ Unknown
(10) Fear of Injections	☐ No ☐ Yes ☐ Unknown
B. Risk Factors	
(11) Underlying Health Conditions	☐ No ☐ Yes ☐ Unknown ※ If "Yes," complete the following: ☐ Immunosuppressant Use ☐ TNF Antagonist Use ☐ Silicosis ☐ Steroid Use ☐ Chronic Renal Failure ☐ Diabetes ☐ Head & Neck - Blood Cancer ☐ Stomach or Intestinal Surgery ☐ Immunocompromised Condition () ☐ Other Conditions ()
(12) Smoking Status	☐ Non-Smoker ☐ Former Smoker (Quit) ☐ Current Smoker
C. Exposure History to TB Patient	
(13) Date of Last Contact with TB Patient	[MM.DD.YYYY.]
(14) Cumulative exposure time	☐ Less than 40hrs ☐ 40hrs-Less than 100hrs ☐ 100hrs-Less than 250hrs ☐ 250hrs-Less than 500hrs ☐ 500hrs or more

Instructions for Completion

1. Contact List: To be completed by public health center officials

- (1) Index patient information: Write the name, resident (foreign) registration number and organization name.
- (2) Contact Information: Write the name, relationship with the TB patient, resident (foreign) registration number, organization name or home address, phone number, the types and results of initial and follow-up tests and the regimen and outcome of treatment.
 - Name: Write in Korean without special characters or spaces (For foreigners, write the English name as stated on the foreigner registration card, and If not registered, write the English name as stated on the passport.)
 - Resident (Foreign) Reg. No.: Write the 13-digit resident registration number (For foreigners, write the foreigner registration number, and If unavailable, write the date of birth as stated on the passport.)
 - Organization Name or Home Address: For contacts in congregate settings, write the organization name, and for household contacts, write the home address.
 - Phone number: Provide a reachable phone number for test scheduling and follow-up, and if unavailable, provide a guardian's phone number.
 - Initial Test Type/Result: Write the initial test types and results.
 - Follow-up Test Type/Result: Write the follow-up test types and results.
 - Treatment Regimen/Outcome: If the contact person undergoes treatment for TB or latent TB infection, write the regimen and outcome of the treatment.

2. Detailed Information for Each Contact Person: Sections A and B to be completed by the contact person; Section C to be completed by public health center officials

A. Pre-Screening Assessment

- (3) TB Symptoms: Place a check mark (✓) in the applicable symptoms if present
- (4) History of TB Treatment: If previously treated for TB, write the year diagnosed and treatment outcome.
- (5) History of Latent TB Infection: If previously diagnosed with latent TB infection, write the year diagnosed and treatment outcome.
- (6) Pregnancy Status: Place a check mark (✓) in the "Yes" field if pregnant or possibly pregnant. Otherwise, place a check mark (✓) in the "No" field.
- (7) History of Live Vaccine Administration in the Past 4 Weeks: Place a check mark (✓) in the applicable field based on vaccination history within the last four weeks.
- (8) BCG Vaccination Status: Write only if the contact person undergoes a tuberculin skin test and place a check mark (✓) in the applicable time of vaccination.
- (9) Keloid Prone Condition: Write only if the contact person undergoes a tuberculin skin test. Keloids are raised scars that extend beyond the original injury, and place a check mark (✓) if applicable.
- (10) Fear of Injections: Place a check mark (✓) in the applicable field.

B. Risk Factors

- (11) Underlying Health Conditions: If you have any underlying health conditions, place a check mark (✓) in the "Yes" field, and if you are currently using or are scheduled to use immunosuppressants, TNF antagonists*, have silicosis, are using or are scheduled to use steroids in doses of 15 mg or more per day for at least one month, are undergoing dialysis for chronic kidney disease, have diabetes, have head and neck cancer or blood cancer, have undergone or are scheduled to undergo a gastrectomy or intestinal bypass surgery, have an immunodeficiency disease [HIV infection, etc.] or have any other medical condition, place a check mark (✓) in the applicable field.
 - * TNF Antagonists: Medications used for chronic inflammatory diseases such as rheumatoid arthritis, ankylosing spondylitis, Crohn's disease and psoriasis, and the active ingredients include infliximab, adalimumab, etanercept, afelimomab, certolizumab pegol and golimumab.
- (12) Smoking History: Place a check mark (✓) in the applicable field.

C. Exposure History to TB Patient

- (13) Date of Last Contact with TB Patient: Write the date of last contact with the TB patient.
- (14) Cumulative exposure time: Place a check mark (✓) in the field corresponding to the total cumulative hours the contact person was exposed to the TB patient during the infectious period.

5. Written Order for (Hospitalization, Quarantine Treatment)

■ Enforcement Decree of the Tuberculosis Prevention Act [Attached Form] (Amended on Jul. 28, 2014)

[] Hospitalization Written Order for [] Quarantine Treatment			
Name		Date of Birth (Gender)	 ([]M, []F)
Place of Hospitalization	(Facility Name)	Date of hospitalization	
	(Address)	Period	to

☐ The person named above is hereby ordered to be hospitalized in accordance with Article 15 of the *Tuberculosis Prevention Act* and Article 4 of its *Enforcement Decree*, as they pose a risk of transmitting tuberculosis to cohabitants or third parties.

※ Failure to comply with this hospitalization order may result in a quarantine treatment order pursuant to Article 15-2, Paragraph 1, Subparagraph 1 of the *Tuberculosis Prevention Act*.

☐ The person named above is at risk of transmitting tuberculosis to the public by refusing hospitalization order, voluntarily discharging themselves during treatment, discontinuing treatment, or temporarily leaves the hospital without authorization. Therefore, in accordance with Article 15-2, Paragraph 1 of the *Tuberculosis Prevention Act* and Article 4 of its *Enforcement Decree*, quarantine treatment is hereby mandated.

※ If the person does not comply with this quarantine treatment order, they may be subject to a fine up to KRW 5 million pursuant to Article 33, subparagraph 3 of the *Tuberculosis Prevention Act*.

[/ /]
[MM/DD/YYYY]

**Special Metropolitan City Mayor · Metropolitan City
Mayor · Special Self-Governing City Mayor
· Do [Province] Governor · Special Self-Governing
Province Governor · Head of a Si/Gun/Gu**

Seal

210mm×297mm(White Paper 80g/㎡)

Annual Report on the Notified Tuberculosis in the Republic of Korea, 2025

Printed in | March 2026

Published in | April 2026

Publisher | Korea Disease Control and Prevention Agency

Published by | Seung-kwan Im, Commissioner of the KDCA

I S S N | 2092-5956

Edited by | Jeongik Hong, Director General of the Department
of Infectious Disease Policy, KDCA
Seungeun Lee, Hyewon Lee, Jaetae Kim, Hyeran Jung
at the Division of Tuberculosis Policy, KDCA

Address | Korea Disease Control and Prevention Agency, 187,
Osongsaengmyeong 2-ro, Osong-eup, Heungdeok-gu,
Cheongju-si, Chungcheongbuk-do, 28159, Republic of Korea

T e l . | (043) 719-7341

F a x . | (043) 719-7334

Annual Report on the Notified Tuberculosis in the Republic of Korea, 2025



**Korea Disease Control and
Prevention Agency**

28159 Korea Disease Control and Prevention Agency, 187,
Osongsaengmyeong 2-ro, Osong-eup, Heungdeok-gu, Cheongju-si,
Chungcheongbuk-do, Korea